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Identification and characterization of novel drug resistance loci in 
Plasmodium falciparum 
ABSTRACT 
 Malaria has plagued mankind for millennia. Antimalarial drug use over the last century 
has generated highly drug-resistant parasites, which amplify the burden of this disease and pose a 
serious obstacle to control efforts. This dissertation is motivated by the simple fact that malaria 
parasites have become resistant to nearly every antimalarial drug that has ever been used, yet the 
precise genetic mechanisms of parasite drug resistance remain largely unknown. Our work pairs 
genomics-age technologies with molecular biology, genetics and molecular epidemiology in 
order to identify and characterize novel genes that contribute to drug resistance in P. falciparum. 
 In the Introduction, we highlight relevant opportunities and challenges in trying to 
identify and understand the genetic basis of malaria drug resistance as it emerges to currently 
used therapies. In Chapter One, we demonstrate how genome-wide association studies (GWAS) 
can be applied to P. falciparum in order to identify novel drug resistance loci. Functional follow-
up revealed that overexpression of the novel candidate gene PF10_0355 made parasites more 
resistant to the drugs halofantrine, lumefantrine and mefloquine. These findings show that 
PF10_0355 plays a role in parasite drug response, as well as provides validation of our GWAS 
approach. 
 In Chapter Two, we further characterize PF10_0355 and show that modulation of the 
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gene by either knockout or allelic replacement changes parasite drug sensitivity. Furthermore, we 
show that moderate changes in drug response measured in the short-term can have dramatic 
effects when parasites are competed with one another under drug pressure. In Chapter Three, we 
use an overexpression approach to functionally follow up other novel drug resistance genes 
generated by GWAS in P. falciparum. We find that overexpression is a useful way to begin to 
screen candidate drug resistance loci in the malaria parasite. 
 In Chapter Four, we use a DAPI-based ex vivo drug assay to monitor drug resistance 
among parasites circulating in Thiés, Senegal. In the future, we will look for genetic markers of 
parasite drug resistance in this population by GWAS. Finally, in the Discussion we present an 
essay about malaria evolution and eradication written for non-specialists. Our hope is that the 
work presented in this dissertation furthers understanding of drug resistance in the malaria 
parasite, both within and beyond the malaria research community. 
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INTRODUCTION 
 
 
 
Watching Evolution in Real-Time: Identifying and understanding the genetic basis 
of malaria drug resistance as it emerges 
 
 
Note: This Introduction was composed by Daria Van Tyne 
 
 
 
Summary 
 
  Malaria is a significant burden on global health, and the evolution of drug resistant 
parasites greatly impedes efforts to treat and control this disease. The malaria community is 
uniquely positioned to watch evolution in real-time, as parasites with reduced sensitivity to 
artemisinin combination therapies (ACTs) have arisen but full-blown, large-scale, and 
widespread resistance has not yet been detected. Current research efforts are aimed at identifying 
mutations that cause ACT resistance, in order to inform proper drug use and provide biomarkers 
for resistance monitoring. This review discusses opportunities and challenges in trying to 
identify and understand the genetic basis of antimalarial drug resistance as it emerges.  
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The Road to Resistance: Definitions and Assumptions  
 
 Malaria in humans can be caused by infection with any one of five different Plasmodium 
species; here we will focus on infection with Plasmodium falciparum, because it causes the most 
malaria-associated deaths worldwide, predominantly among African children under five years 
old [1]. Because P. falciparum infection is often acute and symptomatic, it is also most often 
treated with antimalarial drugs. Widespread treatment with many different antimalarials since the 
1950s has generated resistance to nearly every drug that has been used (Figure 1). Current first-
line treatment for P. falciparum infection includes a derivative of artemisinin and a longer-
lasting partner drug [2]. Unfortunately, parasites showing delayed clearance after ACT treatment 
have recently been observed [3], and it appears to be only a matter of time before full-blown 
ACT resistance develops and spreads throughout the world. 
For the purposes of this introduction, drug will be defined as any molecule that hinders or 
stops the growth of P. falciparum parasites, either by directly killing the parasite (in the case of 
cytocidal drug effects) or by inhibiting parasite growth (cytostatic effects) [4]. Drug resistance is 
the ability of parasites to sustain growth and persist despite the presence of a drug. Fitness is the 
extent to which a parasite can proliferate either in the presence or absence of antimalarial drugs. 
Selective pressure is the restriction on parasite growth imposed by some external force, such as 
antimalarial drug use. This pressure is called selective because it selects a subset of parasites that 
can withstand the imposed force and eliminates all other parasites from the population.  
It should be noted that resistance and fitness are both used here as relative terms. Malaria 
parasites can be “more resistant” or “more fit” than other parasites if they are able to sustain 
growth in an environment containing a higher dose of drug, or are able to grow faster than other 
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Figure 1. Malaria transmission, drug resistance and treatment failure in 2005. Figure 
reprinted with permission from [5]. 
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parasites within a particular host environment. The World Health Organization defines clinical 
malaria drug resistance as the persistence of parasites within a patient after appropriate 
administration and absorption of a drug [6]. This is a useful in vivo definition; however, parasite 
drug susceptibility can also be measured in vitro or ex vivo using a number of standard assays [7] 
[8] [9], and parasites can be classified as “sensitive” or “resistant” according to these tests. 
Additionally, parasite fitness and selective pressures depend heavily upon the context in which 
they are considered. For example, fitness can refer to growth within a human, growth within a 
mosquito, or the ability of parasites to be transmitted from one host to another. Selective 
pressures abound throughout the malaria life cycle, as the parasite must exist in dynamic and 
highly selective host environments (Figure 2), and naturally imposed bottlenecks restrict the 
transition of parasites from one life cycle stage to the next [10]. 
For the purposes of this introduction, we will assume that there is a detectable genetic 
basis for resistance to most, if not all, antimalarial drugs. Non-mutational mechanisms of drug 
resistance exist in other systems [11], and may also exist in malaria [12]; however, these may be 
more difficult to elucidate than drug resistance that is driven by genetic variants, such as point 
mutations (also called single nucleotide polymorphisms or SNPs) or copy number variations 
(CNVs). In malaria, there are several well-known examples of both mutations and copy number 
variation that underlie antimalarial drug resistance. Mutations in drug targets like dihydrofolate 
reductase (dhfr), or in the drug resistance transporters pfcrt and pfmdr1, are understood to cause 
resistance to pyrimethamine, chloroquine and mefloquine, respectively [14] [15]. In the case of 
pyrimethamine and chloroquine, resistance mutations within dhfr and pfcrt appear to have arisen 
in a small number of independent geographic sites and spread globally. This is known because 
resistance mutations can be mapped back to their likely origins by looking for evidence of 
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Figure 2. Plasmodium development within human and mosquito hosts. Reprinted with 
permission from [13].  
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reduced recombination, often called a signature of selection, which surrounds these genetic loci 
in the parasite’s genome [16]. 
Finally, we will assume that mutations are occurring in the malaria genome at a near-
constant rate. Estimates of precise mutation and recombination rates in P. falciparum vary 
widely, but we will focus on the idea that the parasite is constantly acquiring mutations and then 
testing whether each mutation is “contextually beneficial,” meaning whether it improves parasite 
fitness in the current environment, as compared to other parasites without the mutation. Nearly 
all mutations cause no benefit to parasite fitness or are deleterious, and are therefore eliminated 
from the population. Occasionally, a mutation occurs that makes parasites better able to 
withstand a selective pressure, such as treatment with a particular antimalarial drug. At the end 
of the day, timing is everything: mutations must occur in the right place and at the right time in 
order to improve parasite fitness and thus remain in the population. 
 
Road Signs: Identifying malaria drug resistance genes in the post-genome era 
 
 The genome sequence of P. falciparum was completed and published ten years ago, 
beginning the “genomics era” of malaria research [17]. Genomics-age technologies like 
microarrays and whole-genome sequencing have been widely used over the past decade to study 
many different aspects of malaria parasite biology, including drug resistance [18] [19]. The 
overall goal of these efforts is to better understand the basic biology underlying parasite drug 
response, as well as to develop better surveillance and monitoring tools in order to combat 
resistance in clinical settings. As resistance appears to be emerging to ACTs that are currently 
used worldwide, researchers are well positioned to harness the power of genomics in order to 
watch P. falciparum evolve in real time. Various approaches that researchers have used to search 
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for the genetic basis of antimalarial drug resistance are summarized below, along with discussion 
of the most relevant features of each approach to the current challenge of identifying ACT 
resistance mutations as they are emerging. 
One tool to look for the genetic basis of a trait such as drug resistance is to use linkage 
analysis to examine trait inheritance among the progeny of a genetic cross. Parents that have 
differing phenotypes of interest are crossed, and the phenotypes of their progeny can be mapped 
back to parental loci using quantitative trait locus (QTL) mapping. Linkage analysis relies on a 
“genetic map” of markers (such as SNPs or microsatellites) that vary between the two parents, 
and these analyses are most effective when they employ a map with maximum marker density 
and test as many distinct progeny as possible. Three genetic crosses have been conducted in P. 
falciparum to date [20], one of which was used to identify a locus associated with chloroquine 
resistance [21]. This locus was originally mapped to a 400-kilobase stretch of chromosome 7, 
and it took nearly a decade to identify the pfcrt gene within this region as the underlying cause of 
the QTL signal and the principal driver of chloroquine resistance [22]. 
Because linkage studies employ two genetically distinct parents, every parasite studied 
will possess only one of two possible alleles of every gene in their genome. In a case where drug 
resistance is caused by a single mutation or polymorphism, crossing a clearly sensitive parasite 
line with a clearly resistant line will yield progeny that are either sensitive or resistant, with no 
intermediate phenotypes present. But if resistance is caused by a combination of polymorphisms 
at multiple loci, the progeny would likely display intermediate drug responses depending on 
which mutations they inherit, and numerous loci containing many different genes may be 
identified. This appears to be the case for artemisinin response measured in the parents and 
progeny of the HB3 x Dd2 parasite cross [23]. As reduced response to ACTs is currently 
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emerging but high-level resistance has not yet arisen, it may be difficult to apply linkage analysis 
to identify the genetic basis of ACT resistance. Other challenges to this approach include the lack 
of a strong in vitro correlate of delayed parasite clearance, as well as the technical and cost 
limitations of conducting the genetic cross. Linkage-based studies are generally a useful tool to 
identify the genetic basis of numerous parasite phenotypes, but this approach may not be 
effective for understanding ACT resistance until these challenges can be overcome. 
Genome-wide association studies (GWASs) are complementary to linkage-based studies 
for understanding the genetic basis of malaria phenotypes such as drug resistance. GWASs use 
the natural diversity present within parasite populations to identify mutations that are associated 
with a phenotype of interest. Similar to linkage studies, GWASs work best when there are large 
phenotypic differences among the parasites studied, when many parasites are analyzed, and when 
the “genetic map” used is as dense as possible. GWASs in P. falciparum to date have employed 
SNP arrays [24] [25] [26], and more recently, whole-genome sequencing [27], in order to 
identify mutations that are associated with drug response among in vitro culture-adapted parasite 
lines. Low linkage disequilibrium, particularly among African isolates of P. falciparum [28], has 
two consequences for GWASs: first, SNP arrays can only test mutations that are present on the 
array and generally cannot assay other mutations that are not present; and second, association 
signals often map to small genomic regions that contain one or a few genes, rather than large 
regions containing many genes. GWASs in malaria have successfully identified known 
antimalarial resistance loci using as few as 45 parasite isolates [27], and have also identified 
numerous novel loci associated with drug resistance. Functional follow-up has been carried out 
for one recently identified novel locus associated with parasite response to halofantrine [25]. 
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Similar follow-up will be required to validate other novel hits and to distinguish between true 
hits and false positive associations. 
The GWAS approach is made more powerful when it is combined with tests that scan the 
genome for signatures of recent selection, and leverage this information to identify loci that are 
both under positive selection and also associated with the phenotype of interest [29]. These 
include long-range haplotype (LRH) tests such as integrated haplotype score (iHS) [30], and 
cross-population extended haplotype heterozygosity (XP-EHH) [31]. Selection-based tests look 
for areas of the genome that have not yet been broken down by mutation or recombination, but it 
is important to note that these tests alone cannot identify the source of selection. However, 
because antimalarial drug use is a strong selective pressure that has been recently imposed, drug 
use is a useful working hypothesis for the force underlying signals of recent selection found 
within the malaria genome. Recent studies have paired tests for selection with GWASs to 
identify loci that appear to be under recent positive selection only in drug resistant P. falciparum 
isolates [27], as well as genomic regions that are under selection and also associated with 
prolonged ACT clearance rates [32]. The latter study identified a 35-kilobase locus on 
chromosome 13 that contains over a dozen candidate genes and is associated with delayed 
parasite clearance in Thailand and Cambodia. It is possible that one or more of the genes within 
this locus cause delayed parasite clearance, but one can only speculate until functional validation 
experiments are carried out. 
One final approach for understanding the genetic basis of ACT resistance is resistance 
selection, whereby a population of parasites is exposed to drug pressure in vitro and resistant 
parasite lines are generated and analyzed [33]. Resistance selection has been paired with whole-
genome sequencing [34] or genomic tiling arrays [35] to identify the genetic basis of resistance 
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to numerous compounds. While this is a powerful approach, it should be noted that both genetic 
and transcriptional differences likely exist between parasites circulating in malaria-infected 
patients and culture-adapted lines growing in vitro [36] [37]. Furthermore, in vitro protocols may 
not accurately mirror the dynamics of resistance selection when it occurs in the wild. Selection 
for resistance to artemisinin and its derivatives in P. falciparum has been tried many times and in 
many different ways [38] [39] [40], and these studies have generated numerous candidate genes. 
Unfortunately, mutations in these candidate genes do not seem to correlate well with clinical 
observations of delayed parasite clearance [41], suggesting that their effect may be limited to 
culture-adapted parasites and the in vitro laboratory setting. 
All three studies mentioned above—linkage analysis, association studies, and in vitro 
resistance selection—are useful for generating hypotheses and identifying candidate resistance 
genes, as they all take an unbiased approach and consider the entire genome when looking for 
markers of parasite drug resistance. There could be many potential roads to ACT resistance in 
malaria, and it seems fitting that as many relevant approaches as possible are employed to try 
and understand the genetic basis of resistance before it becomes widespread. 
 
Forks in the Road: Understanding malaria drug resistance as it emerges 
 
 The malaria life cycle is complex, requiring the parasite to take up residence in numerous 
different environments within both human and mosquito hosts, and undergoing multiple 
population bottlenecks in order to pass from one developmental stage to the next. And yet 
somehow despite this complexity, and despite treatment and control efforts imposed over the last 
century, malaria parasites remain a serious burden on human health. Malaria certainly is a 
formidable foe, and its adaptability is clearly on display when considered in the context of the 
evolution of drug resistance. This section presents various considerations that may aid in the 
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discussion of how malaria drug resistance evolves. Knowledge of how drug resistance emerges 
in other diseases, as well as the biological consequences of being drug resistant, could better 
inform our understanding of how parasite resistance is emerging to ACTs. 
It is important to first recognize the differences between antimalarial drug use during the 
last century and throughout the “natural history” of malaria evolution. Over the last century, 
synthetic compounds have been developed and deployed one at a time to try and kill all the 
parasites that cause a malaria infection. This imposes strong selective pressure on a diverse 
population of parasites within a patient, and favors the rapid development of high-level 
resistance [42]. Somewhat paradoxically, the emergence of drug resistant P. falciparum parasites 
seems to have accelerated throughout the 20th century, just as drug targets have become better 
defined and more specific [43]. Throughout malaria’s natural history, parasites were likely 
exposed to many different naturally-occurring compounds within the human bloodstream and 
mosquito mid-gut that would exert antimalarial effects, similar to the case of naturally-occurring 
antibiotics among soil microbial communities [44]. The effects of these naturally derived 
compounds on inhibiting parasite growth may have been small, but nonetheless parasites had to 
evolve resistance or tolerance to them in order to persist. Additionally, Artemisia plant extracts 
that contain artemisinin (and likely many other compounds) have been used to treat fever in 
China for hundreds of years [45]. It is only in the last half-century that artemisinin has been 
isolated as the compound within these plants that is most effective at killing malaria parasites, 
leading to its isolation and combination with other synthetic compounds to constitute ACTs. It 
seems that drug exposure is not a new phenomenon, but the way that parasites now encounter 
drugs is far removed from their natural and historical contexts. 
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It is well known that copy number variation (CNV) plays a major role in modulating 
many different biological processes in malaria, including drug resistance [46]. One way that 
parasites are able to adapt to drug pressure is by rapidly increasing the copy number and thereby 
increasing the expression of genes within the pathway or pathways targeted by a particular drug. 
This appears to be the case for GTP cyclohydrolase I amplification in P. falciparum, which 
drives the parasite folate biosynthesis pathway and appears to be a mechanism for resistance to 
the antifolate drugs pyrimethamine and sulfadoxine [47]. Another example can be found in 
amplification of the pfmdr1 locus, which increases parasite resistance to mefloquine, quinine and 
artemisinin, presumably by promoting drug efflux [48] [49]. Additionally, point mutations have 
been discovered within pfmdr1 that seem to make parasites more resistant to chloroquine and 
amodiaquine [50] [51]. The interplay between CNVs and point mutations has been explored in 
other systems, such as host adaptation in double-stranded DNA viruses and antibiotic resistance 
in bacteria. Poxviruses appear to employ “gene accordions” to rapidly increase the copy number 
of a target gene and then accrue different mutations within each copy [52]. Once a highly 
beneficial mutation occurs in one of the amplified genes, the additional copies are lost and the 
accordion collapses back down. A recent study of antibiotic resistance in Salmonella 
typhimurium found that gene amplification was also followed by selection for a resistance-
conferring mutation and subsequent de-amplification [53]. It seems possible that CNVs in P. 
falciparum similarly facilitate adaptive evolution, and that observations of amplifications and 
mutations within important malaria drug resistance genes represent different time points along 
this evolutionary trajectory. 
Studies of drug resistance mutations in bacterial and viral systems have suggested that 
they often make organisms less fit [54] [55], though a possible exception to this rule in cancer 
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has been described [56]. The precise way in which resistance mutations impact parasite fitness 
can be measured by numerous methods, but one relevant measure is the effectiveness of parasite 
transmission to mosquitoes through conversion to sexual stages (called gametocytes). The impact 
of resistance mutations on the transmission potential of parasites has been studied in various 
rodent malaria models, where it was shown that resistant parasites are effectively transmitted 
following drug treatment, but can be outcompeted by sensitive parasites in the absence of drug 
pressure [57] [58]. Similar effects have been observed in P. falciparum, where patients harboring 
drug-resistant infections were found to have increased gametocyte levels following treatment 
with chloroquine and sulfaxoxine/pyrimethamine [59] [60] [61]. Other studies of P. falciparum 
populations across many parasite generations have suggested that in the absence of drug 
pressure, many drug resistance mutations incur a fitness cost over time [62] [63] [64] [65]. 
Although drug resistance mutations may make parasites less fit when they compete with 
sensitive lines in the absence of drug pressure, this effect clearly disappears when sensitive 
parasites are eliminated by drug treatment. 
It also seems clear that many mutations that cause drug resistance are either a 
consequence of or necessitate the acquisition of compensatory mutations that increase parasite 
fitness, either in the presence or absence of drug pressure. In P. falciparum, mutations making 
parasites more tolerant to low-level concentrations of pyrimethamine might have allowed for less 
common and possibly less fit resistance mutations to arise within dhfr [66]. Parasites that show 
delayed clearance in patients treated with ACTs have also been described as “tolerant,” 
suggesting that they could represent an intermediate stop along the road to full-blown ACT 
resistance [3] [67]. Conversely, selection for a mutation conferring high-level resistance could 
generate parasites that are initially unfit, but compensatory mutations can arise which quickly 
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restore fitness. Selection experiments in P. chabaudi have shown that a parasite line selected to 
be pyrimethamine resistant was initially unfit, but additional mutations led to increased fitness 
and allowed subsequent parasites to out-compete wild-type lines [68]. A separate study using 
transgenic yeast expressing the P. falciparum version of dhfr showed that the three most likely 
pathways to pyrimethamine resistance all involved an initial decrease in fitness, which correlated 
with large increases in drug resistance [69]. Finally, in addition to compensatory mutations 
occurring within the same drug target, fitness-restoring mutations can also arise in different 
genes within the same biological pathway, as in the case of dhfr mutations that were found in 
parasites with amplified GTP cyclohydrolase I [70]. In this case, it was suggested that increased 
copy number could compensate for decreased efficiency of the mutated dhfr enzyme by up-
regulating the entire folate metabolism pathway. Whether compensatory mutations play a role in 
drug resistance acquisition or facilitate parasite survival after an un-fit resistance mutation 
occurs, they are clearly important and should be considered within the broader context of 
parasite adaptation to antimalarial drugs. 
Other ways that P. falciparum can compensate for drug resistance are less defined, and 
highlight potential new areas of malaria drug resistance research efforts. Amplification of the 
chromosome 5 locus containing pfmdr1, in addition to making parasites drug resistant, also 
appears to alter the transcription of numerous genes, possibly through the action of neighboring 
regulatory factors [71]. These transcriptional changes could represent parasite adaptation to an 
altered, drug-resistant state. A separate study of parasites with different pfct mutations generated 
in an isogenic background found both expression and copy number changes in growth, 
development, signal transduction and transporter genes, which suggests numerous compensatory 
mechanisms for being chloroquine resistant [72]. A recent sequence-based GWAS for drug 
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resistance determinants in P. falciparum identified a number of genes that were under recent 
positive selection in pyrimethamine-resistant parasites, including chaperones and other proteins 
thought to be involved in lipid metabolism and ubiquitination [27]. These genes may represent 
novel biological pathways, such as stress response or protein turnover, that can help parasites 
survive under drug pressure and/or compensate for resistance mutations within dhfr. Lastly, 
parasites in vitro selected to be resistant to dihydroartemisinin showed the up-regulation of genes 
involved in antioxidant defense, as well as many chaperones [40]. Overall it seems that 
antimalarial drug resistance may involve many more genes and pathways than the subset which 
have been focused on thus far. 
Finally, an important facet of malaria drug resistance that cannot be studied using culture-
adapted parasite lines is the interplay between drug resistance and host immunity. The ability to 
clear chloroquine resistant P. falciparum has been associated with patient age [73], and acquired 
immunity seemed to improve the clearance of drug-resistant parasites in a study of Tanzanian 
children [74]. Three human polymorphisms were recently associated with enhanced ability to 
clear drug-resistant P. falciparum infections; two of these mutations were within pro-
inflammatory and anti-inflammatory response genes [75]. One possible explanation for this 
phenomenon is that selection for drug-resistant parasites could cause reduced variation in the 
parasite’s antigen repertoire, and as a result, resistant parasites would be less fit in the face of 
immune pressure [76]. While it is tempting to think that host immunity could be enlisted to 
enhance the clearance of drug resistant parasites, the biological mechanisms underlying this 
phenomenon remain unclear and require further study. 
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The Road Ahead: Concluding thoughts 
  
Malaria researchers are uniquely poised to observe evolution in real-time, as parasites 
adapt and become resistant to ACTs. The current challenge is to try and understand ACT 
resistance before it becomes widespread, so that resistance mutations can be used as biomarkers 
to guide treatment policy, resistance containment, and malaria control efforts. Numerous studies 
aimed at identifying the genetic basis of ACT resistance have generated a long list of candidate 
genes; however, a causal link between these candidates and in vivo resistance has yet to be 
shown. Nonetheless, malaria researchers are well positioned to use genomics-era technologies in 
order to identify possible “road signs” along the way to ACT resistance.  
Antimalarial drug use over the last half-century has maximized the evolutionary 
advantages of drug-resistant parasites. Synthetic compounds, given as monotherapy and aimed at 
eliminating every parasite in an infection, have driven the emergence and spread of resistant 
parasites. The recent shift in drug policy towards combination therapies is certainly a step in the 
right direction, but the lack of new antimalarial drugs on the horizon underscores the fact that 
once ACTs are rendered ineffective there will be few, if any, treatment options for patients that 
are sick with multi-drug resistant parasites. More diverse combination therapies are certainly 
needed; one recent study uncovered the antimalarial activities of numerous drugs already 
approved for treatment of other diseases, as well as compounds that appear to selectively target 
drug resistant parasites [26]. Collaborative efforts between researchers and drug companies have 
suggested the creation of a “malaria box” of publicly accessible compounds having antimalarial 
activity and would serve as a community resource [77]. Finally, drug resistance monitoring in 
naturally circulating parasite populations is essential, as the only way to know whether resistant 
parasites are in a particular area is to look for them [78]. These are just a few of the many efforts 
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underway to try and keep pace with parasites as they become increasingly drug resistant and 
cause infections that are more and more difficult for clinicians to manage. 
Regardless of how it arises, it is clear that full-blown ACT resistance would be 
devastating for the millions of people stricken with malaria each year. In trying to identify and 
understand the genetic basis of resistance, it is important to keep an open mind. Drug resistance 
is a near-universal phenomenon among rapidly evolving human diseases, and researchers should 
seek applicable insights from other fields wherever possible. We hope that the years ahead will 
bring reliable markers of ACT resistance, a better understanding of how parasites become 
resistant, and new therapies that can combat resistant parasites. All of these will surely aid efforts 
to better manage drug-resistant malaria infections. 
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Abstract 
The Plasmodium falciparum parasite’s ability to adapt to environmental pressures, such 
as the human immune system and antimalarial drugs, makes malaria an enduring burden to 
public health. Understanding the genetic basis of these adaptations is critical to intervening 
successfully against malaria. To that end, we created a high-density genotyping array that assays 
over 17,000 single nucleotide polymorphisms (~1 SNP/kb), and applied it to 57 culture-adapted 
parasites from three continents. We characterized genome-wide genetic diversity within and 
between populations and identified numerous loci with signals of natural selection, suggesting 
their role in recent adaptation. In addition, we performed a genome-wide association study 
(GWAS), searching for loci correlated with resistance to thirteen antimalarials; we detected both 
known and novel resistance loci, including a new halofantrine resistance locus, PF10_0355. 
Through functional testing we demonstrated that PF10_0355 overexpression decreases 
sensitivity to halofantrine, mefloquine and lumefantrine but not to structurally unrelated 
antimalarials, and that increased gene copy number mediates resistance. Our GWAS and follow-
on functional validation demonstrate the potential of genome-wide studies to elucidate 
functionally important loci in the malaria parasite genome. 
 
Author Summary 
Malaria infection with the human pathogen, Plasmodium falciparum, results in almost a 
million deaths each year, mostly in African children. Efforts to eliminate malaria are underway, 
but the parasite is adept at eluding both the human immune response and antimalarial treatments.  
Thus, it is important to understand how the parasite becomes resistant to drugs and to develop 
strategies to overcome resistance mechanisms.  Toward this end, we used population genetic 
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strategies to identify genetic loci that contribute to parasite adaptation and to identify candidate 
genes involved in drug resistance.  We examined over 17,000 genetic variants across the parasite 
genome in over 50 strains in which we also measured responses to many known antimalarial 
compounds.  We found a number of genetic loci showing signs of recent natural selection and a 
number of loci potentially involved in modulating the parasite’s response to drugs. We further 
demonstrated that one of the novel candidate genes (PF10_0355) modulates resistance to the 
antimalarial compounds halofantrine, mefloquine and lumefantrine. Overall, this study confirms 
that we can use genome-wide approaches to identify clinically relevant genes and demonstrates 
through functional testing that at least one of these candidate genes is indeed involved in 
antimalarial drug resistance. 
 
Introduction 
Plasmodium falciparum malaria is a major public health challenge that contributes 
significantly to global morbidity and mortality. Efforts to control and eliminate malaria combine 
antimalarial drugs, bed nets and indoor residual spraying, with vaccine development a longer-
term goal. Genetic variation in the parasite population threatens to undermine these efforts, as the 
parasite evolves rapidly to evade host immune systems, drugs and vaccines. Studying genetic 
variation in parasite populations will expand our understanding of basic parasite biology and its 
ability to adapt, and will allow us to track parasites as they respond to intervention efforts. Such 
understanding is increasingly important as countries move towards reducing disease burden and 
the ultimate elimination of malaria. 
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Given the potential impact of rapid evolution of P. falciparum in response to control and 
eradication strategies, discovery and characterization of P. falciparum genetic diversity has 
accelerated in recent years. Since the first malaria genome was sequenced in 2002 [1], over 
60,000 unique SNPs have been identified by concerted sequencing efforts [2-4], and several 
genomic tiling arrays [5-9] and low-density SNP arrays [10, 11] have been developed to query 
this genetic variation. Recently the first malaria GWAS was published [11], in which 189 drug-
phenotyped parasites from Asia, Africa and the Americas were genotyped using a low-density 
array (3,257 SNPs); that study identified loci under positive selection and found several novel 
drug resistance candidates. 
For our study, we adopted two strategies for identifying genes involved in the malaria 
parasite’s adaptive response: searching for signals of recent or ongoing natural selection, and 
searching for loci associated with one important clinical adaptation—resistance to antimalarial 
drugs. To make these searches possible, we began by sequencing 9 geographically diverse strains 
of P. falciparum to identify novel variation, thereby doubling the number of publicly available 
SNPs to 111,536 (all accessible at plasmodb.org), and used these SNPs to develop a high-density 
genotyping array assaying 17,582 validated markers. After characterizing linkage disequilibrium 
and population structure in our samples, we used the arrays to search for evidence of both 
ongoing balancing selection and recent positive selection, and to carry out a GWAS that sought 
loci associated with resistance to thirteen antimalarial agents. We then followed up one of the 
novel loci associated with drug resistance in order to verify that variation there was biologically 
involved in modulating drug response. 
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Materials and Methods 
Parasites, Drug Testing, and DNA Isolation 
Parasite samples and origins are detailed in Supplemental Methods and Table S1.  
Parasites were maintained by standard methods [12] and were tested for their response to 
amodiaquine, artemether, artesunate, artemisinin, atovaquone, chloroquine, dihydroartemisinin, 
halofuginone, halofantrine, lumefantrine, mefloquine, piperaquine and quinine according to the 
methods outlined by Baniecki, et al. [13] (Table S4, Fig. S13, Supplemental Methods). Follow-
up drug testing was done by measuring uptake of 3H-hypoxanthine [14].  Nucleic acids were 
obtained from parasite cultures using Qiagen genomic-tips (Qiagen, USA). All DNA samples 
were evaluated by molecular barcode [15]. 
Array Genotyping 
We sequenced nine geographically diverse parasite isolates to 1.25x coverage, nearly 
doubling the number of publicly available SNPs to 111,536 (Supplementary Methods). These 
parasites had been previously sequenced to 0.25x coverage [2] and the deeper sequencing 
allowed for more thorough SNP discovery.  Using this combined marker set, we created a high-
density Affymetrix-based SNP array for P. falciparum containing 74,656 markers.  Arrays were 
hybridized to 57 independent parasite samples (Table S1), including 17 previously sequenced 
strains used as a validation set.  Genotype calls were produced using the BRLMM-P algorithm 
[16].  Markers that did not demonstrate perfect concordance between sequence and array data for 
the 17 strains were removed (Supplemental Methods).  The remaining 17,582 SNPs constituted 
the high-confidence marker set used throughout this study (median marker spacing 444 bp, mean 
spacing 1,316 bp). All genomic positions and translation consequences are listed with respect to 
the PlasmoDB 5.0 assembly and annotation.  SNP genotype data are publicly available on 
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plasmodb.org (release 6.0, July 2009) and dbSNP (Build B134, May 2011), accessible by 
searching for submission batches Pf_0002 (sequencing of nine isolates) and Pf_0003 
(genotyping of 57 isolates) from submitter BROAD-GENOMEBIO. 
Principal Component Analyses 
Principal components analysis (PCA) was performed using the program SmartPCA [17]. 
All single-infection samples were used for the analysis in Figure 1.1. Samples that tightly 
clustered with the wrong continental population (A4, Malayan Camp and T2_C6) represented 
likely cases of contamination and were thus omitted from all other analyses. 
Diversity/Divergence Analysis 
We measured diversity using a statistic we term ‘SNP π,’ which quantifies the average 
number of pair-wise differences among samples from a given population at assayed SNPs. 
Population divergence was measured using FST, calculated using the method of Hudson, et al. 
[18]. Statistical evaluation of the significance of differences in SNP π and FST among populations 
was performed using a bootstrapping approach, where the SNP set was re-sampled with 
replacement and each statistic recomputed 1000 times. 
Linkage Disequilibrium (LD) Analysis 
The statistic r2 was calculated within each population for all pairs of SNPs sharing the 
same chromosome [19]; pairs were binned by distance and averaged within each bin. The level 
of LD between unlinked markers was estimated by calculating r2 between all pairs of SNPs on 
different chromosomes. To determine the bias caused by small sample size, the unlinked 
calculation was repeated, with the change that for each pair of SNPs, the genotype for one was 
taken from one strain while the genotype for the second was taken from another strain. This 
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Figure 1.1. Parasite global population structure and genetic diversity vs. divergence. A) 
Population structure is visualized using the first two principal components of genetic variation 
for 57 parasites. Solid circles represent individual parasites, with colors assigned by reported 
origin: Africa in red, America in blue, and Asia in green.  The nine strains used for ascertainment 
sequencing are indicated with (*). B) Genetic diversity (SNP p) in Senegal versus divergence 
(FST) between Senegal and Thailand is reported for 688 genes containing >3 successfully 
genotyped SNPs. Blue diamonds: enzymes, acyl-CoA synthetases (ACS) or transporters; red 
diamonds: antigens, vars, rifins, stevors or surfins; gray diamonds: all other genes. Gene IDs 
(PlasmoDB.org) for highlighted genes are listed in Table S7. A gene with unknown function is 
flagged with (*) to indicate that SNP π is off-scale (0.014). 
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background value of r2 was calculated separately for the possible pairs of different strains and 
then averaged. Only single infections, as assessed by molecular barcode, were used. 
Long Range Haplotype (LRH) Analysis 
 Because of the small number of samples, LRH results for individual continental 
populations had a high level of variance. Thus, we pooled together samples from Africa (n = 26) 
and Asia (n = 18, excluding India), as suggested by our PCA analysis. SNPs included in the 
analysis had a minor allele frequency of at least 0.05 and a call rate of at least 0.8; missing 
genotypes were imputed using PHASE.  LRH analysis was performed using Sweep.  Each SNP 
defined two core alleles, one base pair in length.  We calculated relative extended haplotype 
homozygosity (REHH) for each core allele, to its left and right [20], yielding up to four REHH 
scores per SNP locus. We standardized the REHH scores as a function of core allele frequency, 
defined on a discrete grid from 0.05 to 0.95 with even spaces of 0.025. This yielded a normally-
distributed set of Z-scores for which we calculated corresponding P-values and Q-values. 
Genome Wide Association Study (GWAS) 
We performed a GWAS for drug resistance to thirteen antimalarials across 50 of our 
genotyped samples. 7,437 SNPs that had a minor allele count of five samples as well as an 80% 
call rate under every phenotype condition were used for GWAS.  A Bonferroni significance 
threshold of –log10(P-value) > 5.17 was used for all tests.  See Supplemental Methods for more 
details on GWAS methods.  
The Efficient Mixed-Model Association (EMMA) test [21] models quantitative trait 
associations to a data set with complex population structure and hidden relatedness.  It calculates 
a genotype similarity matrix instead of discrete categories and does not require a priori 
specification of populations.  The resulting P-value distributions demonstrate little remaining 
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effect from population structure (Fig. S8) while retaining power to find a number of associations 
at genome-wide significance (Fig. S8, 1.2A, Table 1.1).  
The Haplotype Likelihood Ratio (HLR) test [22] models the likelihood that a single, 
resistant haplotype rose to dominance while all other haplotypes proportionally decreased.  
PLINK [23] is used to produce sliding window haplotypes across the genome and calculate 
haplotype frequencies for input to the HLR test.  We produced input for all 2-, 4- and 6-marker 
windows. The LOD scores generated by the HLR test were converted to empirical pointwise P-
values by performing approximately 370,000 permutations of the null model for each test 
condition, allowing us to calculate empirical P-values up to a significance of 10-5.6.  We 
preserved population-specific phenotype frequencies by permuting only within each of three 
populations defined by our PCA analysis (Table S1).  Resulting P-value distributions fit 
expectations well for the vast majority of test conditions (Fig. S9, S10) and the test demonstrates 
power to detect a number of loci at genome-wide significance (Fig. 1.2A, Table 1.1). 
Copy Number Variation (CNV) 
Copy number was assessed by evaluating the hybridization intensity at the PF10_0355 
locus on the high-density SNP array (Supplemental Methods). Follow-up analyses were done by 
quantitative real-time PCR (qPCR) of the PF10_0355 locus using the Delta Delta Ct method 
[24]. PF10_0355 was compared to the reference locus PF07_0076 and 3D7 was used as a 
reference strain. A summary of PF10_0355 copy number for all parasite strains tested is 
provided in Table S6. Select resistant strains that were found to have multiple copies of 
PF10_0355 were further analyzed by quantitative Southern blotting and PF10_0355 copy 
number was compared to the dhps gene from the 3D7 strain [25]. 
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Figure 1.2. Genome-wide association study (GWAS) results. A) Genome-wide significant 
associations were found for five antimalarials (out of thirteen tested) using EMMA and HLR 
tests. They include pfcrt (chromosome 7) associated with chloroquine resistance and eleven 
novel associations with resistance to several drugs, listed in Table 1.1. B) Quantile-quantile plots 
for the P-value distributions in A) show no significant confounding from population structure.  
Bonferroni-corrected genome-wide significance is marked with a dashed line; Benjamini-
Hochberg significance is marked with a dotted line.  C-D) Close-ups are shown of the GWAS 
signal (top) and haplotypes (bottom) for resistance to C) chloroquine (CQ) around the gene pfcrt 
and D) halofantrine (HFN) around the gene PF10_0355. Yellow: sensitive allele; red: resistant 
allele; Blue: no data. Isolates are ordered by IC50, with the highest IC50 on the bottom. 
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chr! SNPs! test! drug! P2value! genes! PlasmoDB!description!6! 674,154! EMMA! ATV! 2.36E007! PFF0785w! Ndc80!homologue,!putative!7! 459,787! EMMA! CQ! 4.72E007! MAL7P1_27! chloroquine!resistance!transporter!
10!
1,435,226,!1,435,286,!1,435,370,!1,437,695,!1,437,718,!1,441,590,!1,444,868! HLR_risk_6!(2!overlapping!hits)! HFN! 4.71E006,!4.25E006! PF10_0355,!PF10_0356! erythrocyte!membrane!protein!putative,!liver!stage!antigen!1!11! 657,349! EMMA! ATV! 4.01E006! PF11_0178! conserved!unknown!11! 738,407! EMMA! HFN! 7.20E007! PF11_0203! peptidase,!putative!11! 1,123,028,!1,124,030! HLR_risk_2! ADQ! 5.26E006! PF11_0302! conserved!unknown!12! 1,964,935! EMMA! HFN! 6.15E008! PFL2285c! conserved!unknown!13! 757,689! EMMA! HFN! 1.28E007! PF13_0101! conserved!unknown!14! 1,233,470! EMMA! HFN! 5.32E007! PF14_0293! conserved!unknown!14! 2,814,793,!2,815,714! HLR_risk_2! ARTS! 4.90E006! PF14_0654! aminophospholipid!transporter,!putative!14! 3,130,449! EMMA! ATV! 1.03E006! PF14_0729! early!transcribed!membrane!protein!14.2!
 
 
Table 1.1. Eleven genome-wide significant associations with antimalarial drug resistance. 
Positions are given with respect to the PlasmoDB 5.0 reference assembly of 3D7.  Drug 
abbreviations are ATV: atovaquone; CQ: chloroquine; HFN: halofantrine; ADQ: amodiaquine; 
ARTS: artemisinin.  The HLR test for CQ-pfcrt association is just below the genome-wide 
significance threshold and is omitted here, but is shown in Figure 1.2C. 
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PF10_0355 Overexpression 
The full length ORF of PF10_0355 was amplified from either the Dd2 (HFN sensitive) or 
SenP08.04 (HFN resistant) parasite isolate and cloned into the pBIC009 plasmid under the 
expression of the Hsp86 promoter. Plasmid DNA was isolated, tranfected into the Dd2 parasite 
strain and stable transfectants were selected with 2.5nM WR99210 [26]. Parasites from two 
independent experiments for each vector type (Dd2+Dd2 and Dd2+SenP08.04) were isolated and 
successful transfection was confirmed by plasmid rescue as well as episome-specific PCR and 
sequencing. Additionally, a vector control strain was made by transfecting Dd2 parasites with the 
pBIC009 plasmid containing the firefly luciferase gene (EC 1.13.12.7). 
 
Results 
Genetic Diversity 
We identified global population structure among malaria parasites using principal 
components analysis (PCA) of 57 genotyped culture-adapted parasite samples (Fig. 1.1A, Table 
S1, Fig. S1). African, American and Asian samples form three distinct clusters, reflecting the 
likely independent introduction of P. falciparum from Africa into Asia and the Americas.  There 
was little evidence for structure within Africa, suggesting high gene flow throughout the region 
(Fig. S1). Asian and American parasites however both show substantial internal structure.  
There are also dramatic differences in linkage disequilibrium (LD) between populations, 
with substantial LD extending less than 1 kb in Senegal, 10 kb in Thailand, and 100 kb in Brazil 
(Fig. S2).  These observations are consistent with previous findings, which showed that LD 
decays more rapidly in Africa, due either to founder effects in other continents [27] or to 
elevated outcrossing frequencies in Africa [27, 28], where higher transmission intensity leads to 
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a greater likelihood of sexual outcrossing rather than selfing within the mid-gut of vector 
mosquitoes.  
The short LD in malaria, driven by high levels of recombination, means that a high 
density of markers is required to identify candidate loci in association studies, since causal 
variants not on the array can seldom be tagged by neighboring alleles (Table S2).  On the other 
hand, short LD can aid in fine-mapping candidate associations and greatly accelerates the search 
for causal genes.  Short LD also aids in identifying genomic regions under recent positive 
selection with recombination-based methods, since the increased LD in selected regions should 
stand out against the short-LD background.  
 
Detecting Signals of Natural Selection 
We expect that many parasite proteins that interact with the host immune system will be 
under balancing selection, because they will be under selective pressure to maintain high levels 
of diversity. Indeed, previous studies have shown that regions of the P. falciparum genome that 
are highly polymorphic and appear to be under balancing selection encode antigens that are 
recognized by the human immune system [4]. We examined evidence for balancing selection in 
our data by searching for regions with high nucleotide diversity (as measured by SNP π) and low 
population divergence (as measured by FST) (Fig. 1.1B). When we examined the loci lying in this 
region of the graph (Fig. S3), we found a number of known antigens and vaccine candidates. 
Loci in the same region with unknown function are thus potential novel antigens that trigger 
human immune response to malaria, and may prove useful as biomarkers or as candidate vaccine 
molecules.  
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We carried out a similar search for loci under positive selection by identifying regions 
with both low nucleotide diversity within Senegal and Thailand and high population divergence 
between the two populations (Fig. 1.1B). We observed throughout the genome that nucleotide 
diversity was lower for nonsynonymous SNPs than for intergenic SNPs (Fig. S4), a characteristic 
result of widespread purifying selection. At the same time, nonsynonymous SNPs exhibited 
significantly greater divergence than intergenic SNPs in all pairwise population comparisons, 
suggesting the effect of positive selection in local P. falciparum populations. Nonsynonymous 
SNPs with low diversity within a population and high divergence between the two populations 
studied may represent polymorphisms responsible for adaptive evolution.  
We also carried out a genome-wide scan for recent positive selection using the long-
range haplotype (LRH) test [29], which identifies common variants that have recently spread to 
high prevalence using recombination as a clock.  Approximately 15 genes were identified as 
having undergone recent positive selection by this approach, including known drug resistance 
loci (pfcrt and dhfr) as well as multiple members of the acyl-CoA synthetase (ACS) and 
ubiquitin protein ligase families (Fig. S5 and S6); these latter genes also exhibit high divergence 
between Senegal and Thailand (Fig. 1.1B), evidence for selection that is recent and population-
specific. Taken as a group, the genes identified by the LRH test show a significant enrichment 
for higher than average population divergence (as measured by FST, Mann-Whitney U=1583, 
P=0.0071). All of these loci (Table S3), which include genes in the folate metabolism, lipid 
biosynthesis and ubiquitin pathways, should be viewed as candidates for functional follow-up 
and further characterization.  
 
 
! 39 
Genome-wide Associations with Drug Resistance 
In order to directly assess the genetic basis for one important response to antimalarial 
intervention, we carried out a GWAS to identify loci associated with drug resistance in parasites.  
This same approach can potentially be applied to many other clinically relevant malaria 
phenotypes, e.g. host response, invasion, and gametocyte formation. Our first step was to 
measure drug resistance (IC50 values) to 13 antimalarial drugs (amodiaquine, artemether, 
artesunate, artemisinin, atovaquone, chloroquine, dihydroartemisinin, halofuginone, halofantrine, 
lumefantrine, mefloquine, piperaquine and quinine) in 50 culture-adapted parasites using a high-
throughput assay (Table S4-5, Supplementary Methods).  
We performed the genome-wide association analysis using two statistical tests: efficient 
mixed-model association (EMMA) and a haplotype likelihood ratio (HLR) test (Figs. S7-10, 
Methods).  EMMA identifies quantitative trait associations in individuals with complex 
population structure and hidden relatedness; it has previously been shown to outperform both 
PCA-based and λGC-based correction approaches in highly inbred and structured mouse, maize, 
and Arabidopsis populations [21].  EMMA is particularly applicable for small and structured 
sample sets: one of its first applications was in a study of 24 diploid mouse strains [21], 
essentially the same sample size as in our study (50 haploid strains). The HLR test is a multi-
marker test designed to detect the association of a single haplotype with a phenotype, and is 
particularly powerful when the associated haplotype experienced recent strong selection (and is 
therefore long) and occurs on a low-LD background [22]; it is therefore particularly appropriate 
for this study.  We addressed the effect of population structure in the HLR test using population-
specific permutation (Methods).  When used together, these two complementary approaches 
provide a highly sensitive screen for association signals within the P. falciparum genome.  
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The well-characterized chloroquine resistance locus, pfcrt, served as a positive control for 
our GWAS methods (Fig. 1.2A,C, Table S2), an important test given our small sample size and 
the limited LD present in P. falciparum. As expected, we found evidence for association with 
resistance to chloroquine using both tests, consistent with previous studies [11]; EMMA yielded 
evidence for association with genome-wide signficance, while the signal from the HLR test fell 
just short of genome-wide significance (Fig. 1.2C).  
Applying the same tests to the other drug phenotypes, we detected numerous novel loci 
showing significant associations with drug resistance (Fig. 1.2A,D, Table 1.1). Quantile-quantile 
plots for each test demonstrate that we were able to effectively control for population structure 
(Fig. 1.2B). Despite our small sample size and the low LD in P. falciparum, in total eleven loci 
achieved genome-wide significance for association with resistance to five different drugs: 
amodiaquine, artemisinin, atovaquone, chloroquine and halofantrine. In most cases, the short 
extent of LD allowed localization to individual genes. Among the loci identified were various 
transporters and membrane proteins, as well as five conserved genes with unknown function 
(Table 1.1).  
 
Functional Validation of a Novel Resistance Candidate 
Demonstrating that a signal of association actually reflects a causal molecular process 
requires functional testing and validation of the candidate locus, both because of concerns about 
power and reproducibility of genetic association tests, and because even a robust statistical 
correlation need not imply biological causation.  To confirm the ability of GWAS to identify 
functionally relevant candidates, we investigated one of our association findings, PF10_0355, in 
greater depth. This gene contains multiple SNPs associated with halofantrine resistance (Fig. 
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1.2D), and encodes a putative erythrocyte membrane protein (PlasmoDB.org) characterized by 
high genetic diversity.  
We set out to determine the role of PF10_0355 in halofantrine resistance by transfecting 
halofantrine-sensitive Dd2 parasites with episomal plasmids containing the PF10_0355 gene 
from a halofantrine-resistant parasite (SenP08.04), a technique that is used routinely for stable 
transgene expression [30]. Two independent transfectants overexpressing the PF10_0355 gene 
from SenP08.04 both showed reduced susceptibility to halofantrine when compared with the 
Dd2 parent or a transfection control (Fig. 1.3A), suggesting that this gene is indeed involved in 
modulating parasite drug response.  
Two independent transfectants overexpressing the endogenous PF10_0355 gene from 
halofantrine-sensitive Dd2 also showed reduced susceptibility to halofantrine (Fig. 1.3A), 
however, pointing to a role of overexpression in the observed resistance. Because PF10_0355 is 
annotated as a putative erythrocyte membrane protein and belongs to the merozoite surface 
protein 3/6 family, we tested the hypothesis that the observed effect was the by-product of a 
growth or invasion-related process, rather than resistance due to a direct interaction with the 
antimalarial itself. To that end, we expanded our drug testing in the transfectant lines to include 
other antimalarials, some structurally related and some unrelated to halofantrine.  
Overexpression of PF10_0355 from either the Dd2 or the SenP08.04 parent caused 
increased resistance to the structurally related antimalarials mefloquine and lumefantrine (Fig. 
1.3B,C), but had no effect on parasite susceptibility to the structurally unrelated antimalarials 
chloroquine, artemisinin or atovaquone (Fig. 1.3D,E). Indeed, we found evidence of cross-
resistance between halofantrine and both mefloquine and lumefantrine (Fig. 1.4). We also 
observed cross-resistance between halofantrine and artemisinin, which is expected as cross-
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Figure 1.3. Overexpression of PF10_0355 decreases parasite susceptibility to halofantrine 
(HFN) and related antimalarials. Parasite susceptibility to six antimalarials was measured by 
3H-hypoxanthine incorporation. Comparisons were made between Dd2 (HFN-sensitive strain) 
and SenP08.04 (HFN-resistant strain), as well as 4 transfected lines. “Dd2+Dd2”: Dd2 parasites 
overexpressing PF10_0355 from Dd2; “Dd2+P08”: Dd2 parasites overexpressing PF10_0355 
from SenP08.04. Overexpression of PF10_0355 decreases parasite susceptibility to A) HFN and 
structurally related B) mefloquine (MFQ) and C) lumefantrine (LUM). Overexpression of 
PF10_0355 does not alter parasite susceptibility to D) chloroquine (CQ), E) artemisinin (ARTS) 
or F) atovaquone (ATV). Mean IC50 ± standard error is shown. Significance levels: *: p<0.05, 
**: p<0.01, ***: p<0.001. 
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Figure 1.4. Correlations between antimalarial drugs tested. Pearson correlation values (r) 
between log10(IC50) values are rendered as a color in a symmetric correlation matrix (red: 
correlated; white-uncorrelated, blue: inversely correlated). Thirteen antimalarials are measured: 
artemether (ARTM), artesunate (ARTN), artemisinin (ARTS), dihydroartemisinin (DHA), 
halofantrine (HFN), lumefantrine (LUM), mefloquine (MFQ), quinine (QN), chloroquine (CQ), 
amodiaquine (ADQ), atovaquone (ATV), piperaquine (PIP), and halofuginone (HFG). Drugs are 
grouped by structural relatedness. Correlation plots are given with a linear regression line for 
HFN compared to the 5 other drugs tested for antimalarial resistance with PF10_0355 
overexpression: (B) LUM, (C) MFQ, (D) ATV, (E) CQ, and (F) ARTS. 
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resistance between aminoquinolines and artemisinin compounds has been previously 
demonstrated [11, 31] and resistance to all these drugs has been shown to be mediated by 
changes in pfmdr1 copy number [32, 33].  Overexpression of PF10_0355, however, alters 
parasite susceptibility to the aminoquinolines but not to artemisinin, suggesting that this effect is 
specific for that set of structurally related compounds and distinct from the effect of pfmdr1, 
which seems to exert a global effect of resistance to unrelated compounds (i.e. both 
aminoquinolines and artemisinins). Using the Dd2 parasite line, which has amplified pfmdr1 
copy number, as a background for PF10_0355 overexpression allowed us to distinguish between 
cross-resistance to a structurally related class of compounds (mediated by PF10_0355 
overexpression) and pan-resistance to multiple classes of drugs.  
Given that overexpression of the PF10_0355 gene both from a halofantrine-resistant and 
from a sensitive parasite conferred resistance to halofantrine-related drugs, we investigated 
whether gene amplification might be driving the observed resistance, as it often does for 
antimalarial drugs [34-39]. We quantified PF10_0355 copy number in our transfectants and 
found that the transfectant with the highest IC50 for all three drugs (Dd2+P08B) also had the 
highest PF10_0355 copy number, as measured by quantitative PCR (qPCR) (Fig. 1.5A). 
Furthermore, when we examined the PF10_0355 gene on our SNP array, we detected a 
substantial increase in hybridization intensity at the PF10_0355 locus compared to the genome 
average, suggesting that this gene is amplified in some parasites (Fig. 1.5B). The amplified 
region appears only to contain the PF10_0355 gene itself and not surrounding loci.  We observed 
a similar pattern at pfmdr1 on chromosome 5, where copy number variation is well established 
(Fig. S11).  Follow-up qPCR analysis of 38 parasite lines confirmed that parasites with amplified  
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Figure 1.5. Copy number variation at PF10_0355 is associated with HFN resistance. A) 
Mean PF10_0355 copy number (± standard deviation for three replicates) in the parent Dd2 and 
transfected lines from qPCR analysis. Dd2+Dd2: Dd2 parasites overexpressing PF10_0355 from 
HFN-sensitive Dd2; Dd2+P08: Dd2 parasites overexpressing PF10_0355 from HFN-resistant 
SenP08.04. Copy number was compared to the reference locus PF07_0076. B) Increased 
hybridization intensity at PF10_0355 on the high-density SNP array, measured by Z-scores for 
normalized and background-corrected data, for the HFN-resistant isolate SenP19.04. C) Strains 
with increased copy number of PF10_0355 (as measured by qPCR > 1.2x 3D7) show a 
significantly higher resistance to HFN (p = 0.02, Student t-test). 
 
 
 
 
! 46 
Figure 1.5 (Continued) 
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PF10_0355 have a greater mean halofantrine IC50. (Fig. 1.5C, Table S6). Copy number variation 
was further confirmed in a number of parasites by quantitative Southern blotting (Fig. S12).  
Discussion 
In this study we used natural selection and genome-wide association methods to probe 
the genetic basis of adaptation in P. falciparum. These approaches are complementary: scanning 
for selected loci permits an unbiased search for unknown adaptive changes, but provides little 
information about the processes at work, while GWAS gives a focused look at one easily 
identified (and clinically critical) adaptive phenotype. Results from both approaches open up 
new avenues for study, as we seek to understand the biological significance of the findings.   
The specifics of our strategy were designed to cope with two potential limitations in 
applying genome-wide population genetic approaches to malaria: small sample sizes, due to the 
difficulty in adapting parasites to culture and assessing drug and other phenotypes; and a lack of 
correlation (LD) between nearby variants in the parasite genome, which limits our ability to infer 
untyped SNPs from genotyped markers. The second limitation we addressed by developing a 
high-density genotyping array (based on new sequencing), to increase the fraction of genetic 
variation that we could directly interrogate, while the effect of the first was mitigated by the 
phenotype we targeted in our GWAS.   
Drug resistance is a phenotype well-suited for GWAS because it is expected to be caused 
by common alleles of large effect at few genomic loci [40].  If this is the case, associations will 
be much easier to detect than in a typical human GWAS, in which the phenotype is caused by 
alleles at many loci that are either rare or of small effect. Additionally, the haploid nature of the 
intra-erythrocytic stage of P. falciparum further heightens GWAS power by eliminating the issue 
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of allelic dominance. Finally, the increased LD caused by recent selection for drug resistance 
counteracts the loss of power that comes from short LD, small sample size, and the temporal and 
geographic stratification of the parasite population that we examined. Thus, despite the potential 
limitations, we were able to detect a known drug resistance locus (pfcrt), observed little P-value 
inflation in our GWAS data (Fig. S8, S9, S10), and identified a number of genome-wide 
significant loci associated with drug resistance. Part of this success was likely due to specific 
tests we used to account for population structure.   
Going beyond these statistical tests, we went on to functionally validate one of these loci, 
demonstrating that increased PF10_0355 copy number confer resistance to three structurally 
related antimalarial drugs. This demonstrates the feasibility of coupling GWAS and functional 
testing in the malaria parasite for identifying and validating novel drug resistance loci and 
illustrates the power of GWAS to find functionally important alleles.   
Comparing our results to the recent GWAS described by Mu, et al. [11], which was also 
directed at finding drug-resistance loci, we see that, beyond the well-known pfcrt locus, there 
was no overlap between the associations identified by each study.  Differing sets of drugs tested 
and analytical methods explain much of the disagreement. Of the eleven candidate associations 
in Table 1.1, one (that with pfcrt) was found by both studies, eight were associations with drugs 
not assayed in Mu, et al. (atovaquone and halofantrine), and two were found only with a 
haplotype-based test, an approach not used by Mu, et al. Our candidate locus at PF10_0355, in 
fact, would not have been detectable in the Mu study because it was identified only by the multi-
marker HLR test, because it involved an association with halofantrine, and because the Mu, et al. 
genotyping array lacked markers within 4 kb of the gene (plasmoDB.org).   
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Different parasite populations and marker sets probably explain many of the 
dihydroartemisinin, mefloquine and quinine associations identified by Mu, et al. but not seen in 
our data set. The studies used different parasite population sets—theirs was weighted toward 
southeast Asian strains, and ours toward African strains—and selection pressures and selected 
alleles can both vary between populations. Our smaller sample size also means that we might 
lack power to identify some associations accessible to Mu, et al. These difficulties are reflected 
in human GWAS studies as well, where the ability to replicate associations using multiple tests 
and in different sample sets has also been challenging to achieve [41].   
Ultimately, the disparities in loci identified point to the role of population analysis as a 
tool for candidate gene discovery and not as a definitive study. Even within each study, there is 
little overlap between the signals observed with different methods—our study detects only one 
gene (pfcrt) by both GWAS tests (EMMA and HLR), while Mu, et al. detected only two genes 
(unknowns, not pfcrt) by both of their GWAS tests (Eigensoft and PLINK). Even a well-
designed GWAS serves only as a hypothesis-generating experiment, and it is vital to empirically 
validate candidate loci associated with a phenotype of interest.  Especially given the small 
sample sizes and relatively sparse marker density used in both malaria GWAS studies to date, 
functional validation of candidates is necessary to address concerns about false positive results.   
Our functional result, that increased PF10_0355 copy number confers decreased 
susceptibility to halofantrine, mefloquine and lumefantrine, raises additional questions for study.  
Further work will be needed to determine the precise contributions of copy number variation and 
gene mutation to the parasite’s response to these drugs. The biological function of this gene’s 
product is unknown, but previous work indicates putative localization to the parasite surface 
[42], as well as it being a potential target of host immunity and balancing selection [43]. While 
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the protein itself does not appear to be a transporter, it is possible that it directly binds drug or 
perhaps couples with transport proteins to modulate drug susceptibility; interaction between 
membrane transporters and non-channel proteins has been demonstrated in cancer, plant and 
yeast systems [44-46].   Additional experiments are certainly required to determine the precise 
role of PF10_0355 in modulating parasite response to this class of compounds, including 
assessing its relevance to resistance in natural populations, but it is clear that alteration of this 
locus can mediate drug resistance in P. falciparum.   
Although halofantrine, mefloquine and lumefantrine are not commonly used as primary 
interventions, widespread halofantrine use has recently been documented in West Africa. 
Notably, halofantrine was used to treat nearly 18 million patients between 1988 and 2005 [47, 
48], and it remains in production and use today. Use of halofantrine, mefloquine or lumefantrine 
as monotherapy may further explain how mutations and copy number variation in the 
PF10_0355 gene were selected. Lumefantrine is also currently used as a partner drug in the 
artemisinin-based combination therapy (ACT) Coartem.  The shorter half-life of artemether 
allows lumefantrine to be present as monotherapy, making it vulnerable to selection of drug 
resistant mutants.  As genetic loci associated with drug responses are identified and validated, 
these provide new molecular biomarkers to evaluate drug use and response in malaria endemic 
settings.  Thus, our findings have implications for defining molecular biomarkers for monitoring 
partner drug responses as intervention strategies, such as ACTs, are applied.   
Beyond identifying a novel drug resistance locus, this study illustrates the general utility 
of a GWAS approach for the discovery of gene function in P. falciparum. Even with a small and 
geographically heterogeneous sample of parasites, we identified a number of new loci associated 
with drug response and validated one of them. Larger samples from a single population will have 
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much greater power to detect additional loci, including those where multiple and low frequency 
alleles contribute to resistance. Future GWAS have the potential both to provide greater insights 
into basic parasite biology and to identify biomarkers for drug resistance and other clinically 
relevant phenotypes like acquired protection, pathogenesis, and placental malaria.   
 Future GWAS will be able to counteract the loss of power caused by low LD, either by 
focusing on parasite populations with reduced outcrossing rates, or by studying cases of very 
strong selective pressure. This issue will soon become moot, however, as the declining cost of 
whole-genome sequencing makes it practical to assay every nucleotide in the genome on a 
routine basis. Culture-adapted parasites are amenable to robust and reproducible phenotypic 
characterization, but their limitations—the potential for artifactual mutations during adaptation 
and for a biased selection of clones within a given infection—mean that genetic changes 
identified using them require both functional validation and demonstration that the changes are 
important during natural infection.  As direct sequencing of clinical isolates with demonstrable 
clinical phenotypes such as ex vivo drug response or invasion properties becomes increasingly 
feasible, sequencing will enable us to directly identify genetic changes in the parasite associated 
with clinically relevant phenotypes.  In the years ahead, genome analysis of P. falciparum has 
the potential to identify genetic loci associated with many phenotypes, enhance our 
understanding of the biology of this important human pathogen, and inform the development of 
diagnostic and surveillance tools for malaria eradication. 
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Abstract 
Malaria’s ability to rapidly adapt to new drugs has allowed it to remain one of the most 
devastating infectious diseases of humans. Understanding and tracking the genetic basis of these 
adaptations is critical to the success of treatment and other intervention strategies. The novel 
antimalarial resistance locus PF10_0355 was previously associated with parasite response to 
halofantrine, and functional validation confirmed that overexpression of this gene lowered 
parasite sensitivity to both halofantrine and the structurally related antimalarials mefloquine and 
lumefantrine. PF10_0355 copy number variation (CNV) appeared to affect parasite drug 
response in both natural parasite isolates as well as laboratory-generated transgenic lines, 
however the possible contribution of point mutations within PF10_0355 remained unknown. 
Here we further characterize the role of PF10_0355 in mediating antimalarial drug response in 
P. falciparum. Knockout of PF10_0355 increased parasite sensitivity to halofantrine, mefloquine 
and lumefantrine, but not to unrelated antimalarials, further suggesting that resistance is 
mediated by copy number variation at this locus. We focused on a single nucleotide 
polymorphism (SNP) encoding a C591S mutation in PF10_0355, which had the strongest 
association with halofantrine response. Allelic replacement experiments revealed an allele-
specific effect on drug response in the absence of copy number variation. Finally, growth 
competition experiments showed that under drug pressure, the more resistant parasite line out-
competed the more sensitive line within a small number of generations. Together these 
experiments demonstrate that modulation of PF10_0355 affects drug response in the malaria 
parasite. 
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Introduction 
 Malaria drug resistance poses a serious threat to treatment and control efforts [1] [2]. 
While resistance loci such as pfcrt, dhfr and pfmdr1 are all known to play a role in mediating 
Plasmodium falciparum drug resistance [3], the precise mechanisms of resistance for many 
antimalarials are poorly understood. Additionally, these well-known loci do not fully explain the 
range of responses observed in resistant parasites, suggesting that other loci may be involved in 
mediating parasite drug response [4] [5]. 
PF10_0355, also called MSP3.8 and PfMSPDBL2, is a novel antimalarial resistance locus 
recently identified in a genome-wide association study (GWAS) of 50 global parasite isolates 
using a high-density SNP array [6]. Overexpression of either the sensitive or resistant allele of 
PF10_0355 made parasites less sensitive to halofantrine, mefloquine and lumefantrine, but not to 
structurally unrelated antimalarials. While this work validated PF10_0355 as a novel 
antimalarial resistance locus, the gene was originally identified through association between 
SNPs and drug response and the possible effects of these mutations on parasite drug response 
remained unclear.  
PF10_0355 is a merozoite surface protein containing a Duffy binding-like (DBL) domain 
as well as a secreted polymorphic antigen associated with merozoites (SPAM) domain [7]. The 
PF10_0355 DBL domain binds to red blood cells as a dimer, and binding is dependent on 
specific metal ions [8]. Additionally, the PF10_0355 gene is highly polymorphic, appears to be 
under balancing selection and is a likely target of host immunity [9]. Immunofluorescence 
studies have shown that PF10_0355 is located on the merozoite surface in both schizonts and 
free merozoites [7] [8], despite lacking a membrane anchor.  
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Here we further characterize the role of PF10_0355 in mediating parasite response to 
antimalarial drugs. We wanted to probe the differential effects of both CNVs and SNPs on drug 
sensitivity, and we did this through knockout and allelic replacement experiments. We found that 
both copy number variation and mutations within PF10_0355 affect parasite drug response. 
Additionally, we found that moderate changes in drug response measured in the short-term can 
cause dramatic differences when parasites are competed with each other in the presence of drug. 
 
Materials and Methods 
Parasite culture and drug testing  
Parasites were maintained under standard culture conditions [10], in RPMI media 
supplemented with 5% human O+ serum and 5% Albumax II. Where indicated, parasites were 
synchronized with 5% D-sorbitol. Drug testing of knockout and allelic replacement lines was 
performed by measuring parasite incorporation of tritium-labeled hypoxanthine [11]. Other drug 
data were generated using a high-throughput SYBR Green I-based assay and results have been 
previously reported [12]. In all cases, IC50s were calculated using GraphPad Prism (San Diego, 
CA) using a four-parameter, log-logistic nonlinear regression of fluorescence intensity versus 
log10-transformed drug concentration. Drug assays were performed with at least two technical 
replicates, and data shown are averaged over at least two biological replicates. 
Generation of knockout vectors and parasite lines  
PF10_0355 knockout parasites were generated by double crossover recombination in the 
3D7 parasite background using the pCC1 vector ([13]; Uboldi et al. manuscript in prep). 
PF10_0355 knockout was confirmed by Southern blot and Western blot using rabbit polyclonal 
antibodies raised against PF10_0355 [8]. 
!!
62 
Association between PF10_0355 SNPs and halofantrine response  
Whole-genome sequencing of 45 culture-adapted parasite lines from Senegal and 
genome-wide association studies were performed previously [12]. The SNP Pf_10_001435509 
(PlasmoDB v5.0 coordinates; Pf_10_001434265 in PlasmoDB v5.5-v7.2; Pf_10_001434268 in 
PlasmoDB v9.1) encodes a cysteine-to-serine point mutation at position 591 within the SPAM 
domain of PF10_0355. SNP calls at this position in 3D7, Dd2 and the P. reichenowi Oscar strain 
were verified previously [6]. 
Allelic replacement parasites  
Allelic replacement vectors were generated by cloning the PF10_0355 gene sequence 
minus the first 74 nucleotides from Dd2 (derived allele; DR) and Senegal P26.04 (ancestral 
allele; AC) parasites into the pHH1 vector [14]. Plasmids were transfected into the Dd2 parasite 
line and stable transfectants were selected with 2.5 nM WR99210 [15]. Transfectants were twice 
cycled off WR99210 for two weeks each time, and stable integration and loss of episome was 
confirmed by Southern blot using ClaI and NotI and a probe generated with the following 
primers: F: 5’-GGG GAA AGC ATA TAA TAA TAC TAT AGA TGC-3’; R: 5’-CTT GGA 
GGA ACA AGA ACC CCC TTA TTA TCA-3’. Protein expression of HA-tagged PF10_0355 in 
the Dd2 0355 DR line was measured by Western blotting with monoclonal anti-HA and anti-
LDH antibodies using the Li-cor system (Lincoln, NE).  
Immunofluorescence was performed by harvesting mixed-stage parasites growing in 
culture, pelleting the red blood cells and washing with 1xPBS before fixing in rotating 
suspension using 4% paraformaldehyde/0.0075% glutaraldehyde for 30 minutes at room 
temperature. After washing, parasites were permeabilized in rotating suspension using 0.1% 
Triton X-100 and 3% bovine serum albumin in 1xPBS for 45 minutes at room temperature. 
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Parasites were then blocked in 3% bovine serum albumin in 1xPBS for at least one hour, 
followed by rat anti-HA 3F10 antibody (150ng/uL) staining overnight at 4 degrees. After 
washing, parasites were stained with anti-rat alexa 488 antibodies (1:750 dilution) for 1 hour at 
room temperature. Cells were mounted using Vectashield Mounting Medium with DAPI (Vector 
Laboratories, Burlingame, CA) and were imaged using the 100x objective on a Nikon Eclipse 
TE300 microscope. Images were obtained using MetaMorph software v7.5 (Sunnyvale, CA) 
with a Hamamatsu C4742-95 camera, and were processed using Adobe Photoshop CS 5.0 (San 
Jose, CA). 
Growth competition experiments  
Competition assays were performed by mixing synchronized ring-stage cultures of 0355 
DR and 0355 AC lines in equal ratios either in the absence of drug or in the presence of 1nM 
halofantrine. Parasites were harvested after 1, 4, 8, or 14 asexual cycles and genomic DNA was 
extracted. Ratios of each line were determined by quantitative real-time PCR (qPCR) using a 
custom TaqMan assay designed to detect the two different alleles of SNP Pf_10_001435509. 
Assay primer sequences were: F: 5’-GGG TCA TCA TCT CTT GAA CAA CAC T-3’ and R: 5’- 
TCG CTT TCA TTA GCT ATC TGT TCA ATA TCC-3’ and probe sequences were: Allele 1 
(0355 AC; VIC): 5’-CAA TTC TAA AGC ACT TCC CTT-3’ and Allele 2 (0355 DR; FAM): 5’- 
ATT CTA AAG CAC ATC CCT T-3’. Ct values were normalized to a standard curve of known 
genomic DNA mixtures of the two parasite lines. 
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Results 
Knockout of PF10_0355 makes parasites more sensitive to halofantrine, mefloquine and 
lumefantrine  
The PF10_0355 locus was successfully disrupted in the 3D7 parasite line (Figure 2.1).  
Southern blotting revealed disruption of the endogenous locus (Figure 2.1A; Uboldi et al. 
manuscript in prep) and Western blotting of schizont-stage parasites using anti-PF10_0355 
polyclonal antibodies revealed an absence of protein in the knockout (KO) line (Figure 2.1B). 
Drug testing by incorporation of tritium-labeled hypoxanthine showed that PF10_0355 KO 
parasites were more sensitive than 3D7 wild-type parasites to halofantrine, mefloquine and 
lumefantrine (Figure 2.1C), but had similar responses to chloroquine, artemisinin and 
atovaquone (Figure 2.1D).  
 
A mutation within the SPAM domain of PF10_0355 is associated with parasite response to 
halofantrine, mefloquine and lumefantrine  
SNP 1434268 (PlasmoDB v9.1; 1434265 in PlasmoDB v5.5-v7.2 and 1435509 in 
PlasmoDB v5.0) on chromosome 10 encodes a non-synonymous, cysteine-to-serine mutation at 
position 591 within the SPAM domain of PF10_0355. This SNP was the non-synonymous SNP 
within PF10_0355 most strongly associated with halofantrine response in a recent sequence-
based genome-wide association study (GWAS) of 45 Senegalese parasites [12]. Both the 
Plasmodium reichenowi Oscar strain and the P. falciparum 3D7 line have cysteine at position 
591 [6], suggesting that cysteine is the ancestral (AC) allele and serine is the derived (DR) allele. 
Only 9 of the 45 Senegalese parasites tested have cysteine at this position and 36 parasites have
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Figure 2.1. Knockout of PF10_0355 increases parasite sensitivity to halofantrine, mefloquine 
and lumefantrine but not to structurally unrelated drugs. A) Southern blot showing the 
PF10_0355 locus in 3D7 wild-type (WT) and knockout (KO) parasites. Digestion of the WT 
PF10_0355 locus produces a 6.6Kb band while digestion of the integrated locus produces two 
bands of 3.9Kb and 8.3Kb. B) Western blot of schizonts from 3D7 WT and KO parasite lines, 
using polyclonal anti-PF10_0355 and monoclonal anti-LDH antibodies. C) Drug responses in 
3D7 WT and KO lines to halofantrine (HFN), mefloquine (MFQ), and lumefantrine (LUM), 
measured by tritium-labeled hypoxanthine incorporation. D) Drug responses in 3D7 WT and KO 
lines to chloroquine (CQ), artemisinin (ART), and atovaquone (ATV). Drug responses are shown 
as mean ± s.e.m. of at least two biological replicates.  * P< 0.05 by two-tailed, unpaired t-test.  
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Figure 2.1 (Continued) 
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serine, resulting in a derived allele frequency of 80% in this population. Parasites with C591 
were more sensitive than those with S591 to halofantrine as well as mefloquine and lumefantrine 
(Figure 2.2, P < 0.05 for each drug). The same mutation was not significantly associated with 
parasite response to chloroquine, artemisinin or atovaquone (data not shown).  
To further investigate the association between the C591S mutation and parasite drug 
response, we generated Dd2 parasite lines where a 3’ portion of the endogenous PF10_0355 
locus was replaced by a hemagglutanin (HA)-tagged version of either the derived (0355 DR) or 
ancestral (0355 AC) allele. Stable integrants containing the 0355 DR or 0355 AC constructs 
were confirmed by Southern blotting (Figure 2.3A). Western blotting of synchronized lysates 
from the 0355 DR line using anti-HA antibodies showed proper expression of the tagged protein 
in schizonts (Figure 2.3B), and immunofluorescence showed correct localization of the HA-
tagged protein on the merozoite surface (Figure 2.3C). Drug testing by incorporation of tritium-
labeled hypoxanthine revealed that 0355 AR parasites were more sensitive than 0355 DR 
parasites to halofantrine, mefloquine and lumefantrine (Figure 2.3D), but showed similar 
responses to chloroquine, artemisinin and atovaquone (Figure 2.3E).  
 
Parasites expressing the PF10_0355 derived allele out-compete parasites expressing the 
ancestral allele under drug pressure 
We wondered if the differences we observed between 0355 DR and 0355 AC drug 
responses were relevant when parasites are directly competed with one another. 0355 DR and 
0355 AC parasite lines were synchronized and ring-stage parasites were mixed in a 1:1 ratio. 
Parasite mixtures were allowed to grow in normal media containing no drug or in media
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Figure 2.2. A mutation at position 591 within the SPAM domain of PF10_0355 is associated 
with parasite response to A) halofantrine, B) mefloquine, and C) lumefantrine in 45 Senegalese 
parasites. SNP calls and drug data are from [12]; horizontal lines show the mean IC50 for each 
group. P-values for two-tailed, unpaired t-test for S591 vs. C591 are P = .021 for halofantrine,   
P = .016 for mefloquine and P = .014 for lumefantrine. 
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Figure 2.3. Mutations in the absence of copy number variation affect parasite response to 
halofantrine and structurally related antimalarials. A) Southern blots of Dd2 wild-type (WT) and 
PF10_0355 allelic replacement parasites, where the endogenous locus has been replaced with 
HA-tagged versions of the derived allele (0355 DR, containing S591 from Dd2) or the ancestral 
allele (0355 AC, containing C591 from Senegal P26.04). Digestion of the WT PF10_0355 locus 
with ClaI and NotI generates a band at 5.0Kb while digestion of the integrated locus generates 
two bands of 4.1Kb and 8.0Kb. B) Western blot of ring, trophozoite (Troph) and schizont (Schiz) 
stage cultures of the 0355 DR line using anti-HA and anti-LDH antibodies, showing expression 
of HA-tagged PF10_0355 in schizonts. C) Immunofluorescence of a representative schizont and 
representative merozoites of the 0355 DR line using anti-HA antibodies and DAPI staining. D) 
Drug responses in 0355 DR and 0355 AC lines to halofantrine (HFN), mefloquine (MFQ) and 
lumefantrine (LUM), measured by tritium-labeled hypoxanthine incorporation. E) Drug 
responses in 0355 DR and 0355 AC lines to chloroquine (CQ), artemisinin (ART) and 
atovaquone (ATV). Drug responses are shown as mean ± s.e.m. of at least three biological 
replicates.  * P< 0.05 by two-tailed, unpaired t-test.  
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Figure 2.3 (Continued) 
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containing 1nM halofantrine, and the ratio between 0355 DR and 0355 AC parasites was 
determined after 1, 4, 8 and 14 asexual replication cycles using a quantitative real-time PCR-
based TaqMan SNP assay (Figure 2.4). The ratio of the two parasite lines was unchanged in the 
absence of drug pressure, remaining close to the 1:1 starting ratio. However when parasites were 
incubated with 1nM halofantrine, 0355 DR parasites quickly out-competed 0355 AC parasites, 
reaching a roughly four-fold excess after 8 replication cycles. These results indicate that modest 
differences in IC50s measured using the standard 72-hour drug assay can be compounded over 
time to generate large fitness differences when parasites are competed under drug pressure.  
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Figure 2.4. 0355 DR parasites outcompete 0355 AC parasites in the presence of halofantrine. 
Parasites were mixed at equal ratios and grown in no drug or in 1nM halofantrine (HFN). Ratio 
between 0355 DR and 0355 AC parasites was determined after 1, 4, 8 or 14 asexual cycles by 
quantitative real-time PCR using TaqMan probes and is shown as fold abundance of the derived 
allele. Two biological replicates (#1 and #2) are shown and error bars show standard deviation 
between technical replicates. 
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Discussion 
Drug resistance poses a serious threat to efforts aimed at eliminating malaria from 
endemic regions, and much attention is currently focused on understanding the molecular basis 
of resistance. Nonetheless, precise mechanisms of antimalarial drug action and drug resistance 
remain poorly defined, even for currently used first-line treatments [16]. In the present study, we 
wanted to know how CNVs and SNPs within PF10_0355 alter parasite susceptibility to 
antimalarials, in order to better understand the role of this locus in mediating P. falciparum drug 
response.   
Previous work showed that increased PF10_0355 copy number made parasites more 
resistant to halofantrine and structurally related antimalarials [6]. Consistent with this result, we 
found that PF10_0355 knockout parasites were more sensitive to halofantrine, mefloquine and 
lumefantrine but not to structurally unrelated drugs. Knockout parasites showed no growth 
defects compared to wild-type parasites and their increased sensitivity was limited to a specific 
class of molecules. These findings further support a role for PF10_0355 copy number variation 
in modulating parasite drug response, as drug resistance seems to scale with PF10_0355 copy 
number in a similar manner to CNVs at other drug resistance loci such as pfmdr1 and pfgchI [17] 
[18].  
 We focused on a specific mutation (C591S) within the SPAM domain of PF10_0355 for 
two reasons. First, in the original, global GWAS that identified PF10_0355 as a novel 
antimalarial resistance locus, the genome wide-significant association signal mapped to the 3’ 
portion of the gene and spanned the C591S mutation [6]. Second, C591S was the mutation 
within PF10_0355 that was most strongly associated with parasite response to halofantrine in a 
recent whole genome sequence-based GWAS [12], though the association did not reach genome-
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wide significance. Importantly, only 20% of the 45 sequenced Senegalese parasites retained the 
ancestral allele at this position, suggesting that selection of some kind has driven the derived 
allele to high prevalence. Because we used genomic DNA from natural parasite isolates to 
generate the allelic replacement constructs used here, the 0355 AC parasite line contains 
additional mutations within PF10_0355 besides C591S. While it remains possible that mutations 
other than or in addition to C591S could underlie the changes in drug response that we observed, 
these results confirm that mutations within PF10_0355, in the absence of copy number variation, 
also mediate parasite drug response. 
 The precise mechanism of how PF10_0355 affects antimalarial drug response remains 
unknown. The PF10_0355 protein localizes to the merozoite surface, despite lacking a 
membrane anchor. Other merozoite surface proteins are known to form complexes [19], and we 
found PF10_0355 to be associated with domains of MSP1 by immunoprecipitation (Appendix B, 
Figure B1). We also wondered whether PF10_0355 binds to halofantrine directly, however 
attempts to investigate this binding were confounded by high rates of non-specific drug binding 
to a reference protein (Appendix B, Figure B2). PF10_0355 was recently shown to bind to 
erythrocytes [8], suggesting that the protein may interact with a specific receptor on the red 
blood cell surface. Perhaps parasites are better able to bind and invade red blood cells in the 
presence of specific antimalarials when they have more copies of PF10_0355, or when the 
protein is in a specific conformation.  
Overall, these experiments demonstrate that genetic manipulation of PF10_0355 affects drug 
response in P. falciparum. Similar to other malaria drug resistance genes, we find effects of both 
CNVs and SNPs in modulating parasite drug response. Importantly, our findings demonstrate 
that large differences in parasite fitness can be revealed when parasites are competed over 
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multiple generations under drug pressure, as they likely would in their natural setting of an 
infected patient.   
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Abstract 
 Efforts to control and eliminate Plasmodium falciparum malaria are hampered by the 
rapid emergence and spread of drug resistant parasites. Furthermore, precise mechanisms of 
antimalarial drug resistance as well as resistance-causing mutations are largely unknown. 
Genome-wide association studies (GWASs) take an unbiased approach to identify mutations 
within the P. falciparum genome that are associated with parasite drug resistance, and generate 
hypotheses that require direct testing in order to validate novel hits. Here we take an 
overexpression approach to functionally follow-up on hits identified in previous GWASs for 
antimalarial drug resistance. We tested five genes with non-synonymous mutations that were 
associated with drug resistance in previous GWASs, as well as one hit identified by other 
approaches that had a strong, but not genome-wide significant, association signal. We 
overexpressed sensitive and resistance alleles of each candidate gene in sensitive parasite lines 
and identified putative false-positive associations that did not validate by this approach. We also 
validated true associations and found that differences in drug response were greater when the 
alleles were overexpressed in a field parasite from the same population in which the GWAS was 
conducted. Finally, we found that drug resistance hits from other studies can be combined with 
GWAS data to generate testable hypotheses. This approach is a useful way to begin to screen the 
many hits that have been and will be generated by GWASs for drug resistance determinants in 
the malaria parasite. 
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Introduction 
 Malaria caused by Plasmodium falciparum kills hundreds of thousands of people each 
year [1]. Drug resistant parasites are rampant throughout the world, and pose a serious hurdle to 
malaria treatment and control efforts. Resistant isolates of P. falciparum have been identified for 
nearly all antimalarial drugs that have ever been used, and resistance also appears to be emerging 
against artemisinin combination therapies (ACTs), the best available current treatment for 
malaria [2]. Although antimalarial drug resistance is widespread, little is known about the precise 
mechanisms of action of many antimalarials or the genetic determinants of parasite drug 
resistance. A better understanding of how drugs act and how parasites become drug resistant 
could improve antimalarial drug design, allow for more effective resistance monitoring, and 
better inform drug use. 
 The genome-wide association study (GWAS) is a useful tool to identify mutations that 
might underlie drug resistance in P. falciparum. GWASs pair genotype data in the form of single 
nucleotide polymorphisms (SNPs) with drug phenotype data, and identify SNPs that are enriched 
among drug resistant parasites. GWASs conducted in P. falciparum to date have successfully 
identified both known and novel drug resistance loci [3] [4] [5] [6], as well as loci that may 
underlie delayed clearance times in parasites exposed to ACTs [7]. The GWAS is an unbiased 
method that can identify both known and novel mutations associated with parasite drug response, 
however novel hits still require validation to verify that they are true hits and not false positive 
associations. Only one malaria GWAS to date has included functional follow-up of a novel locus 
associated with drug resistance [4]. Genetic validation in the parasite is both time and labor 
intensive, as transfection efficiency of parasites is exceedingly low and transgenic P. falciparum 
lines can take many months to generate. 
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 Genomic studies such as GWASs in malaria have several advantages over their 
counterpart studies in humans. Human GWASs are constrained by genome size as well as 
linkage disequilibrium, which causes association signals to map to large loci containing multiple 
genes. The malaria genome is 23 megabases, which is roughly on par with the human exome [8], 
and decreasing costs have made malaria full-genome sequencing approximately the same cost as 
genotyping arrays [6]. Short linkage disequilibrium, especially among African isolates of P. 
falciparum [9], means that association signals are likely to map to only one or a few genes. One 
shortfall of malaria genotyping arrays is that markers on the array are generally unable to flag 
mutations that are not genotyped, however this is not at issue when the entire genome is 
sequenced and all possible mutations are typed.  
 Here we use an overexpression approach to functionally validate six novel GWAS hits 
for parasite response to amodiaquine, chloroquine and dihydroartemisinin. We identified three 
putative false positive associations and validated two novel loci associated with 
dihydroartemisinin response. We also show how GWAS data can be combined with other studies 
to identify associations that do not reach genome-wide significance but may still be biologically 
relevant. Overall, this approach constitutes a useful method for functional follow-up of novel 
drug resistance loci in the malaria parasite. 
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Materials and Methods 
Genome-wide association studies and association tests 
 Genes for functional follow-up were selected from the following association studies: 50 
global parasite isolates genotyped using a high density SNP array and tested against 13 
antimalarials [4], and 25 or 45 Senegalese parasites that were whole genome sequenced and 
tested against 12 antimalarials [6] (Table 3.1). “25 Senegal” refers to an initial subset of the 45 
parasites that were included in [6]. Association tests used included the multi-marker haplotype 
likelihood ratio (HLR) [4], single-marker efficient mixed-model association (EMMA) and multi-
marker cross-population extended haplotype homozygosity (XP-EHH) [6]. Two hits (PFD0595w 
and PF10_0342) were generated by Meta analysis, combining p-values from both EMMA and 
XP-EHH tests [10] [11].  
Functional follow-up 
 Five hits were chosen for functional follow-up because they contained non-synonymous 
SNPs that were near or above genome-wide significance for association with drug response by 
one or more GWAS tests, and because the SNPs were in single exon genes less than 5Kb in 
length (Figure 3.1). Hits for pyrimethamine were excluded because the overexpression vectors 
used made parasites pyrimethamine resistant. One additional hit (PFI0925w) was chosen because 
it was identified in a recent study of artemisinin-resistant P. yoelii parasites [12], and a mutation 
within the P. falciparum homolog was associated with dihydroartemisinin response by GWAS.  
 For each gene chosen for functional follow-up, the full-length open reading frame (ORF) 
minus the stop codon was amplified from two different parasite lines representing the sensitive 
(sens) and resistant (res) alleles as designated by GWAS (Figure 3.1). ORFs were amplified from 
the following parasites: PF11_0302: Dd2 and Senegal P26.04; PF10_0344: Senegal P31.01 and
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Table 3.1. Genes associated with antimalarial drug resistance selected for overexpression 
functional follow-up 
Gene ID Gene Name Study Population Test SNP Drug 
PF11_0302 Parasitophorous vacuolar protein 1 (Pf-PV1) 
Array-based 
GWAS 50 world-wide HLR multiple Amodiaquine 
PF10_0344 Glutamate-rich protein (GLURP) Seq-based GWAS 25 Senegal EMMA A500P Chloroquine 
PFD0595w Conserved unknown Seq-based GWAS 25 Senegal Meta multiple Chloroquine 
PF10_0342 Probable protein, unknown function Seq-based GWAS 25 Senegal Meta multiple 
Dihydro-
artemisinin 
PFE0355c Subtilisin-like protease 3 (PfSUB3) Seq-based GWAS 25 Senegal EMMA D397Y 
Dihydro-
artemisinin 
PFI0925w Gamma-glutamylcysteine synthetase 
Other study; Seq-
based GWAS 45 Senegal EMMA I173K 
Dihydro-
artemisinin 
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Figure 3.1. Overview of experimental design. Genes were selected for functional follow-up if 
they were above or near the cut-off for genome-wide significance by GWAS, or if they were 
identified by other studies and also had signals by GWAS. Only genes with non-synonymous 
mutations in single-exon genes less than or equal to 5Kb in size were considered for follow-up. 
ORFs were cloned from parasite genomic DNA representing the sensitive and resistant alleles 
for each gene, and overexpression vectors were transfected into laboratory lines (Dd2 or 3D7) 
and the field isolate Senegal P26.04. Transgenic parasite lines were verified and then tested 
against a panel of antimalarial drugs. See Methods for additional details. 
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Figure 3.1 (Continued) 
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Senegal P26.04; PFD0595w: Senegal P31.01 and Senegal Th15.04; PF10_0342 and PFE0355c: 
Senegal P26.04 and Senegal P19.04; PFI0925w: 3D7 and Senegal P51.02. ORFs were cloned 
into the pBIC009 overexpression vector under the Hsp86 promoter [4], and were grown in E. 
coli PMC103 bacterial cells.  
Parasite culture, transfection and drug testing 
 Parasites were cultured under standard conditions [13]. Plasmid DNA was isolated from 
each of the constructs described above and DNA was transfected into Dd2, 3D7 or Senegal 
P26.04 parasites. Transfectants were selected with 2.5nM WR99210; stable transfectants were 
confirmed by episome-specific PCR and parasite background was confirmed by SNP-based 
molecular barcode [14]. Drug testing for the Dd2 parent line and PF11_0302 transfectants was 
conducted by measuring incorporation of radiolabeled hypoxanthine [15]. Drug testing for all 
other transfectants was carried out with a high-throughput, SYBR Green I-based assay [6]. 
 
Results and Discussion        
 Overexpression of GWAS hits has been used previously to validate a novel antimalarial 
resistance locus in P. falciparum [4], and has been listed as a relevant follow-up approach of 
GWAS hits in human diseases [16] [17]. Genetic manipulation in the malaria parasite is 
hampered by poor transfection efficiency, long doubling time of the parasite and a small number 
of available selectable markers. Yet when compared to knockout or allelic replacement 
experiments, overexpression of genes in P. falciparum takes the least amount of time, because 
once transfected parasites emerge they can be immediately drug tested without having to wait for 
integration of the construct or parasite sub-cloning. We therefore used overexpression to screen 
novel drug resistance loci generated by GWAS, in order to determine which hits are likely to be 
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true positive associations that warrant further functional characterization.  
Six genes were chosen for overexpression-based validation as novel antimalarial 
resistance loci (Table 3.1, Figure 3.1). Four hits (PF11_0302, PF10_0344, PFD0595w, and 
PF10_0342) were chosen because they were genome-wide significantly associated with malaria 
drug response in GWASs conducted previously [4] (Methods). Additionally, PFE0355c was the 
top hit in the genome associated with dihydroartemisinin by the EMMA association test, 
however the association fell just short of genome-wide significance. Finally, PFI0925w was 
chosen because it was implicated in artemisinin response [12] and was associated with response 
to dihydroartemisinin by GWAS [6], although the association did not reach genome-wide 
significance.     
We first tried overexpressing the sensitive and resistant alleles for each GWAS hit in the 
standard laboratory parasite lines Dd2 and 3D7 (Figure 3.2). Three hits (PF11_0302, 
PF10_0344, and PFD0595w) contained non-synonymous mutations that reached genome-wide 
significance for association with amodiaquine or chloroquine (Figure 3.2A, C, E), but these hits 
did not validate when the sensitive and resistant alleles were overexpressed in Dd2 or 3D7 
parasite backgrounds (Figure 3.2B, D, F). We therefore consider these hits to be putative false 
positive associations. Although these hits did not validate by our overexpression approach, it is 
possible that other follow-up approaches such as allelic replacement, knockout, or 
overexpression under the endogenous promoter could reveal a role for these genes in modulating 
parasite response to the drugs they were associated with. The global, SNP array-based GWAS 
that identified PF11_0302 included Dd2 as part of the study population, but the GWAS that 
identified PF10_0344 and PFD0595w included a population of Senegalese parasites that did not 
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Figure 3.2. Putative false positive GWAS associations. Overexpression follow-up of three 
GWAS hits suggests they may be false positive associations. A) GWAS plot showing single 
nucleotide polymorphisms (SNPs) along chromosome 11 and their association with amodiaquine 
(ADQ) response. Dashed horizontal lines in all GWAS plots indicate the cut-off for genome-
wide significant associations, and arrows point to SNPs that map to the gene of interest. B) 
Summary of ADQ response, as measured by the 50-percent inhibitory concentration (IC50), for 
Dd2 wild-type parasites (white bar), and Dd2 parasites overexpressing the PF11_0302 sensitive 
allele (Dd2+sens, yellow bar) or resistant allele (Dd2+res, red bar). C) GWAS plot showing 
SNPs along chromosome 10 and their association with chloroquine (CQ) response. D) Summary 
of CQ IC50s for 3D7 wild-type parasites (white bar), and 3D7 parasites overexpressing the 
PF10_0344 sensitive allele (3D7+sens, yellow bar) or resistant allele (3D7+res, red bar). E) 
GWAS plot showing SNPs along chromosome 4 and their association with CQ response. F) 
Summary of CQ IC50s for 3D7 wild-type parasites (white bar), and 3D7 parasites overexpressing 
the PFD0595w sensitive allele (3D7+sens, yellow bar) or resistant allele (3D7+res, red bar). Bar 
charts show mean IC50 ± standard deviation of at least three biological replicates for each 
parasite line. 
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Figure 3.2 (Continued) 
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include 3D7. Thus it remains possible that overexpressing these genes in a different parasite 
background, such as one of the Senegalese parasites used in the GWAS that generated these hits, 
might reveal an effect for these genes in parasite drug response.     
We were able to test the effect of parasite background by overexpressing sensitive and 
resistant versions of the PF10_0342 gene in both 3D7 and Senegal P26.04 parasite lines (Figure 
3.3). The association signal between mutations in PF10_0342 and parasite response to 
dihydroartemisinin (DHA) reached genome-wide significance (Figure 3.3A), but overexpression 
of the resistant allele in 3D7 parasites had no effect on DHA response (Figure 3.3B). When the 
sensitive and resistant alleles were overexpressed in the Senegal P26.04 line however, parasites 
overexpressing the resistant allele were more resistant to DHA than parasites overexpressing the 
sensitive allele, and these parasites were also more resistant than 3D7 parasites overexpressing 
the same resistant allele (Figure 3.3B, P < 0.05). When parasites were tested against artemisinin 
(ART), the resistant allele overexpressed in either genetic background made parasites more 
resistant than overexpression of the sensitive allele, however the effect was greater in the 
Senegal P26.04 background (Figure 3.3C, P < 0.05). None of the overexpressing lines showed 
differential responses to lumefantrine (LUM, Figure 3.3D), mefloquine (MFQ, Figure 3.3E), or 
chloroquine (CQ, Figure 3.3F), suggesting that the effect of PF10_0342 is specific to artemisinin 
derivatives. Finally, overexpression of the resistant allele in 3D7 made parasites slightly more 
sensitive to quinine than overexpression of the sensitive allele, however overexpression of either 
the sensitive or resistant alleles in Senegal P26.04 made parasites much more sensitive (Figure 
3.3G, P < 0.05). These results suggest that there are other loci that may exert epistatic effects on 
parasite drug response, and that follow-up experiments may yield different results depending on 
the parasite background employed. 
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Figure 3.3. PF10_0342 is a true positive GWAS association. Functional follow-up of 
PF10_0342 shows that overexpression of the resistant allele makes parasites more resistant to 
dihydroartemisnin (DHA) and artemisinin (ART), when the gene is overexpressed in the field 
isolate Senegal P26.04. A) GWAS plot showing single nucleotide polymorphisms (SNPs) along 
chromosome 10 and their association with DHA response. The dashed line indicates the cut-off 
for genome-wide significance and the arrow points to SNPs that map to PF10_0342. B) 
Summary of DHA response, as measured by fold-change in 50-percent inhibitory concentration 
(Fold IC50) relative to wild-type parasites, for transgenic 3D7 (solid bars) and Senegal P26.04 
(hatched bars) parasite lines overexpressing either the sensitive (+sens, yellow) or resistant (+res, 
red) alleles of PF10_0342. The remaining panels show drug data for the same parasites tested 
against C) ART, D) lumefantrine (LUM), E) mefloquine (MFQ), F) chloroquine (CQ), and G) 
quinine (QN). Bar charts show mean Fold IC50 ± standard deviation of at least three biological 
replicates for each parasite line. Bracketed lines show statistical comparisons between parasites, 
and stars indicate P-values < 0.05 by two-tailed, unpaired t-test.   
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Figure 3.3 (Continued) 
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We wondered if hits that fell below the cut-off for genome-wide significance might still 
identify true modulators of parasite drug resistance. The single-marker EMMA GWAS test 
identified PFE0355c as the top signal in the genome for association with DHA response, 
however the association fell just below the cut-off for genome-wide significance (Figure 3.4A). 
Similar to PF10_0342, overexpression of the resistant allele of PFE0355c in the 3D7 
background had no effect on DHA response, but an effect was apparent when the resistant allele 
was overexpressed in Senegal P26.04 parasites (Figure 3.4B, P < 0.05). Overexpression of the 
resistant allele also made both 3D7 and Senegal P26.04 parasites more resistant to ART (Figure 
3.4C, P < 0.05), but had no effect on LUM, MFQ, CQ or QN (Figure 3.4D, E, F, G). It appears 
that the threshold for genome-wide significance may be a somewhat arbitrary line and that there 
can be true association signals that fall below the significance cut-off but are still biologically 
relevant.  
We envision the GWAS as one of many tools that can be used to generate testable 
hypotheses, and we wondered if GWAS data could be combined with hits from other studies to 
identify novel drug resistance loci for functional follow-up. PFI0925w encodes the P. falciparum 
homolog of gamma-glutamylcysteine synthetase (gamma-GCS), a gene recently found to be 
down regulated in artemisinin-resistant and chloroquine-resistant Plasmodium yoelii lines [12]. 
We identified a GWAS association between a non-synonymous isoleucine-to-lysine mutation at 
position 173 within the P. falciparum gamma-GCS protein and parasite response to DHA. 
Although the association fell short of reaching genome-wide significance, it was the strongest 
DHA association signal within a 100 kilo-base region surrounding PFI0925w (Figure 3.5A). We 
therefore decided to overexpress the sensitive and resistant alleles of PFI0925w (as designated 
by the GWAS signal) in 3D7 parasites. Overexpression of the sensitive allele made parasites 
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Figure 3.4. PFE0355c overexpression alters parasite drug response. The association signal at 
PFE0355c does not reach genome-wide significance but is nonetheless a true positive GWAS 
hit. A) GWAS plot showing single nucleotide polymorphisms (SNPs) along chromosome 5 and 
their association with dihydroartemisinin (DHA) response. The dashed line indicates the cut-off 
for genome-wide significance and the arrow points to a non-synonymous D397Y SNP within 
PFE0355c. B) Summary of DHA response, as measured by fold change in 50-percent inhibitory 
concentration (Fold IC50) relative to wild-type parasites, for transgenic 3D7 (solid bars) and 
Senegal P26.04 (hatched bars) parasite lines overexpressing either the sensitive (+sens, yellow) 
or resistant (+res, red) alleles of PFE0355c. Remaining panels show drug data for the same 
parasites tested against C) artemisinin (ART), D) lumefantrine (LUM), E) mefloquine (MFQ), F) 
chloroquine (CQ), and G) quinine (QN). Bar charts show mean Fold IC50 ± standard deviation of 
at least three biological replicates for each parasite line. Bracketed lines show statistical 
comparisons between parasites, and stars indicate P-values < 0.05 by two-tailed, unpaired t-test. 
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Figure 3.4 (Continued) 
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Figure 3.5. Functional follow-up supports a role of PFI0925w in parasite response to artemisinin 
and its derivatives. Genes identified by other approaches can be combined with GWAS data to 
generate testable hypotheses. A) GWAS plot showing single nucleotide polymorphisms (SNPs) 
in a 100Kb window of chromosome 9 and their association with dihydroartemisinin (DHA) 
response. The arrow points to a non-synonymous I173K SNP within PFI0925w, which is the 
strongest association within this genomic region. B) Summary of DHA response, as measured by 
the 50-percent inhibitory concentration (IC50), for 3D7 wild-type parasites (white bar), and 3D7 
parasites overexpressing the PFI0925w sensitive allele (3D7+sens, yellow bar) or resistant allele 
(3D7+res, red bar). Remaining panels show drug data for the same parasite lines tested against 
C) artemisinin (ART), D) lumefantrine (LUM), E) mefloquine (MFQ), and F) chloroquine (CQ). 
Bar charts show mean IC50 ± standard deviation of at least three biological replicates for each 
parasite line. Bracketed lines show statistical comparisons between parasites, and stars indicate 
P-values < 0.05 by two-tailed, unpaired t-test. 
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Figure 3.5 (Continued) 
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more sensitive to DHA (Figure 3.5B, P < 0.05). Parasites overexpressing the sensitive allele 
were more also sensitive to ART, however overexpression of the resistant allele made parasites 
slightly more resistant to ART compared to overexpression of the sensitive allele (Figure 3.5C, P 
< 0.05). This suggests that there may be an allele-specific effect on drug response, as indicated 
by the GWAS signal. Drug response was unchanged when 3D7 wild-type and overexpressing 
parasites were tested against LUM, MFQ, and CQ (Figure 3.5D, E, F). Transgenic parasites were 
not generated in a field isolate for this gene, but doing so may reveal a more dramatic or 
differential effect on parasite drug response, as it has for PF10_0342 and PFE0355c. 
GWASs have the potential to identify multiple loci that individually have a small impact 
on malaria drug response, but when considered together could make the difference between 
treatment success and failure. It seems clear that parasite response to artemisinin and its 
derivatives may involve multiple genes in different biological pathways. A recent analysis of the 
HB3 x Dd2 genetic cross revealed multiple genetic loci associated with artemisinin response, as 
well as a range of responses among the progeny that was greater than that of the two parent lines 
[18]. None of the loci identified overlap with the genes studied here, however the parasites 
analyzed were derived from different populations and only variants present in either parent could 
be detected by the genetic cross. Furthermore, none of the current candidate marker genes for 
artemisinin resistance were associated with reduced in vivo sensitivity to artemisinin among 
parasites on the Thai-Cambodian border [19], suggesting that additional loci are involved in 
modulating parasite drug response in this area. 
This study highlighted three novel genes that appear to be involved in modulating 
parasite response to artemisinin and its derivatives, but a mechanistic understanding of their roles 
in parasite drug resistance remains unclear. PF10_0342 is highly polymorphic and shows peak 
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transcription during schizont and merozoite stages [20], and was also identified as a possible 
novel erythrocyte invasion and human virulence gene [21]. PFE0355c is a putative serine 
protease and little is known beyond its expression and localization within the parasite and 
parasitophorous vacuole [22] [23]. PFI0925w is the rate-limiting enzyme in the synthesis of 
glutathione, and this pathway is believed to play a role in mitigating oxidant stress on the 
parasite during infection. Unsuccessful attempts to knockout PFI0925w suggest that the gene is 
essential [24], however knockout of the gene in P. berghei showed that gamma-GCS is 
dispensable in that parasite, but that it does play a significant role in mosquito-stage parasite 
development [25]. Our finding that parasites overexpressing PFI0925w were more sensitive to 
ART and DHA is in agreement with previous results, namely that more resistant parasites show 
lower expression of the gene [12]. Nonetheless, it remains unclear exactly how PFI0925w 
mediates parasite response to these drugs.       
Overall, these findings show that overexpression is a worthwhile and useful method for 
functional follow-up of GWAS hits in the malaria parasite. We found that half of the loci we 
studied, which were all genome-wide significantly associated with parasite drug resistance, 
showed no effect on parasite drug response when tested by our approach. We also found that 
overexpression of two novel genes associated with DHA response did change parasite response 
to artemisinin and its derivatives, and that the effect was strongest when the genes were 
overexpressed in a field isolate rather than a laboratory parasite line. Finally, we show how 
GWAS data can complement other studies of genetic loci that mediate parasite drug response, 
and our findings suggest that combining independent approaches can identify additional novel 
drug resistance loci in the malaria parasite. 
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Abstract 
BACKGROUND: Malaria treatment efforts are hindered by the rapid emergence and spread of 
drug resistant parasites. Simple assays to monitor parasite drug response directly from patient 
samples are needed, as they can detect drug resistance before it becomes clinically apparent and 
inform changes in treatment policy to prevent the spread of resistant parasites. 
METHODS: We surveyed P. falciparum malaria cases in a clinic in Thiés, Senegal from 2008-
2010 and used a DAPI-based drug assay to test parasite response to amodiaquine, chloroquine 
and mefloquine in approximately 300 clinical isolates gathered directly from patients (ex vivo). 
We genotyped known drug resistance-associated mutations and culture adapted a subset of 
parasites to compare ex vivo and in vitro drug responses. 
RESULTS: The prevalence of resistance-associated mutations in pfcrt and pfmdr1 changed 
between 2008 and 2011, with some mutations increasing and others decreasing in prevalence. 
Furthermore, these mutations were associated with expected changes in ex vivo drug response. 
We also observed strong concordance between ex vivo and in vitro 50-percent inhibitory 
concentrations (IC50s) in a subset of parasite samples that were culture adapted.  
CONCLUSIONS: Directly measuring ex vivo parasite drug response complements resistance 
mutation genotyping, and both approaches provide important information about parasite drug 
response in field samples.  
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Introduction 
Plasmodium falciparum malaria has an enormous public health impact, infecting millions 
and killing hundreds of thousands of people each year [1]. Drug resistance further magnifies the 
burden of this disease, as the malaria parasite has evolved resistance to nearly every antimalarial 
drug developed to date. Recent reports of parasites with reduced susceptibility to the most 
effective current treatment, artemisinin combination therapies (ACTs) [2] [3], underscore the 
importance of closely monitoring parasite drug response and optimizing control strategies to 
prevent the spread of resistant parasites.  
Routine monitoring of known drug resistance markers can determine whether 
antimalarials will be effective against the parasites circulating in an endemic area, and can signal 
the reemergence of drug-sensitive parasites after a drug is removed from the treatment arsenal. 
Mutations in a number of loci have been shown to contribute to antimalarial drug resistance, 
including pfcrt and pfmdr1, among others [4]. These markers are important surveillance tools for 
malaria-endemic areas, and can be paired with clinical and parasite drug response data to better 
inform drug use and extend the therapeutic life of current and future treatments [5]. 
Assays that directly measure antimalarial drug response in naturally circulating parasite 
populations can detect decreases in drug efficacy before resistance becomes clinically evident 
and widespread. Two classic tests for parasite drug resistance measure inhibition of parasite 
growth by microscopic measurement of schizont maturation [6] or parasite incorporation of the 
radiolabeled metabolite hypoxanthine [7]. More recently, assays measuring parasite drug 
response by DNA staining with DAPI or SYBR Green I have been developed [8] [9]. DNA 
stain-based assays are more amenable to measuring parasite drug response directly from patient 
samples (ex vivo) because they do not generate radioactive waste and do not rely on microscopy 
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for data acquisition, which can be variable and reader-dependent. Malaria drug assays have also 
been successfully deployed in field settings, including DNA stain-based assays [10] [11] and 
ELISA-based assays that measure parasite-produced lactate dehydrogenase (LDH) and histidine-
rich protein II (HRP2) [12] [13]. 
Here we tested whether parasites circulating in Thiés, Senegal are becoming more or less 
resistant to current and previously-administered antimalarial drugs. We directly tested parasite 
drug response to amodiaquine, chloroquine and mefloquine using a previously developed DAPI-
based ex vivo assay [11]. We also genotyped known drug resistance-associated mutations in pfcrt 
and pfmdr1 to see if mutation prevalence changed over time and whether mutations correlate 
with ex vivo parasite drug response. Finally, we tested whether parasite drug responses in our ex 
vivo assay were good surrogates for in vitro drug responses following culture adaptation. 
 
Materials and Methods 
Study Population  
Individuals seeking treatment for uncomplicated Plasmodium falciparum malaria at the 
Section de Lutte Antiparasitaire (SLAP) clinic in Thiés, Senegal during the fall transmission 
seasons of 2008-2010 were tested for malaria infection by microscopy and rapid diagnostic test 
(RDT). P. falciparum-positive patients were enrolled if they met the eligibility criteria described 
below and the patient or their legal guardian provided informed written consent or assent. 
Eligibility criteria were: patients older than 2 years, axillary temperature above 37.5oC or history 
of fever within the preceding 24 hours, infection with only P. falciparum, no recent antimalarial 
drug use, and a hemoglobin level greater than 6 g/dL. Patients with symptoms of severe malaria 
were excluded and referred for appropriated care. Study protocols and informed consent 
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documents were approved by the Institutional Review Boards of both the Senegal Ministry of 
Health and the Harvard School of Public Health.   
Among 682 patients with uncomplicated malaria screened at the SLAP clinic in 2008-
2010, 291 patients met the inclusion criteria for this study. The subset of included patients was 
comparable to the larger set of screened patients with respect to demographic parameters (age, 
gender) and most clinical characteristics (temperature, hematocrit, weight) with the exception of 
parasitemia (Table 4.1). 
Sample Collection and DAPI Ex Vivo Testing   
From each subject, 5-10mL venous blood were collected and processed on the same day. 
Approximately 1mL of blood was spotted onto Whatman FTATM filter paper cards for 
subsequent DNA extraction; the remaining blood was spun at 1500rpm for 10 minutes, plasma 
and buffy coat were removed and infected red blood cells were washed twice with 
unsupplemented RPMI media. Aliquots of each sample were cryopreserved in Glycerolyte 57 
(Fenwal) supplemented with AB+ serum for subsequent culture adaptation. 
Parasites were drug tested using the previously described DAPI ex vivo assay [11]. 
Briefly, 180µL of supplemented RPMI media containing parasitized erythrocytes at 2% 
hematocrit were distributed into 96-well plates preloaded with 20µL serial dilutions of 
amodiaquine (USP 1031004), chloroquine (Sigma 6628) and mefloquine (Sigma M2319). Drug 
concentrations ranged from less than 1nM to greater than 1µM and each plate included 6-8 
negative control wells with media only. Plates contained two wells of each drug concentration 
and were prepared in a single batch and frozen prior to use. When possible, samples with 
parasitemia greater than 1% were diluted into leukocyte-free donor O+ erythrocytes to a final 
plating parasitemia of 0.5-1%. 
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Table 4.1. Clinical Parameters in Screened Patients and the Subset Included in the DAPI 
Ex Vivo Assay 
  All screened patients DAPI patients P  
Number  682 291 - 
Gender (% male) 66 64 0.68 
Age (years) 21 (15, 29) 21 (15, 27) 0.48 
Weight (kg) 57 (45, 65) 55 (42, 65) 0.64 
Temperature (oC) 38.2 (37.2, 39.9) 38.4 (37.4, 40.0) 0.12 
Hematocrit (%) 38 (32, 40) 38 (33, 41) 0.42 
Parasitemia (%) 0.50 (0.20, 1.00) 0.65 (0.40, 1.01) <.0001 
 
Median values (with interquartile ranges) are reported for age, weight, temperature, hematocrit 
and parasitemia. 
P-values were calculated using Pearson X2 for categorical variables and Wilcox rank-sum test 
for continuous variables. 
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Parasites were cultured 48-72 hours at 37oC under standard conditions (1% O2, 5% CO2, 94% 
N2) before addition of 4',6-diamidino-2-phenylindole (DAPI) solution, as described previously 
[8] [11]. Data were collected by measuring relative fluorescence units (RFUs) using a 
Fluoroskan plate reader (Thermo Scientific; ex 358nm, em 461nm). 3D7 parasites were tested on 
each batch of drug plates to control for batch variation. 
DNA Extraction, Clonality of Infection and HRM Genotyping 
DNA was extracted from 4-5 circular 6mm punches of blood preserved on Whatman 
FTATM filter paper cards using either a QIAmp DNA Blood Mini Kit (Qiagen) or a Maxwell 
DNA IQ Casework Sample Kit (Promega). Parasite genomic DNA was quantified by 
quantitative PCR and clonality of infection, defined as monoclonal or polyclonal, was assessed 
using the 24-SNP molecular barcode [14].  
High resolution melt (HRM) technology was used to genotype a set of single nucleotide 
polymorphisms (SNPs) associated with reduced drug sensitivity [15]. Briefly, 0.01ng of parasite 
template, as quantified by qPCR [14], was used for each 5µL reaction, which included 2.5x 
LightScanner Master Mix with LCGreen Plus dsDNA dye (Idaho Technology, Inc.). HRM 
analysis and genotype determination was performed on a LightScanner-384 (Idaho Technology, 
Inc).  
Culture Adaptation and In Vitro Drug Testing 
 To assess whether ex vivo drug responses were reproducible in vitro, we culture adapted 
16 parasites derived from monoclonal infections collected in 2009. Culturing was conducted 
under standard conditions [16] with gentle shaking. Parasites were in vitro drug tested against a 
panel of known antimalarials using a SYBR Green I-based drug assay [17] with modifications 
for 384-well format. Briefly, synchronized ring-stage parasites were cultured with serial dilutions 
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of test compounds in 40µL supplemented RPMI media at 1% hematocrit and 1% initial 
parasitemia, in black clear-bottom plates (Greiner Bio-one 781090). Following 72-hr incubation, 
a 1:5,000 dilution of SYBR Green I dye (Invitrogen S7563) was added and plates were stored at 
room temperature until fluorescence signal was read on a Spectramax M5 plate reader 
(Molecular Devices; ex 480nm, em 530nm).  
Calculation of IC50s and Data Exclusion 
Fluorescence data from drug assays were analyzed using GraphPad Prism (San Diego, 
CA) through a four-parameter, log-logistic nonlinear regression of fluorescence intensity versus 
log10-transformed drug concentration. To include control wells with no drug in the analysis, 1nM 
was added to each concentration value. Dose-response curves were visually inspected for fit of 
the sigmoidal dose-response model. Among 291 samples tested in the DAPI ex vivo assay, 9 
samples were considered assay failures due to no parasite growth or assay contamination and 
were excluded from further analysis. We excluded an additional 2 patient samples with an initial 
parasitemia below 0.1% and 30 samples with an initial parasitemia above 1.5%, because there 
was no clear association between initial parasitemia and fluorescence intensity in the no-drug 
wells, perhaps due to insufficient growth or saturation. 
Drug curves that did not exhibit the standard sigmoidal dose-response shape were 
classified as either fitting an exponential or linear decay model and had their IC50s estimated 
through these alternative models, or were excluded. Excluded curves were generally flat, 
possibly due to no parasite growth or assay contamination. When IC50s from technical replicates 
could not be estimated due to a single outlier point, this point was excluded. 
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DAPI Assay Validation 
Fluorescence intensity in no-drug wells was linearly correlated with input parasitemia (ρ 
= 0.51, linear slope P < .0001) (Figure 4.1A). Fluorescence signal was not substantially affected 
by human DNA from white blood cells or DNA from dead parasites, as suggested by the weak 
correlation between initial parasitemia and fluorescence signal in the maximum-drug wells (ρ = 
0.33). Dynamic range was assessed through the signal-to-noise ratio (SNR) of each assay, 
measured by dividing fluorescence signal from no-drug wells by fluorescence signal from 
maximum drug wells. Median SNR among all samples tested was 4:1 (Interquartile Range = 3:1, 
6:1) (Figure 4.1B). SNR was weakly correlated with parasitemia (ρ = 0.26, P < 0.001) and was 
not different across years (Kruskal-Wallis P = 0.29). We also calculated the Z’-factor for each 
assay using the following equation: Z’ = 1- [(3 standard deviations of positive controls + 3 
standard deviations of negative controls)/absolute difference between negative and positive 
controls] [18]. The median Z’-factor among all assays was 0.61 (Figure 4.1C).  
Reliability of the DAPI assay was measured by evaluating agreement between technical 
replicates in the untransformed scale using the intraclass correlation coefficient (ICC, calculated 
using irr in R-2.11.1 for Windows) for agreement. We analyzed only sigmoidal curves to avoid 
biases due to lack of fitness of different IC50 curve-fitting models. Agreement between the two 
technical replicates for each subject was excellent (Figure 4.1D-F). For all drugs, mean 
differences in IC50 between replicates were approximately zero, as expected. Except for a few 
outliers, differences between replicates were small compared with the IC50 range of each drug.  
Data Analysis 
Data analysis was performed in GraphPad Prism (v5.0d, San Diego, CA) and R-2.11.1 
for Windows. To monitor population drug sensitivity, IC50 variations over time were measured 
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Figure 4.1. Validation of the DAPI ex vivo drug assay. A) Fluorescence intensity versus initial 
parasitemia of maximum growth (no-drug) wells for parasites tested in the DAPI ex vivo assay. ρ 
= 0.51, linear slope P < .0001. B) Signal-to-noise ratio (SNR), and C) Z’-factor for parasites 
tested in the DAPI assay, shown as box plots with whiskers extending to the 2.5th and 97.5th 
percentiles. D-F) Bland-Altman plots of differences between IC50s of each technical replicate vs. 
average IC50 for D) amodiaquine, E) chloroqine, and F) mefloquine. Horizontal lines indicate the 
mean difference in IC50 between replicates. Intraclass correlation coefficients (ICC, with 
corresponding 95% confidence intervals in parentheses) are displayed on each graph. To aid data 
visualization, two outlier points are not shown in panels D and F and three outlier points are not 
shown in panel E. 
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Figure 4.1 (Continued) 
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through linear regression with log10-transformed IC50s. Primary analysis focused on non-linear 
trends (using indicator variables for years) but results were confirmed by assessing linear trends. 
We used multiple regression models to measure whether IC50s changed significantly over time 
after accounting for the effect of potential confounders. We also evaluated associations between 
IC50s and possible predictors such as parasitemia (natural logarithm-transformed). Percentage 
changes in IC50 were calculated by exponentiating regression coefficients, subtracting one, and 
multiplying the result by 100. The equivalent calculation, using clonality of infection as an 
example, would be 100 x [IC50 (polyclonal infection) - IC50 (monoclonal infection)] / IC50 
(monoclonal infection). For age, ln(parasitemia) and hematocrit, we evaluated the linearity of the 
association by a generalized additive model. For each individual covariate the results of all 
models were comparable, therefore we report the results including all covariates.   
We tested whether the prevalence of any drug resistance marker changed over time by 
Pearson Χ 2 (or Fisher’s exact test, as appropriate). We assessed whether there was an association 
between IC50 and the occurrence of drug resistance-associated mutations in pfcrt and pfmdr1 
through the Wilcoxon rank-sum test. Finally, we assessed whether IC50s measured ex vivo were 
comparable to in vitro IC50s from culture-adapted parasites by calculating the intraclass 
correlation coefficient (ICC) for consistency, and by linear regression. 
 
Results 
Distribution of Parasite Drug Responses Across Years 
 The purpose of malaria drug resistance monitoring is to evaluate parasite response to 
antimalarial drugs and/or the prevalence of resistance mutations, and to examine changes in a 
population over time. We tested P. falciparum drug response in patient samples collected over 
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three years from a clinic in Thiés, Senegal using a DAPI-based ex vivo assay [11]. Parasite drug 
responses measured each year are shown in Figure 4.2 and are summarized in Table 4.2. All 
parasites tested except one had amodiaquine IC50s less than 70nM, suggesting that sensitivity to 
this drug is maintained in Senegal despite the fact that amodiaquine has been widely 
administered since 2006 [19]. The proportion of parasites resistant to chloroquine (IC50 greater 
than 100nM) was 26.5% in 2008, 11.5% in 2009 and 22.7% in 2010, indicating that chloroquine-
resistant parasites continue to circulate in this area. Mefloquine IC50s varied within the same 
range as chloroquine, from the single to hundreds of nanomolar. 
Parasite drug response across years was significantly different only for mefloquine 
(Figure 4.2; P of categorical year in linear regression of log10IC50 = 0.01), however mefloquine 
summary statistics were similar across years (Table 4.2). Of the three drugs tested, none had a 
consistent trend of increasing or decreasing IC50 over time, suggesting that parasite responses 
stayed constant throughout the study period. There were notable changes from one year to the 
next, however: median IC50s for both amodiaquine and chloroquine decreased from 2008 to 2009, 
but increased again in 2010. Conversely, the median IC50 for mefloquine was slightly higher in 
2009 compared to both 2008 and 2010. 
Prevalence of Resistance-Associated Mutations Over Time  
While we did not observe large temporal changes in parasite drug response as measured 
by the DAPI ex vivo assay, the prevalence of resistance-associated mutations in both pfcrt and 
pfmdr1 did change between 2008 and 2010 (Figure 4.3). The mutant pfcrt haplotype at amino 
acids 72-76 as well as A220S were found in more than 50% of patient samples in 2008, and 
while not significant, both mutations decreased between 2008 and 2010. Conversely, the pfcrt 
N326S and I356T mutations were much less prevalent, and both mutations increased slightly 
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Figure 4.2. IC50s in Senegalese parasites tested with the DAPI ex vivo drug assay in 2008, 2009 
and 2010. Scatter plots show log10-transformed IC50s for A) amodiaquine, B) chloroquine, and 
C) mefloquine. Horizontal lines indicate median IC50s for each year. The asterisk in panel A 
indicates an IC50 off-scale (amodiaquine IC50 = 1140nM). P-values of categorical year in linear 
regression of log10IC50 were 0.14 for amodiaquine, 0.43 for chloroquine, and 0.01 for mefloquine. 
P-values for linear trend were 0.52 for amodiaquine, 0.92 for chloroquine, and 0.12 for 
mefloquine. 
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Table 4.2. Parasite Drug Responses Measured in the DAPI Ex Vivo Assay 
  2008 2009 2010 
Amodiaquine       
Number 85 78 80 
Median IC50 9.6 6.5 11.2 
Interquartile Range 5.8, 15.8 11.9, 114.9 10.0, 58.6 
Percent resistant  4.7% 5.1% 5.0% 
Chloroquine 
   Number 83 78 75 
Median IC50 30.7 15 22.4 
Interquartile Range 5.2, 9.6 9.1, 79.5 28.3, 56.6 
Percent resistant  26.5% 11.5% 22.7% 
Mefloquine       
Number 85 70 81 
Median IC50 34.5 44.6 32.6 
Interquartile Range 8.5, 16.3 13.0, 92.0 20.8, 48.1 
Percent resistant  2.4% 1.4% 1.2% 
 
IC50 values are in nM. Resistance cut-offs were 100nM for chloroquine, and mean plus 2 
standard deviations within each year for amodiaquine and mefloquine. 
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Figure 4.3. Prevalence of resistance-associated mutations in A) pfcrt, and B) pfmdr1 over time, 
measured by high-resolution melt (HRM) technology. Prevalence was calculated by dividing the 
number of samples containing at least one mutant allele by the total number of samples tested 
each year. *P ≤ 0.05 by Pearson X2. **P < .0001 by Fisher’s exact test.  
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between 2008 and 2010 (Pearson Χ2 P = 0.08 and P = 0.047 for N326S and I356T, respectively). 
Prevalence of the Y184F and D1246Y mutations in pfmdr1 also increased over time (Pearson Χ2 
P < .0001 and Fisher’s exact test P < .0001, respectively) however the prevalence of N1042D 
decreased over time (Fisher’s exact test P < .0001) and the prevalence of N86Y did not change.  
Correlation Between Resistance Mutations and Ex Vivo Drug Response 
 We next looked for associations between resistance markers and ex vivo parasite drug 
responses (Table 4.3). Increased amodiaquine IC50 was associated with the mutant pfcrt 
haplotype at amino acids 72-76 as well as pfcrt A220S and pfmdr1 D1246Y, however the 
differences in median IC50 between samples with and without each mutation were small. 
Chloroquine resistance was strongly associated with all the mutations we genotyped in pfcrt, as 
well pfmdr1 N86Y and D1246Y. Increased mefloquine sensitivity was significantly associated 
only with pfmdr1 N86Y and D1246Y mutations. We did not detect significant associations 
between responses to any of the three drugs and pfmdr1 Y184F or N1042D. 
Association Between Clinical Parameters and Ex Vivo Drug Response 
 We wanted to know whether ex vivo drug responses were influenced by clinical variables, 
including clonality of infection, hematocrit, age and parasitemia. Parasite IC50s for each drug 
were not associated with clonality, measured as either monoclonal or polyclonal by the 
molecular barcode [14] (Table 4.4). IC50s were similarly not associated with patient hematocrit 
or age. In agreement with previous findings [20], the only statistically significant predictor of 
IC50 was parasitemia, which was significant in both crude and adjusted analyses and in all 
models, with both the percent change in IC50 and P-values similar in all models.  
Correlation Between Parasite IC50s Ex Vivo and In Vitro 
 IC50s calculated ex vivo may be confounded by host factors and assay variability. 
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Table 4.3. IC50 Distributions of Mutant and Wild Type Alleles for Genotypes Associated 
with Antimalarial Drug Resistance 
 
 
Allele 
Median IC50 (Interquartile Range) 
         Amodiaquine              Chloroquine   Mefloquine 
wild-type mutant P  wild-type      mutant     P  wild-type mutant P 
 N(wt)/N(mut)            
pfcrt 72-76a 9 (5,14) 11 (7,18) 0.01  13 (10,23) 94 (48,173) < 0.0001  45 (21,60) 34 (20,51)      0.09 
132/138                  
pfcrt A220S 9 (5,13) 11 (7,19) 0.001  13 (10,23)   94 (48,173) < 0.0001  45 (21,60) 34 (21,51)   0.2 
133/137            
pfcrt N326S 9 (6,16) 10 (6,18) 0.7  25 (12,93) 109 (64,163) 0.01   38 (21,57) 36 (20,50)      0.5 
247/21                  
pfcrt I356T 10 (6,16) 10 (6,16) 0.6  24 (12,79) 97 (44,119) < 0.0001  38 (20,56) 36 (22,58)   0.8 
228/42            
pfmdr1 N86Y 10 (6,15) 10 (6,20) 0.4  26 (12,85) 106 (13,202) 0.02   44 (26,59) 17 (9,22) < 0.0001 
224/41                  
pfmdr1 Y184F 10 (6,18) 10 (6,15) 0.6  28 (12,115) 26 (13,93) 0.4  44 (21,62) 35 (21,51) 0.08 
 123/148            
pfmdr1 N1042D 10 (6,16) 8 (5,16) 0.3  26 (12,94) 47 (15,115) 0.5   37 (21,56) 38 (18,59)     0.8 
239/31                  
pfmdr1 D1246Y 10 (6,15) 24 (19,31) < 0.0001  26 (12,91) 220 (202,268) < 0.0001  38 (22,57) 16 (13,19) 0.0005 
        264/10                    
            
IC50 values are in nM. N(wt) = number of samples possessing only the wild-type allele. N(mut) = 
number of samples possessing at least one mutant allele. Genotypes were determined by high-
resolution melt (HRM) genotyping. Analysis excludes rare genotypes, (genotypes present at less 
than 2.5%). P-values were calculated using the Wilcoxon rank-sum test. 
apfcrt protein positions 72-76 were all perfectly correlated and were analyzed as a haplotype 
rather than individually.  
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Table 4.4. Association Between Clinical Parameters and IC50s Measured in the DAPI Ex 
Vivo Assay 
Variable Percent (%) Change P 
Amodiaquine (N = 243a) 
Clonality (monoclonal vs. polyclonal) -4 0.46 
Hematocrit (per % unit) 0.8 0.09 
Parasitemia (per ln unit) 18 < 0.001 
Age -0.1 0.59 
Chloroquine (N = 236a) 
Clonality (monoclonal vs. polyclonal) 6 0.49 
Hematocrit (per % unit) 0.3 0.65 
Parasitemia (per ln unit) 18 0.006 
Age -0.2 0.91 
Mefloquine (N = 236a) 
Clonality (monoclonal vs. polyclonal) -8 0.17 
Hematocrit (per % unit) -0.8 0.07 
Parasitemia (per ln unit) 18 <0.001 
Age -0.1 0.80 
 
Association is measured by linear regression of IC50 with clinical and demographic variables that 
could impact drug response. Analyses included all variables simultaneously, including 
temperature; all models produced comparable coefficients and P-values. ln = natural logarithm.  
a Patients with non-sigmoidal drug curves were excluded from this analysis. 
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Therefore, we culture adapted 16 parasites derived from monoclonal infections collected in 2009 
and repeated drug testing on the culture-adapted lines. Chloroquine IC50s were consistent 
between ex vivo and in vitro measurements (Pearson ρ = 0.94; ICC for consistency = 0.80) 
(Figure 4.4). We also observed good agreement between mefloquine IC50s (ρ = 0.86). 
Associations between amodiaquine IC50s measured ex vivo and in vitro were weaker, likely 
because all parasites tested were sensitive to the drug and the range of observed IC50s was 
narrow.
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Figure 4.4. Comparison of ex vivo with in vitro IC50s for chloroquine among 16 culture-adapted 
parasites collected in 2009. All parasites were derived from monoclonal infections. Ex vivo IC50s 
were measured using the DAPI ex vivo assay and in vitro IC50s were measured using a high-
throughput SYBR Green I assay. Mean in vitro IC50s are plotted with error bars showing the 
standard error of at least two biological replicates. ρ denotes the Pearson correlation coefficient.
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Discussion 
Ex vivo assays are an important tool for malaria drug resistance monitoring in direct 
patient samples. These assays complement in vivo studies by allowing researchers to test parasite 
response to different compounds individually and in the absence of patient factors that might 
introduce noise or confound results. Importantly, ex vivo monitoring of malaria parasite drug 
response can provide an early warning of decreased parasite sensitivity before parasites become 
highly resistant and cause infected patients to fail drug treatment.  
The IC50s we observed in Thiés, Senegal between 2008 and 2010 were comparable to 
other ex vivo studies of P. falciparum drug response [10] [21] [22]. Drug use in Senegal changed 
from chloroquine monotherapy to sulfadoxine, pyrimethamine and amodiaquine combination 
therapy in 2003, and again to ACTs in 2006 [19]. While the number of chloroquine-resistant 
parasites we tested decreased between 2008 and 2009, this was followed by a near doubling 
between 2009 and 2010, suggesting that chloroquine sensitivity may not be returning to Senegal 
as rapidly as it has to other areas [23] [24] [25]. Data from future years of ex vivo monitoring will 
be needed to observe how parasite drug responses continue to change in this population.  
The prevalence of several resistance-associated mutations in pfcrt and pfmdr1 varied 
between 2008 and 2011, with some mutations increasing and others decreasing in prevalence. 
We found a higher prevalence of the mutant pfcrt 72-76 haplotype than recent reports either of 
the mutant haplotype elsewhere in Senegal [26], or the K76T mutation in Dakar [27], but similar 
to these reports there appears to be a decreasing trend in mutant haplotype prevalence over time. 
Nonetheless, the prevalence of mutations typed within the same gene was not consistent: the 72-
76 haplotype and A220S in pfcrt track together, but the other mutations we typed in pfcrt and all 
the mutations typed in pfmdr1 show different prevalence from one another and inconsistent 
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changes over time. This suggests that selection and/or recombination may be affecting these 
mutations differently, and that multiple selective forces, such as use of other antimalarial drugs 
or other control measures, may be acting on this population.   
When we looked for associations between known drug resistance mutations and parasite 
drug response measured ex vivo, we found strong correlations in almost all cases. All the 
genotyped pfcrt mutations as well as pfmdr1 N86Y and D1246Y were associated with 
chloroquine resistance as measured in the DAPI ex vivo assay. These mutations have been 
previously associated with chloroquine resistance and clinical treatment outcomes [28] [29]. 
Conversely, we found no association between chloroquine resistance and pfmdr1 Y184F nor 
N1042D, in disagreement with previous findings [30]. The Y184F mutation was not significantly 
associated with any of the drug we tested, but it nearly doubled in prevalence, from 36% to 70%, 
in the three years that we measured. Perhaps other drugs, such as quinine or artemisinin 
derivatives, or other selective pressures are driving this mutation to high prevalence in this 
population.  
Ex vivo drug assays have the potential for high variability, however we found that the 
DAPI assay generated reliable and reproducible estimates of parasite IC50 in clinical samples. 
The dynamic range of the DAPI ex vivo assay was greater than that observed in previously 
published antimalarial drug assays using whole blood or patient samples [31] [32]. We observed 
strong correlation between assay technical replicates, expected associations between ex vivo 
IC50s and genotyped resistance mutations, and strong correlations between ex vivo and in vitro 
drug responses in parasites that were culture adapted. It seems that even though ex vivo responses 
are only measured once, the DAPI assay still provides useful data.   
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Drug resistance monitoring using the DAPI ex vivo drug assay is a powerful tool for 
malaria control. Directly testing parasite drug responses ex vivo complements the genotyping of 
resistance mutations, and allows researchers to measure parasite response to drugs that have no 
known resistance markers. The DAPI ex vivo assay could also provide phenotype data for 
genome-wide analyses aimed at identifying novel drug resistance markers [33] [34] [35] [36]. As 
ACTs have replaced monotherapy in many areas, the ability to detect both artemisinin and 
partner drug resistance as they emerge will become increasingly important in order to inform 
treatment decisions and preserve the efficacy of these drugs.  
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Shall we dance?  
 Human and malaria evolution in an era of eradication   
 
 
 
Note: This essay was composed by Daria Van Tyne and was submitted for the  
Bowdoin Prize, Harvard University 
 
 
Summary   
Humans are intertwined in a complex evolutionary dance with Plasmodium falciparum—
the parasite responsible for the fatal disease we know as malaria. Today, our sights are set on 
malaria eradication, yet achieving this goal requires that we first appreciate the resilience of our 
relationship with this important parasite. 
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Falcutate magis quam violentia.1 
- Hippocrates 
 
Dynamics of a disease 
 The child sits limply on her mother’s lap, her lips parted, eyes half closed. 
Outside the clinic, the hot African sun takes no prisoners—it beats down 
unrelentingly on the dirt roads of the village, the crops already parched though 
the rains have barely ceased, the tin roof and clay walls of the clinic. Mother and 
child left home before dawn in order to reach the clinic before the sun rose high 
and the child’s fever came; now she is as hot as the sun, listless and uninterested 
in the bustle of patients moving around the busy clinic. She doesn’t flinch when 
her finger is pricked. A single drop of blood reveals that she has malaria, as both 
her mother and the doctor suspected. Inside her bloodstream, the parasites are 
multiplying so quickly that they can destroy one-quarter or more of her red blood 
cells in just two days. Without treatment, the prognosis is quite grim. But with the 
proper medication, the parasites will disappear from her bloodstream in a matter 
of hours, and she will come out of her daze to resume her normal, day-to-day life. 
That is, until the next mosquito bite. 
 
 Imagine this same scene played out every eight seconds, which is about as often as 
someone becomes sick with malaria somewhere in the world.2 Sometimes the child in this story 
gets better; sometimes, for any number of reasons, they do not. The child might fall into a coma 
if the parasites adhere to the small vessels in their brain and block the blood from passing 
                                                
1 “By skill, rather than by violence.” 
 
2 "World Health Organization fact sheet on malaria." http://www.who.int/mediacentre/ factsheets/fs094/en (accessed 
November 5, 2010). 
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through. They might succumb to anemia and septic shock caused by parasites that literally eat up 
red blood cells in droves. Sometimes the patient is not a child but rather a pregnant woman in 
Mozambique, who comes perilously close to losing her baby’s life, as well as her own, when 
malaria parasites invade the placenta of a first-time mother. Sometimes the patient is a rural 
forest worker in Thailand or Brazil, who makes his living cutting down trees in the jungle until 
he is stricken with a multi-drug-resistant form of malaria that responds to treatment at first but 
comes roaring back again weeks or months later.  
These scenarios share the common thread of a terrible disease, which is both preventable 
and treatable, yet still remains a formidable obstacle to global health. In this essay, I aim to build 
an understanding of the relationship that has formed between humans and the malaria parasite. I 
view this relationship as something akin to a dance, with both partners influencing and 
responding to the actions of the other. A global campaign aimed at eradicating malaria is now 
underway, however this campaign will only be successful if we can first understand the dance – 
its tempo and rhythms, its movements and steps – that has made malaria such a remarkably 
successful infectious disease. This understanding is essential because it will form the step that 
has been missing in the past, which may allow us to finally bring the dance to a close. 
 
Setting the scene 
Our engagement with Plasmodium falciparum stretches back so far that it is difficult to 
know precisely when we, as a species, first became infected. We would undoubtedly prefer to be 
rid of malaria; P. falciparum is a parasite that causes nearly a million deaths every year.3 But this 
unique organism has responded to our attempts to eliminate it by adapting to each advance, 
                                                
3 "World Health Organization fact sheet on malaria." http://www.who.int/mediacentre/ factsheets/fs094/en Accessed 
November 5, 2010. 
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evolving ways to escape the human immune system and resistance to anti-malarial drugs. Like 
any good dance partner, we lead and it follows. Conversely, malaria has had a role in shaping our 
own evolutionary history, by preserving various red blood cell disorders that together have 
formed unmistakable malaria “fingerprints” on the human genome. As the tempo quickens and 
we now seek to eradicate malaria parasites, it is essential that we first understand the nature of 
our dance with these cunning and crafty creatures.  
 The vast majority of malaria deaths today occur in children under five years old and 
pregnant women living in Sub-Saharan Africa. However, nearly half of the world’s population – 
3.3 billion people – is at risk of being infected with Plasmodium parasites.4 In Africa, malaria 
accounts for nearly 20% of all childhood deaths and is the largest single killer of children on the 
continent. But malaria is a tremendous problem in other parts of the world as well: Southeast 
Asia is a hotbed for drug-resistant parasite strains, which first surfaced in the jungles of Thailand 
and Cambodia and quickly spread worldwide. In Latin America, as many as 3 million people are 
chronically infected with malaria;5 this high morbidity takes its toll not only on those infected 
but also on their families and local communities, through lost days of work and diminished 
productivity.  
 Clearly, malaria is an enormous global health problem. A renewed effort is currently 
underway to control malaria, and ultimately to eradicate it from the face of the earth. National 
governments, private donors, and researchers worldwide have issued calls to work together and 
"close the book" on this fatal disease. Of course, malaria eradication has been tried in the past. In 
the 1950s and 60s, the World Health Organization mobilized a global effort aimed at malaria 
                                                
4 "Malaria Key Facts." http://www.rollbackmalaria.org/keyfacts.html (accessed November 5, 2010). 
 
5 Mendis et al. (2001). The neglected burden of Plasmodium vivax malaria. American Journal of Tropical Medicine 
and Hygiene 64: 97-106. 
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eradication; its director Marcolino Candau confidently declared in 1955: "We have the tools; we 
know what needs to be done; it is [now] simply a matter of going out and doing it." 
Unfortunately, the only thing that this global campaign eradicated was interest in malaria, and a 
lack of sustained effort led to the eventual resurgence of the disease. The failure to eliminate 
malaria during the 20th century was likely in part due to a lack of understanding of the 
step/counterstep dynamic of our relationship with this parasite, whereby the forces that were 
applied toward disease eradication resulted in genetic adaptations that allowed malaria parasites 
to overcome those forces and thrive once again. The current malaria eradication effort can be 
successful only if scientists and citizens alike first understand how our uneasy dance with the 
malaria parasite came to be. We must understand how we have shaped malaria's evolutionary 
history and, conversely, how it has shaped our own evolution.  
 
Malaria 101: the basic steps 
 The disease "malaria" refers to infection with any one of five distinct species that 
scientists and doctors refer to as Plasmodium. Plasmodium falciparum, the major focus of this 
essay, is the most well known parasite of the group because it is the most widespread and most 
deadly form of malaria. But malaria can also be caused by any of four other species: Plasmodium 
vivax, Plasmodium malariae, Plasmodium ovale, or Plasmodium knowlesi, the last of which has 
only recently been discovered to infect humans.6 Malaria caused by one of these other parasites 
is generally milder than a P. falciparum infection. Nevertheless, chronic infection with a non-
falciparum species, like P. vivax, is a major contributor to the morbidity caused by Plasmodium 
parasites. 
                                                
6 Cox-Singh et al. (2008). Plasmodium knowlesi malaria in humans is widely distributed and potentially life 
threatening. Clin Infect Dis. 46(2):165-71. 
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 P. falciparum is a single-celled protozoan: it has a nucleus and is more biologically 
complex than a bacterium, but it remains fundamentally different from other unicellular 
organisms such as yeast, and equally different from the cells that make up plants and animals. 
The P. falciparum genome—all the DNA within the organism—contains 23 million molecules of 
DNA, which encode instructions for how to produce and control over 5,000 genes.7 This large 
number of genes makes malaria among the more complex of human infectious agents. By 
contrast, viruses typically have only 10 to 15 genes, while bacteria have 500-2,000 genes. 
 Plasmodium parasites were first described in the late 19th century by Alphonse Laveran, a 
French army doctor in Algeria, who observed strange-looking organisms inside the red blood 
cells of a soldier suffering from anemia and fever.8 However, the first description of the 
symptoms of malaria is much older; it is found in Chinese medical writings that date from about 
2700 B.C.E.9 In ancient Greece, Hippocrates observed patients bearing the salient symptoms of 
malaria. Noting the regular fevers and powerful chills that caused this "bad air," Hippocrates 
correctly presumed that the disease was in some way associated with the marshes that existed 
around Athens, which harbored large mosquito populations in the summer and fall.10 The malaria 
parasite was even found in King Tut's remains from 1324 B.C.E., and researchers recently 
declared that the young pharaoh likely died in part because of a severe bout of malaria caused by 
P. falciparum.11 King Tut is in pretty good company, though: other famous figures that are likely 
                                                
7 Gardner et al. (2002). Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 419(6906): 
498-511. 
 
8 Laveran A. (1893). Paludism: marsh fever and its organism. New Sydenham Society Publications 146, London. 
 
9 Man (1950) Nei Ching, the Chinese Cannon of Medicine. Chinese Medical Journal 68(1-2): 1-33. 
 
10 Cunha and Cunha (2008). Brief history of the clinical diagnosis of malaria: from Hippocrates to Osler. Journal of 
Vector Borne Diseases 45: 194-9. 
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to have died from malaria infection include Alexander the Great, Oliver Cromwell, Genghis 
Khan, and Dante Alighieri.12 
To complicate matters, the uneasy dance in which we’re locked with malaria is actually 
something of a threesome. For without female Anopheles mosquitoes acting as the middleman, 
P. falciparum could not be passed from one person to another. Inside the human bloodstream, 
malaria parasites replicate asexually, making each daughter parasite a clone of its mother. But 
deep within the belly of a mosquito, malaria takes up a sexual life cycle, whereby different 
parasites are able to swap genetic material and generate unique offspring.  
The malaria parasites that we find throughout the world today are highly diverse, 
meaning that parasites can belong to the same species but have very different DNA. There are 
tens of thousands of elementary genetic differences—scientists call them single nucleotide 
polymorphisms (“SNPs”) or mutations—which distinguish one parasite from another, much in 
the same way that people possess different traits such as hair or eye color, which are genetically 
encoded by different versions of the same genes. This happens in malaria too, but the traits are 
less aesthetic and have more to do with things like how well the parasite infects a red blood cell 
or whether it will be recognized by the human immune system and removed before it makes a 
person feel sick.  
 The elementary genetic differences that make each parasite (and each human) unique are 
the basis for the process of biological evolution. From one generation to the next, nature 
randomly introduces mutations into the genome. Usually these mutations are not beneficial, but 
in rare instances, a random mutation gives the individuals bearing it a comparative advantage 
                                                                                                                                                       
11 Hawass et al. (2010). Ancestry and pathology in King Tutankhamun's family. Journal of the American Medical 
Association 303(7): 638-47. 
 
12 "Malaria Site: History of Malaria: Famous Victims." http://www.malariasite.com/malaria/ history_victims.htm 
(accessed November 11, 2010). 
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over their peers. Advantageous mutations generally confer a greater chance of survival and 
reproductive success in a particular environment, and both of these ensure that a beneficial 
mutation will be preserved and passed on to the next generation. As a result, advantageous 
mutations can propagate rapidly through a population in just a few generations. 
 To increase the chances of hitting upon one of those rare but beneficial mutations, 
humans rely on meiosis. This is a unique process of cell division that mixes and matches 
maternal and paternal DNA and results in gametes that, when combined, produce a progeny that 
is much more diverse than a mere carbon copy of either parent would be. Plasmodium parasites, 
by contrast, achieve a similar result through a slightly different process. Asexually-replicating 
parasites in the human bloodstream are sensitive to environmental triggers, such as anemia or 
low blood sugar, which spur them to differentiate into sexual forms of the parasite. Biologists 
refer to these forms as “gametocytes.” When a mosquito ingests gametocytes, these develop 
further into male and female gametes, and the gametes subsequently combine to produce a 
unique zygote.13  
The sexual stage of the malaria life cycle allows for the shuffling of mutations that will 
ultimately prove beneficial or deleterious to parasite progeny, depending on the nature of the 
mutations and the environment that the progeny encounter. For example, a mutation that confers 
resistance to a commonly used anti-malarial drug would give the progeny bearing that mutation 
the ability to survive inside the bloodstream of people who have taken the drug. However, the 
same drug would kill their “brother” and “sister” parasites that lack the mutation, effectively 
eliminating their genes from the gene pool. This "natural selection" of organisms that are able to 
survive in a particular environment is familiar to us as evolution. When viewed from the 
                                                
13 Talman et al. (2004). Gametocytogenesis: the puberty of Plasmodium falciparum. Malaria Journal 3: 24. 
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standpoint of malaria’s relationship to its human hosts, it could also be conceived as an uneasy 
dance occurring between two hostile partners. 
The beat goes on: malaria evolution 
 Let us now take a closer look at the elaborate dance linking us with P. falciparum, and in 
particular, how malaria can “follow our lead” and adapt to the unwelcoming environments it 
encounters inside the human body.  
 Imagine that you are a malaria parasite. By necessity, you must live inside a person, 
which will involve some pretty intricate footwork. The human immune system is a complex and 
sophisticated machine designed to identify and destroy invaders, just like you. Additionally, the 
immune system is designed to “remember” each and every invader, so that the second time a 
particular pathogen tries to establish an infection, the body’s defenses are already primed against 
it. The most successful pathogens have figured out ways to bypass the immune system and thrive 
inside their human hosts—despite the body's best attempts to clear the infection. One particularly 
successful strategy for immune evasion is to constantly “change outfits,” so that the recognition 
machinery of the human immune system always thinks that you are a brand-new organism that it 
has never seen before. 
Malaria parasites do just this. The immune system normally identifies pathogens by the 
proteins that they express at surface level. By periodically switching surface proteins (namely, 
different versions of a protein called var), P. falciparum parasites are able to hide from the 
normal actions of the human immune system. To understand how this is achieved, note first that 
the malaria genome contains all of the information necessary to keep the parasite alive, including 
all of the “recipes” for each protein that it will need during its lifecycle. The P. falciparum 
genome includes at least 60 different copies of the gene that contains the var protein recipe. The 
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vars are also highly polymorphic, meaning that the protein sequence of the same var varies 
dramatically between different parasites. The ability to “switch” rapidly, displaying distinct 
versions of the var protein in succession, is what gives the parasite a leg up on our immune 
system. It takes five to seven days for the human body to mount an effective immune response to 
a pathogen that it has encountered. Since the P. falciparum life cycle in the human bloodstream 
is only 48 hours, the parasite has more than enough time to “change outfits” and switch to a 
different var protein that the immune system no longer recognizes. 
In addition to the var genes, P. falciparum contains several other groups of polymorphic 
genes that are all dedicated to the task of keeping the human immune system at bay. This kind of 
constant variation is not unique to malaria parasites; the switching of surface proteins (also 
known as antigens) in the influenza virus is the reason why people need to get a flu shot each 
year, as it would be impossible to make a vaccine that would protect against every possible flu 
strain. In the case of flu, a new vaccine is made each year that protects against the most common 
circulating virus strains. It’s possible that this approach could eventually be applied to malaria, 
though at the moment there is no easy way to identify which parasite strains are circulating in a 
particular area. Furthermore, because P. falciparum has 50-fold more genes than the influenza 
virus, it is likely that there are simply too many distinct parasite strains circulating in malaria-
endemic areas for this approach to be effective. 
With its capacity for antigenic variation, the malaria parasite clings to us like a shadow, 
despite the human immune system’s best efforts to break from its embrace. Indeed, recent 
analysis of the P. falciparum genome has revealed that the most highly diverse genes (i.e., the 
genes with the greatest number of mutations) in the entire P. falciparum genome are those that 
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encode variable surface proteins.14 This suggests that the strongest force for the selection of 
beneficial mutations in the parasite—so-called “positive selection”—is the human immune 
system itself.  
 After the human immune system, the second strongest type of selective pressure that we 
have placed on the malaria parasite involves the use of anti-malarial drugs. Interestingly, two of 
the most effective medicines for the treatment of malaria, artemisinin and quinine, are also the 
two oldest known anti-malarials. Artemisinin, extracted from the wormwood Artemisia annua, 
was first used in China as early as 168 B.C.E., and forms a crucial part of the currently 
recommended treatment for P. falciparum malaria, known as artemisinin combination therapies 
or ACTs. Quinine was discovered during the early 17th century by Jesuit missionaries in Latin 
America. After learning from indigenous tribes that tea made from the bark of the Quinquina 
calisaya tree could cure their dreaded fevers, the missionaries quickly shipped the bark back to 
Europe for the treatment of malaria there. In the mid-19th century, British colonists in India 
realized that quinine-infused tonic water could be combined with gin to make a refreshing 
beverage that also happened to have anti-malarial properties.15 Today, quinine is still widely 
used, and it remains the only recommended treatment for patients suffering from severe malaria. 
Artemisinin and quinine are not the only drugs that have been used to treat malaria, but 
unfortunately, the vast majority of anti-malarials have been rendered ineffective by the rise of 
drug-resistant P. falciparum strains. 
 Incidentally, the very same anti-malarial drug that gave scientists in the 1950s the 
confidence to declare malaria eradication possible failed because it drove the evolution of drug 
                                                
14 Volkman et al. (2007). A genome-wide map of diversity in Plasmodium falciparum. Nature Genetics 39(1): 113-
9. 
 
15 "The History of Gin and Tonic." http://www.bbc.co.uk/dna/h2g2/alabaster/A568677 (accessed November 16,  
2010). 
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resistant parasites. During the First World War, Germany was unable to obtain quinine from 
Java, where it was harvested, and as a result, German soldiers had no way to properly treat the 
malaria that many of them contracted while fighting in Southern Europe.16 This sparked the 
commission of a group of pharmaceutical chemists tasked with searching for a synthetic 
alternative to quinine, which at the time was the only available anti-malarial in Europe. The 
chemists came up with several alternative compounds that were all derivatives of quinine. One of 
these derivatives was further modified by American chemists, and this compound, named 
chloroquine, was widely hailed as a new, safe, and remarkably effective anti-malarial drug.17 
Cheap and highly effective at killing malaria parasites, chloroquine was the first (and 
last) anti-malarial drug to be mass administered to entire populations that were at risk of malaria 
infection in the tropics. Just as iodine has been added to table salt for almost a century in order to 
protect against deficiencies in this essential element, chloroquine was also added to table salt 
beginning in the 1950s in an attempt to “pre-treat” populations in malaria-endemic areas.18 
Chloroquine’s low cost and lack of toxic side effects made it an easy choice for prophylactic 
treatment—but soon, the malaria parasite mutated and chloroquine-resistant parasites rapidly 
developed in both Southeast Asia and South America. From there, resistance was quick to spread 
to Africa, and by the 1980s, chloroquine was rendered completely ineffective as a worldwide 
treatment for malaria. 
 With our newly developed ability to scan the malaria parasite’s genome for evidence of 
recent selective pressures, we are able to peer into malaria's evolutionary history. It is now 
                                                
16 Butler et al. (2010). A brief history of malaria chemotherapy. The Journal of the Royal College of Physicians of 
Edinburgh 40(2): 172-7. 
 
17 Surrey et al. (1946). Some 7-substituted 4-aminoquinoline derivatives. Journal of the American Chemical Society 
68: 113-6. 
 
18 Payne (1988). Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? 
Parasitology Today 4(4): 112-5. 
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possible to uncover the tell-tale fingerprints of recent pressures that we have imposed on the 
parasite population through the use of anti-malarial drugs, particularly chloroquine. The 
emergence of chloroquine-resistant parasites is almost entirely due to mutations in a gene that 
biologists call the chloroquine resistance transporter. This gene encodes a cellular pump that, 
when mutated, is able to quickly remove poisonous chloroquine from the parasite, allowing the 
mutant parasites to continue growing even in the presence of high concentrations of the drug.19 
An analogous mutation appeared when patients were treated with mefloquine, which selected for 
parasites bearing mutations in a separate transporter gene. Likewise, treating patients with 
pyrimethamine was met by resistance mutations in a different gene called dihydrofolate 
reductase. 
 The list of gene mutations goes on and on. Indeed, drug resistant parasites have 
developed in response to every single anti-malarial drug that has been used to treat infected 
patients. Every new drug (or step) that we try has resulted in a counterstep from the parasite; 
namely, the appearance of parasites bearing mutations that make them resistant to that drug, 
sometimes within as little as a few months. We now know that when a large population of 
pathogens (whether bacteria, viruses or parasites) is treated with a single drug for a long time, it 
is possible to select one "special" individual that has a critically beneficial mutation. This 
individual alone is able to survive in the face of the drug pressure that has been imposed. It can 
multiply and repopulate the environment, spreading its resistance mutation or mutations far and 
wide. For this reason it is critically important to monitor the efficacy of the anti-malarial drugs 
used in a particular area, and to discontinue their use in favor of other drugs if it appears that the 
parasite population has developed resistance. 
                                                
19 Martin et al. (2009). Chloroquine transport via the malaria parasite's chloroquine resistance transporter. Science 
325(5948): 1680-2. 
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 Anti-malarial drug resistance among P. falciparum parasites was one of the major 
contributors to the failed malaria eradication campaign of the 1950s and 1960s. In 2004, the 
World Health Organization finally acknowledged that any anti-malarial drug that was given 
alone would likely generate drug-resistant parasites. This so-called “monotherapy” was banned, 
and the Organization began instead to recommend treatment through combinations of drugs. 
Usually this consists of a form of artemisinin (which while effective, is rapidly broken down in 
the bloodstream) combined with a long-lasting partner drug. Currently, artemisinin combination 
therapies (ACTs) are the most widely used and most effective treatment for malaria. But a 
reduction in the efficacy of ACTs has already been observed on the Thai-Cambodian border, 
which has historically been a hotspot for drug-resistant malaria strains.20 It seems that it may 
only be a matter of time before this latest step—the move to combination therapies—results in 
parasites that are resistant to every possible drug combination that we can use.  
 
Complicated choreography: malaria’s imprint on human evolution 
 It is clear that both the human immune system and our use of anti-malarial drugs have 
had a dramatic impact on the malaria genome: we lead and the parasite follows, adapting and 
responding to our every move. But like a well-chosen dance partner, P. falciparum is also able to 
mirror our steps with its own, and in this way, malaria has had a marked effect on the 
evolutionary history of humans. In the same way that our immune systems and anti-malarial drug 
use have selected for the parasites that are most "fit" to survive in a particular environment, so 
too has P. falciparum exerted a strong selective pressure on human evolution. 
                                                
20 Noedl et al. (2008). Evidence of artemisinin resistant malaria in western Cambodia. New England Journal of 
Medicine 359: 2619-20. 
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 In the midst of the global malaria eradication effort of the 1950s, doctors and researchers 
started to notice a curious coincidence: many human red blood cell disorders are most common 
in precisely the same regions of the world where infection with malaria is most common—the 
tropics and subtropics.21 Sickle cell anemia is the classic example of this phenomenon. Among 
some African tribes, as much as 40% of the population carries sickle cell mutations in either one 
or both copies of their hemoglobin gene.22 Hemoglobin is the molecule inside red blood cells that 
delivers oxygen to all the cells in the body, and sickle cell mutations result in misshapen 
hemoglobin that is less effective at transporting oxygen to body tissues. Here a puzzle arises: if 
sickled red cells are less effective at delivering oxygen and are thus detrimental to humans, how 
can it be that evolution has not removed these deleterious mutations from the gene pool? 
 To understand how this can happen, imagine an African man and woman who both carry 
the sickle cell trait; that is, they each have one normal copy of the hemoglobin gene and one 
defective copy. If this couple has four children, the odds are that one of their children will inherit 
both copies of the sickle-cell hemoglobin gene (one from each parent) and will have a high risk 
of dying from sickle cell anemia, since the child’s red blood cells will be unable to transport 
oxygen efficiently to their body tissues. Another child is likely to receive two normal copies of 
the hemoglobin gene, and will be perfectly healthy—that is, until they are infected with P. 
falciparum and succumb to malaria. The other two children are likely to be lucky: they would 
both inherit one normal copy and one sickle cell copy of the hemoglobin gene. Like their parents, 
they might experience mild symptoms of sickle cell anemia, such as pain in their extremities, 
dizziness or shortness of breath. But because they are heterozygous for the sickle trait (meaning 
                                                
21 Allison (1954). Protection afforded by the sickle-cell trait against subtertian malareal infection. British Medical 
Journal 1(4857): 290-4. 
 
22 Each of us has two copies of every gene: one inherited from our mother and one from our father. 
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they have one normal copy and one mutated copy of the hemoglobin gene), they have a huge 
“fitness advantage” over their healthy sibling when it comes to malaria. If either of the two 
heterozygous children becomes infected with P. falciparum, the parasite will be unable to live 
within their sickled red blood cells, and they will have a much easier time surviving the 
infection. Because only half of their red cells are sickled, the children would still become 
infected with malaria, but the advantage is enough to tip the balance towards the human partner. 
This neatly explains why otherwise harmful mutations in the hemoglobin gene are preserved 
within the genomes of those at risk for malaria infection. 
 Earlier we considered scientists’ ability to scan the malaria genome in order to learn 
about the various ways that we have directed malaria’s evolution, both through our immune 
systems and more recently through the use of anti-malarial drugs. Recent analysis of the human 
genome has similarly revealed that many people living in malaria-endemic areas harbor identical 
hemoglobin mutations that cause sickle cell anemia, suggesting that they descended from a 
common ancestor that originally carried those mutations.23 The hemoglobin gene is just the tip of 
the iceberg: numerous other disorders of red blood cells, such as dysregulation of hemoglobin 
protein levels and ovalocytosis (oval-shaped red blood cells) have also been preserved in 
populations at risk for malaria infection. Indeed, malaria has shaped our genome more 
dramatically than any other evolutionary force known to date. This counterbalance of two-way 
evolutionary pressure does not exist between us and any other parasitic disease, and it makes 
malaria unique in having dramatically shaped our biological history. Like an overbearing dance 
partner, the parasite seems to pull us closer even as we try to push away. 
 
                                                
23 Kwiatkowski (2005). How malaria has affected the human genome and what human genetics can teach us about 
malaria. American Journal of Human Genetics 77(2): 171-92. 
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Exiting the floor: The "E" word 
 Our uneasy dance with the malaria parasite has endured for thousands of years; the 
constant back-and-forth has resulted in dramatic changes in both the parasite's genome and our 
own. As we now set our sights on malaria eradication, an appreciation for the resilience of our 
relationship with this parasite is critical to the understanding of how we might be able to rid 
humanity of this disease. 
 The nearly one million annual deaths caused by P. falciparum each year make malaria a 
devastating burden to global health. Yet if Bill and Melinda Gates have their way, in just a few 
years malaria will be extinct—eliminated from the planet at large and confined to biology 
research labs and textbooks. The Gates Foundation has partnered with organizations such as Roll 
Back Malaria, the Global Fund, and the Medicines for Malaria Venture, and together they have 
set the ambitious goal of completely eradicating malaria before the year 2050.24 It is an 
enormous task, but one that in principle seems feasible using currently existing technologies. We 
have anti-malarial drugs that, when given in combination, are highly effective at eliminating 
parasites from the bloodstreams of infected patients. We have insecticide-treated bed nets that 
can prevent infectious mosquito bites. We have enough knowledge of the mosquito life cycle to 
realize that simple measures, like draining standing water near homes, will reduce the numbers 
of mosquitoes to which people are exposed. Still, the fact that eradication is possible in principle 
does not mean that the task will be straightforward. 
The global malaria eradication campaign of the 1950s and 1960s was unsuccessful for 
three major reasons: (1) P. falciparum parasites became resistant to chloroquine; (2) Anopheles 
mosquitoes became resistant to insecticides, DDT chief among them; and (3) governments all 
over the world lost their political will and failed to keep up a sustained effort to identify new 
                                                
24 Roberts and Enserink (2007). MALARIA: Did They Really Say … Eradication? Science 318(5856), 1544 - 1545. 
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cases and combat malaria with education, the only tool that was still effective even after drug 
resistance had emerged and spread. While we now know much more than we did in the 1950s 
about the biology of both the parasite and the mosquito, the previous failed attempt to rid 
humanity of the scourge of malaria should make us more than a little skeptical that this parasite 
will be easily brought under control. 
 Malaria was once common throughout the United States, and for a long time it was a 
particularly large problem in the American South. As Oliver Wendell Holmes observed, malaria 
also appeared in limited outbreaks around Lake Champlain and along numerous rivers in 
Massachusetts.25 Government-led malaria eradication campaigns during the 1930s and 1940s 
successfully drove the parasite out of North America, primarily due to the draining of mosquito 
breeding habitats and through widespread use of insecticides like DDT. Malaria was successfully 
eliminated from temperate zones in the US and Europe because these areas had lower 
transmission rates compared with the tropical climates that exist in large parts of Africa and 
Asia. It was much easier to drive transmission below the level needed to propagate the infection 
when the rate of transmission was already low to begin with. These were also relatively resource-
rich areas that could afford to invest in the manpower necessary to tackle the disease. Despite the 
hard work of numerous people over many years, Anopheles mosquitoes that remain capable of 
transmitting malaria are still found throughout the United States today. As people travel to 
distant places with increasing frequency, it is not difficult to imagine how one malaria-infected 
person would have the potential to spark a new epidemic of the disease, even in America. 
 Just as we now know that the most effective treatment for a person who is sick with 
malaria is to use a combination of anti-malarial drugs, we also understand that the most effective 
way to eliminate P. falciparum from an area is to use a combination of intervention strategies. 
                                                
25 Holmes, Oliver Wendell. Medical Essays, 1842-1894. Houghton, Mifflin and Company, 1891.  p. 324. 
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This is why current efforts at malaria eradication seek to combine interventions—anti-malarial 
drugs to treat the sick, insecticides to kill mosquitoes, a malaria vaccine to protect from infection, 
and possibly even genetically-modified mosquitoes that are unable to transmit malaria parasites. 
Each strategy used alone would be relatively ineffective: parasites will become resistant to anti-
malarial drugs, mosquitoes will become resistant to insecticides, a malaria vaccine is unlikely to 
fully protect against every possible parasite strain, and genetically-modified mosquitoes may not 
survive outside of the laboratory. But even with these limitations in mind, each control strategy 
targets a separate aspect of the malaria life cycle, and thus concerted efforts that employ 
combinations of these measures have the potential to dramatically alter malaria’s impact in an 
endemic area. More important that any of these interventions, however, is the necessity for 
government leaders to continue to look for new cases of malaria for many years after control 
measures have been implemented. Only then can we be sure that our dance with the parasite has 
truly come to an end. 
 Consider the case of smallpox, the only human disease that has been successfully 
eradicated from the planet. Smallpox is a virus that only infects humans; it was eliminated in 
large part due to the development of an effective vaccine and a sustained effort to make sure that 
everyone in the entire world who could possibly be infected received the vaccine. Although P. 
falciparum is a much more complex organism, it causes a type of malaria that also only infects 
humans. While mosquitoes are required for malaria transmission, there is no other animal 
“reservoir” to which parasites can escape. In that sense, there is no option for malaria to sit out a 
song or two and then re-emerge to resume its dangerous dance with us. Thus it seems that 
combining our “tools” with enough sustained political will, the dream of the Gates Foundation is 
likely to one day come true. 
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 Oliver Wendell Holmes also noted that "Nature withheld the fatal gift of malaria,” as a 
true epidemic, from his part of the world, but “[Nature filled the world] with exhalations that 
breed the fever of inquiry in our blood and in our brain."26 This "fever of inquiry" has led us to 
turn our eyes to the inner-workings of the malaria parasite and to explore how its evolutionary 
history is tied inextricably to our own. Today, as we are called once more to work towards 
malaria eradication, we must remember the missteps of the past and appreciate the long and 
dynamic history that we have with the malaria parasite. The dance has been going on for 
thousands of years, but an end may finally be within reach. 
                                                
26 Holmes, Oliver Wendell. Medical Essays, 1842-1894. Houghton, Mifflin and Company, 1891. p. 206. 
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APPENDIX A 
 
 
 
Supplemental Methods, Tables and Figures for Chapter One:  
Van Tyne et al. (2012). Identification and Functional Validation of the Novel 
Antimalarial Resistance Locus PF10_0355 in Plasmodium falciparum. PLoS Genetics 
7(4): e1001383. 
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Supplemental Methods 
Parasites 
Parasites (Table S1) were obtained from the Malaria Research and Reagent Resource 
Repository (MR4, malaria.mr4.org) or additional sources noted (Supplemental Methods, Table 
S1, Acknowledgements). The following parasite lines were obtained through MR4: parasite line 
3D7 (MRA-151, deposited by D. Walliker); parasite line 7G8 (MRA-152, deposited by D. 
Walliker); parasite line HB3 (MRA-155, deposited by T.E. Wellems); parasite line Dd2 (MRA-
156, deposited by T.E. Wellems); parasite line K1 (MRA-159, deposited by D.E. Kyle); parasite 
line V1/S (MRA-176, deposited by D.E. Kyle); parasite line RO-33 (MRA-200, deposited by D. 
Walliker, U. Certa and R. Reber-Liske); parasite line D10 (MRA-201, deposited by Y. Wu); 
parasite line TM90C2A (MRA-202, deposited by D.E. Kyle); parasite line TM90C6A (MRA-
205, deposited by D.E. Kyle); parasite line TM91C235 (MRA-206, deposited by D.E. Kyle); 
parasite line WR87 (MRA-284, deposited by D.E. Kyle); parasite line D6 (MRA-285, deposited 
by D.E. Kyle); parasite line Malayan Camp (MRA-330, deposited by L.H. Miller and D. 
Baruch); parasite line Indochina I (MRA-347, deposited by W.E. Collins); parasite line Santa 
Lucia (MRA-362, deposited by W.E. Collins); parasite line FCC-2 (MRA-733, deposited by W. 
Trager); and parasite line T2-C6 (MRA-818, deposited by X. Su). Patient samples were obtained 
as part of ongoing studies in Senegal and Malawi described elsewhere in accordance with human 
subject guidelines. Additional parasites were the kind gift of: Alejandro Miguel Katzin (51, 
10_54, 36_89, and 9_411); Christian Happi (APO41); Abdoulaye Djimde and Chris Plowe 
(PS189); Joseph Smith (A4); Karen Day (Muz51.1); Dennis Kyle and Sodsri Thaithong (TD203, 
TD257, TM327, TM345, GH2, and PR145); Sandra do Lago Moraes (JST); and Xin-zhuan Su 
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(MR24). DNA from P. reichenowi was kindly provided by John Barnwell. 
PCR Genotyping 
Genomic regions (458850-459204) surrounding the pfcrt (MAL7P1.27) locus were 
amplified by polymerase chain reaction using oligonucleotide primer sequences 
(CCTTGTCGACCTTAACAGATG, CTATTCCACCTACCAATATAAAAC) and the resulting 
DNA sample was sequenced using standard methods. In a similar manner the genomic region 
(754984-755584) surrounding the dhfr locus (PFD0830w) (oligonucleotide primer sequences: 
CAAGATTGATACATAAAGATAATAT, TTCTTGATAAACAACGGAACCTCCT); and the 
pfmdr1 locus (PFE1150w) (oligonucleotide primer sequences: TGTTGAAAGATGGGTAAAG 
AGCAGAAAGAG, TACTTTCTTATTACATATGACACCACAAACA) were utilized [1]. 
SNP Discovery 
The SNP discovery methodology was similar to that described in Volkman 2007 [2]. 1X 
ABI shotgun sequence was obtained for nine geographically diverse parasite isolates that were 
previously sequenced to 0.25X coverage, bringing total coverage to 1.25X per isolate. These 
nine isolates include: 7G8, Santa Lucia (El Salvador), V1/S, D10, FCC-2/Hainan, D6, RO-33, 
Senegal V34.04 and K1. Three of the twelve previously sequenced isolates in Volkman 2007 
were excluded from additional sequencing, as they were previously found to be nearly 
genetically identical, suggesting possible contamination in culture [2]. Read ends with low 
quality (PHRED <10) bases were trimmed. Reads less than 100 bases, containing greater than 
3% internal N's, or containing a mononucleotide repeat covering greater than 80% of the read 
were discarded. Reads were aligned to the PlasmoDB version 5 of the 3D7 genome using 
BLAT37 [3] requiring 95% identity, a minimum score of 100, less than 20% gaps, and coverage 
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of at least half of the read. Only the highest scoring alignment for each read was kept and paired 
reads which aligned more than 10kb apart or in the wrong orientation were discarded. The 
Neighborhood Quality Standard (NQS) algorithm was used to distinguish real polymorphisms 
from sequence errors [4]. We required the SNP to have a minimum quality score of 25, and the 
five base neighborhood to have a minimum score of 20. We allowed one mismatch and no indels 
in the neighborhood. We discarded SNPs when another read from the same sample met the NQS 
criteria at that position but did not have a sequence difference. 
Array Development and Assessment 
Based on all 111,536 discovered SNPs [2,5,6] in P. falciparum, and given design 
parameters and unique sequence constraints, we were able to design assays for 74,656 markers. 
Each of 74,656 SNPs is represented by a probe set of 12 to 84 probes, for a total of 4.4 million 
genotyping probes on the Affymetrix 49-format array. These were hybridized to 63 unique 
samples (totaling 81 arrays with replicates). Genotype calls were produced using the BRLMM-P 
algorithm, a variant of the RLMM algorithm [7], included in Affymetrix Power Tools version 
1.8.5, and clustered over all 81 arrays. BRLMM-P was forced into a haploid calling mode by 
setting assigning all SNPs to the “Y chromosome” and setting all arrays to “male”. 
The array with sample TM93C1088 is eliminated immediately after clustering 
(arbitrarily, since the chip claiming to be TM90C6A and the chip claiming to be TM93C1088 are 
identical). We also remove samples CF04.010 and Senegal Th10.04, which were suspected to be 
multi-clonal based upon molecular barcode analysis [8]. A halofuginone-resistant version of 
Dd2, a human-DNA sample, and the P. reichenowi ancestral samples were also removed at this 
stage, leaving 57 unique samples (totaling 75 arrays with replicates) for analysis. We then 
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calculate a call rate for each SNP and removed 7,778 SNPs that had below an 80% call rate, 
leaving 66,878 SNPs. Since technical replicates showed 99.9% repeatability between chips, we 
merged replicate data for each of the 57 samples, producing a no-call when the replicates 
indicated discordant genotypes. 
Concordance against sequencing data was calculated in both major and minor alleles for 
17 sequenced reference strains [9]. The following 17 samples were compared against sequencing 
data for concordance: 3D7, Dd2, FCC-2, Malayan Camp, D10, K1, V1/S, RO33, D6, Senegal 
P31.01, Senegal P51.02, Senegal V34.04, Senegal V35.04, 7G8, A4 (subclone of IT04 [10]), 
Santa Lucia, and HB3. These are the 18 parasites presented in Fig 1 of Volkman 2007 [2], 
removing the three found to be genetically identical, and adding the two strains 3D7 and A4. A 
total of 18,303 SNPs lacked call overlap between array genotypes and sequencing genotypes in 
minor alleles and were thus removed, since concordance in both alleles could not be fully 
calculated. Another 30,993 SNPs were removed due to imperfect concordance, and of these 
discordant SNPs, most (28,789) exhibited monomorphic behavior on the array, suggesting that 
much of the discordance may be attributed to either a faulty assay or false discovery. The 
remaining 17,582 perfectly concordant SNPs constituted the high confidence set of assays used 
in our analyses. 
Copy Number Variation (CNV) Analysis 
We examined the ability to detect copy number variants (CNV) using the array by first 
studying a known CNV using the hybridization intensity signal of the SNP genotyping probes on 
the array. Kidgell, et al. (2006) [11] reported that the pfmdr1 locus was present in 3-4 copies in 
the Dd2 strain relative to a collection of other strains. We compared Z-scores of the normalized 
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hybridization intensity of perfect match probes for SNPs in the neighborhood of pfmdr1 for Dd2 
and six parasites estimated by Kidgell, et al. to contain only 1 copy of the locus (3D7, 7G8, HB3, 
D10, D6, K1). For each SNP assay we utilized the average hybridization intensity of all perfect-
match probes. Hybridization intensity values were background corrected and normalized to 
reduce inter-array variation artifacts. SNPs with a hybridization intensity standard deviation 
equal to or greater than half the magnitude of the average hybridization intensity across all arrays 
were excluded from analysis. Figure S11 illustrates that probes for many of the SNPs assayed 
within the pfmdr1 locus exhibit notably higher hybridization intensity values in Dd2 relative to 
the other parasites, with 13 assays exhibiting average intensities greater than 2 standard 
deviations higher than observed in the other parasites. 
Genome-wide Association Study (GWAS) 
We performed GWAS for drug resistance to thirteen antimalarials: amodiaquine (ADQ), 
artemether (ARTM), artesunate (ARTN), artemisinin (ARTS), atovaquone (ATV), chloroquine 
(CQ), dihydroartemisinin (DHA), halofuginone (HFG), halofantrine (HFN), lumefantrine 
(LUM), mefloquine (MFQ), piperaquine (PIP) and quinine (QN). 50 out of 59 samples had drug 
phenotype data. IC50 data are shown in Table S4 and Figure S13 for these 50 parasites against 
the 13 drugs. 
The following drugs were obtained from Sigma Aldrich: artemisinin, dihydroartemisinin, 
chloroquine, mefloquine, and quinine. The following were obtained from AK Scientific: 
artemether, artesunate, halofantrine, lumefantrine, and piperaquine. The following were obtained 
from USP: amodiaquine and atovaquone. Each drug was tested in triplicate for each parasite. 
Additionally, some parasites were tested with multiple biological replicates: 3D7 (nine biological 
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replicates per drug, each in triplicate), Dd2 (three replicates) and RO-33, D10, and 207-89 (two 
replicates). 
SNPs were filtered down to a set that contained at least 5 strains with a minor allele as 
well as an 80% call rate under every phenotype condition. The final data set includes 7,437 
SNPs. This gives us a genome-wide significance threshold of –log10(P-value) > 5.17 by 
Bonferroni correction for multiple testing. For binary phenotype tests (Fisher’s exact test, 
Fisher’s permuted, CMH, and HLR), we used IC50 cutoffs shown in Table S4. For tests 
requiring defined geographic clusters (CMH, HLR, Fisher’s permuted), the three population 
clusters are defined by PCA, as in the LRH analysis, and the assignments are shown in Table S1. 
Pointwise P-values were computed using PLINK [12]. Quantile-quantile plots (qq-plots) 
were used to examine the resulting P-value distributions for inflating effects due to population 
structure (Fig. S7). Because most of the genome is assumed to fit the null hypothesis (most of the 
genome should not be in association with the phenotype), significant, early deviations from this 
expectation may result in a high false positive rate. The null expectation is plotted as the unity 
diagonal line in Figure S7. Bonferroni significance is plotted as the dashed line and Benjamini-
Hochberg significance is marked with the dotted line. Since most Fisher’s results show evidence 
of inflation, we do not report these results in Figure 2 or Table 1. 
Permutations of Fisher’s exact test can be used to compute empirical pointwise P-values 
based on a simulated null distribution. We used PLINK to perform this permutation while 
respecting the phenotype frequencies present in our three predefined population clusters. The 
resulting P-value distributions (Fig. S7) do not show inflation due to population structure, 
however no significant hits were found for any drug. 
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Similarly, the Cochran-Mantel-Haenszel (CMH) test can perform population-stratified 
analyses for association. We used PLINK to compute P-values (Fig. S7), and again, we saw 
appropriate corrections for population structure, but no hits reached genome-wide (Bonferroni) 
significance. 
The Efficient Mixed-Model Association (EMMA) test was specifically designed to 
handle quantitative trait associations to a data set with complex population structure using a 
linear mixed model [13]. It calculates a genotype similarity matrix instead of discrete categories 
and does not require a priori specification of population structure. The resulting P-value 
distributions demonstrate little remaining effect from population structure (Fig. S8) while 
retaining power to find a number of associations at genome-wide significance (Fig. S8, 2A, 
Table 1). 
The Haplotype Likelihood Ratio (HLR) test is a multi-marker association test [14]. 
Unlike a standard, χ2-based multi-marker test which looks for differences in haplotype 
frequencies in cases vs. controls, the HLR test specifically models the likelihood that a single 
haplotype rose to dominance in cases while all other haplotypes proportionally decreased. It 
produces a LOD score, which is the maximum likelihood estimate for the haplotype frequencies 
observed in cases (O1...Ok), given the distribution in controls (f1...fk): 
 
where j is the haplotype on which the mutation arose, 1-α is the recombination rate, and ej=1 
when i=j and ej=0 when i≠j. The test produces maximum likelihood estimates for j and α. 
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where j is the haplotype on which the mutation arose, 1-α is the recombination rate, and ej=1 when i=j 
and ej=0 when i≠j.  The test produces maximum likelihood estimates for j and α. 
 
So while a χ2 -based association finds any significant differences in haplotype frequencies, the HLR test 
models a specific scenario that is common in rapid selective events.  The HLR test does not provide 
significantly more power than a single marker test in regions of high LD—in extreme cases, these 
regions may only have two haplotypes, and a multi-marker test will have the same power as a bi-allelic 
SNP test.  But in regions where LD is low in controls and a single, long haplotype is prevalent in cases, 
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So while a χ2-based association finds any significant differences in haplotype frequencies, 
the HLR test models a specific scenario that is common in rapid selective events. The HLR test 
does not provide significantly more power than a single marker test in regions of high LD—in 
extreme cases, these regions may only have two haplotypes, and a multi-marker test will have 
the same power as a bi-allelic SNP test. But in regions where LD is low in controls and a single, 
long haplotype is prevalent in cases, the HLR test is highly sensitive. The HLR test is a one-
sided test and we ran separate tests for both drug resistance (called “risk”) and drug sensitivity 
(“protect”). Results for drug sensitivity are available in Fig. S10, but are not reported generally 
as we are more interested in selective events for drug resistance. 
We used PLINK to produce sliding window haplotypes across the genome and calculate 
haplotype frequencies for input to the HLR test. We produced input for all two, four and six-
marker windows. The resulting LOD scores did not map well to known distributions, such as the 
χ2 1-degree of freedom distribution. We instead converted the point-wise LOD scores to 
empirical point-wise P-values by performing approximately 370,000 permutations of the null 
model for each test condition. This allows us to calculate empirical P-values up to a significance 
of about –log10(P-value) = 5.6. Similar to the permuted Fisher’s test, we preserved population-
specific phenotype frequencies by only allowing permutations within each of our three defined 
populations. Resulting P-value distributions fit expectations well for the vast majority of test 
conditions (Fig. S9, S10) and the test demonstrates power to detect a number of loci at genome-
wide significance (Fig. 2A, Table 1). 
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Supplemental Methods Figures 
Figure M1. SNPs located in genes (28,576) were more likely to pass concordance filtering than 
intergenic SNPs (19,999). 
 
 
Figure M2. SNPs that were discovered from only one sequenced strain (35,727 SNPs) show a 
higher rate of monomorphism on the array than those with higher minor allele counts (12,848 
SNPs). Any amount of this discordance may be explained by false discovery from sequencing 
data. 
 
 
 
 
 
! 160 
Figure M3. To show the effect of GC composition, we took 16bp of flanking sequence on each 
side of the SNP to construct a 3D7-based 33mer and calculated the percent GC. The window 
boundaries for the graph below are chosen as the octiles of the GC distribution. SNP 
performance appears to worsen at GC levels below 20%, which accounts for roughly half of the 
SNPs. 
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Figure M4. The effect of unique sequences in flanking regions. Although the initial design of 
the array excluded probes that had exact matches elsewhere in the genome, many of the 
remaining SNPs are in neighborhoods that contain 1 or 2 base mismatch similarity to other parts 
of the genome. We took 16bp of flanking sequence on each side of the SNP to construct a 3D7-
based 33mer and aligned it to 3D7 using SSAHA (word length 10, step length 1, max gap 2, max 
insert 1, min hits 24) [15]. 28,352 SNPs aligned uniquely to their location of origin. The 20,223 
SNPs that aligned in multiple locations showed a much higher rate of discordance. 
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Figure M5. A histogram of marker spacing. Most markers are spaced closely with a few large 
gaps in coverage. The mean spacing of concordant markers is 1316bp with a median spacing of 
444bp. 
 
 
Table M1. Statistics on marker spacing (gaps) by chromosome. The table gives the number of 
gaps, as well as the median, mean gaps, 90% percentile (90% gap), and maximum gap length 
(max gap) by chromosome (1 – 14). 
 
! 163 
Figure M6. Final concordant marker density across all fourteen chromosomes. 
 
 
 
 
Figure M7. Distribution of markers per gene: 59% of all P. falciparum genes contain at least one 
concordant marker. Below is a plot of the number of markers per gene. Most genes that have 
markers have only one or two (median marker count per gene is two). Mean marker count per 
gene is 4.1. 
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Supplemental Tables 
Table S1. 63 parasites used in the study with the name (parasite), geographic origin (region, 
country), source, and molecular barcode[8], as well as which samples were included in SNP 
discovery (SEQ), population characterization (POP), long-range haplotype (LRH), and GWAS 
analyses.  For GWAS, * indicates that the sample was used, but not included in any population 
cluster for stratified or permuted analyses.  The human control sample and the ancestral P. 
reichenowi sample were not used in any analyses reported here. 
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Table S1 (Continued) 
 
Sample'Information' Used'in'Analysis'
Parasite Region Country Source Barcode SEQ' POP'! LRH! GWAS!
51! America! Brazil! Alejandro!Miguel!Katzin! CATTGCAGACTXCACCTTAGATTG ! x! ! x!
608! America! Brazil! Alejandro!Miguel!Katzin! TACCCGGGATTACAAACTAGACTT ! x! ! x!
10_54! America! Brazil! Alejandro!Miguel!Katzin! CACTGCAGACTXTACACTAACCTG ! x! ! x!
36_89! America! Brazil! Alejandro!Miguel!Katzin! TACTGCAGATCGCCCCTACGCCTG ! x! ! x!
365_89! America! Brazil! Alejandro!Miguel!Katzin! TGCTCCGGATTACAAACAAGACTT ! x! ! !
3D7! Europe! Netherlands! MRAG151! TACTCCGGTCCGCACCCACGATGG ! x! x! *!
7G8! America! Brazil! MRAG152! TACCCCAGACTXTCAATTAACCTG x! x! ! x!
9_411! America! Brazil! Alejandro!Miguel!Katzin! CACTCCAGACTGCAACTACGACTG ! x! ! x!
A4! America! Brazil! J.!Smith! TATTCCGGTTCATACCCXAGATTG ! x! x! !
APO41! Africa! Nigeria! Christian!Happi! CATTGGGGTCTACACCCAAGACTG ! x! x! !
CF04.008_12G! Africa! Malawi! Dan!Milner! TACCCGGGACCGCCCACAAGATTG ! x! ! x!
CF04.008_1F! Africa! Malawi! Dan!Milner! TATTCGGAACCGCACCCTAAATTG ! x! x! x!
CF04.009! Africa! Malawi! Dan!Milner! TATTCCGAACCGTACCCTCGATTG ! x! x! x!
D10! Asia! PNG! MRAG201! CACTCCAGATTGCAACTTAGCTTG x! x! x! x!
D6! Africa! Sierra!Leone! MRAG285! TACTGGAAACTGCAACCAAACTTG x! x! x! x!
Dd2! Asia! Indochina/Laos! MRAG156! CATCGCAATTCGCCCCTTAGACTG ! x! x! x!
FCC2! Asia! China! MRAG733! TACCCCAAATCGCACATTAACCTG x! x! x! x!
GH2! Asia! Thailand! S.!Thaitong/D.!Kyle! CACTGCGGTTTATCAATTAGCCTG ! x! x! x!
HB3! America! Honduras! MRAG155! TACTCCAGACTACACACTCACTTG ! x! ! *!
IGHCR14! Asia! India! Aditya!Dash/Chetan!Chitnis! TACCCCAGACCXCACACTAGACGG ! x! ! *!
Indochina_I! Asia! Indochina/Laos! MRAG347! TACTCGAGTCTACAACCACGATTG ! x! x! x!
JST! America! Brazil! Sandra!do!Lago!Moraes! CACCGCGGTTTATAAACAAGATTG ! x! ! x!
K1! Asia! Thailand! MRAG159! TATTCGGATTTGTCCCTACGCCTG x! x! x! x!
M24! Africa! Kenya! X.!Su! CATTGCGGTTTACCCATAAGCCTG ! x! x! x!
Malayan!Camp! Asia! Malaysia! MRAG330! TATTCCGGATTGTCACTTAGACTG ! x! x! *!
Muz51.1! Asia! PNG! Karen!Day! TACTCCAGATTATCACCTAGCCTG ! x! x! x!
PR145! Asia! Thailand! S.!Thaitong/D.!Kyle! CACTCCAGATCACAACCAAAACTG ! x! x! x!
PS189! Africa! Mali! C.!Plowe/Djimde! CACTCCGGATTACAAACAAGCTTT ! x! x! !
RAJ116! Asia! India! Aditya!Dash/Chetan!Chitnis! CACTCCGAACTGCAACCACAACGG ! x! ! *!
RO33! Africa! Ghana! MRAG200! CACCCGGGATCGCAAACTAAACTT x! x! x! x!
Santa!Lucia! America! El!Salvador! MRAG362! CACCCGGGATTACAAACAAACCTT x! x! ! *!
SenP05.02! Africa! Senegal! S.!Mboup! CACCCGGGATTACAAACAAGCTTT ! x! x! x!
SenP08.04! Africa! Senegal! S.!Mboup! TACCCCGGATCGCAAACAAACTTT ! x! x! x!
SenP09.04! Africa! Senegal! S.!Mboup! CACTCGGGTTTATACATXCAACGT ! x! x! x!
SenP11.02! Africa! Senegal! S.!Mboup! CGCTCGAGATTACAAACTAGACTT ! x! x! x!
SenP19.04! Africa! Senegal! S.!Mboup! TGTTCCGGTCTACAAATTAACCGT ! x! x! x!
SenP26.04! Africa! Senegal! S.!Mboup! TATCCGAATTTATCAATACAACGT ! x! x! x!
SenP27.02! Africa! Senegal! S.!Mboup! TACTCCGGTTTATACACTCAACGT ! x! x! x!
SenP31.01! Africa! Senegal! S.!Mboup! TACTGCGGTCCGCAAACAAGATTG ! x! x! x!
SenP51.02! Africa! Senegal! S.!Mboup! TATCCGGGACTGCAACTTCGACGG ! x! x! x!
SenP60.02! Africa! Senegal! S.!Mboup! TACTCGAAACCGCAAACTAACCTT ! x! x! x!
SenT15.04! Africa! Senegal! S.!Mboup! TGCTCCAAATCGTACCCAAGCTGT ! x! x! x!
SenT26.04! Africa! Senegal! S.!Mboup! CGCTCGGATTTATCCCTACGCCGT ! x! x! x!
SenT28.04! Africa! Senegal! S.!Mboup! CACCCCAGTTTATCAACAAACTGT ! x! x! x!
SenV34.04! Africa! Senegal! S.!Mboup! TXCTCCAGATTATACCTAAACCTG x! x! x! x!
SenV35.04! Africa! Senegal! S.!Mboup! CGCTCGAGTCCGTCCACACACTGT ! x! x! x!
SenV42.05! Africa! Senegal! S.!Mboup! TGTTCCGATCTATCCACAAGACXT ! x! x! x!
T2_C6! Asia! Thailand! MRAG818! TACTCCGGATTATACACTAAACGT ! x! x! !
TD203! Asia! Thailand! S.!Thaithong/D.!Kyle! CGCCCCAGATCATAAATTAAACGT ! x! x! x!
TD257! Asia! Thailand! S.!Thaithong/D.!Kyle! TACTCGGGATCGTAACCACACTGT ! x! x! x!
TM327! Asia! Thailand! S.!Thaithong/D.!Kyle! TGTCCGAATCTATAAACACAACGT ! x! x! x!
TM345! Asia! Thailand! S.!Thaithong/D.!Kyle! CACCCCAGTCTATCACTACACCGT ! x! x! !
TM90C2A! Asia! Thailand! MRAG202! TATTCCGATTTATCAACTCACCGT ! x! x! x!
TM90C6A! Asia! Thailand! MRAG205! CACCCCAGTCTATCACTACACCGT ! x! x! !
TM91C235! Asia! Thailand! MRAG206! CGCTCCGGACTGCACCCAAGATTG ! x! x! x!
V1/S! Asia! Vietnam! MRAG176! TGCCCCAGATCACAACTAAGATTT x! x! x! X!
WR87! Asia! Vietnam! MRAG284! TACTGGAAATCACAACTAAGACTT ! x! x! X!
CF04.010! Africa! Malawi! Dan!Milner! mixed ! ! ! !
Dd2_HFG_280! Asia! Indochina/Laos! !  ! ! ! !
Human!Control! !! !! !  ! ! ! !
Preichenowi! !! !! John!Barnwell!  ! ! ! !
SenT10.04! Africa! Senegal! S.!Mboup! NACTNGGGACTATAACCAAACCTG ! ! ! !
TM93C1088! Asia! Thailand! MRAG207! CACCCCAGTCTATCACTACACCGT ! ! ! !
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Table S2. Analysis of the ability of SNPs on the array to act as a proxy for or “tag” other 
untyped markers on the array in genome-wide association. This ability is measured using the 
standard correlation metric r2. In our data set, 28% of SNPs in the Brazilian sample (which has 
the most LD) had a nearby SNP on the array in strong LD (r2 > 0.5) with it, while in the Senegal 
sample the proportion was only 16%. Most of the time, therefore, we will only be able to detect 
association with markers that have been directly typed. The exception is strong selective sweeps, 
which affect many markers within a region. 
 
 
  
Fraction of  
SNPs 
r2 > 0.3 r2 > 0.5 r2 > 0.8 
Senegal 26% 16% 10% 
Thailand 34% 24% 18% 
Brazil 33% 28% 24% 
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Table S3.  Long Range Haplotype (LRH) hits.  All REHH hits with Q-value < 0.25. 
 
 
chr pos core allele hap len qvalue gene description 
2 608790 G 14428 0.2071 PFB0675w hypothetical protein 
2 617743 T 16930 0.2133 PFB0685c acyl-CoA synthetase, PfACS9 
2 623146 C 22333 0.0323 PFB0687c RING zinc finger protein, putative 
3 466483 A 35321 0.0568 PFC0460w hypothetical protein, conserved 
3 466610 A 35448 0.0133 PFC0460w hypothetical protein, conserved 
4 755220 T 15162 0.1236 PFD0830w bifunctional dihydrofolate reductase-thymidylate synthase 
4 755243 C 15139 0.2133 PFD0830w bifunctional dihydrofolate reductase-thymidylate synthase 
4 764100 G 50270 0.1528 PFD0840w hypothetical protein, conserved 
5 1042120 A 18768 0.0075 PFE1250w acetyl-CoA synthetase, PfACS10 
5 1042527 A 18361 0.0085 PFE1250w acetyl-CoA synthetase, PfACS10 
5 1056621 T 14545 0.0591   
5 1159412 C 12844 0.0085 PFE1400c beta adaptin protein, putative 
5 1159501 T 12755 0.0085 PFE1400c beta adaptin protein, putative 
5 1333609 G 5132 0.2341 PFE1640w erythrocyte membrane protein 1 (PfEMP1), truncated 
5 1333639 G 5102 0.2341 PFE1640w erythrocyte membrane protein 1 (PfEMP1), truncated 
5 1333690 T 5051 0.0664 PFE1640w erythrocyte membrane protein 1 (PfEMP1), truncated 
5 1333703 A 5038 0.2341 PFE1640w erythrocyte membrane protein 1 (PfEMP1), truncated 
5 1333716 G 5025 0.2341 PFE1640w erythrocyte membrane protein 1 (PfEMP1), truncated 
5 1333729 T 5012 0.2341 PFE1640w erythrocyte membrane protein 1 (PfEMP1), truncated 
5 1333741 G 5000 0.2341 PFE1640w erythrocyte membrane protein 1 (PfEMP1), truncated 
5 1333790 A 4951 0.2341 PFE1640w erythrocyte membrane protein 1 (PfEMP1), truncated 
6 741192 A 55183 0.2335   
6 741293 C 55082 0.2133 PFF0855c rifin 
6 741366 A 55009 0.2133 PFF0855c rifin 
6 1025852 A 17872 0.2133 PFF1220w hypothetical protein, conserved 
6 1065237 G 33215 0.1492 PFF1280w hypothetical protein, conserved 
6 1098314 C 26112 0.0905 PFF1325c c3h4-type ring finger protein, putative 
6 1114565 C 25158 0.0905 PFF1350c acetyl-coenzyme a synthetase 
6 1114929 G 23554 0.0323 PFF1350c acetyl-coenzyme a synthetase 
6 1115373 A 23998 0.0323 PFF1350c acetyl-coenzyme a synthetase 
6 1115454 C 23938 0.0430 PFF1350c acetyl-coenzyme a synthetase 
6 1116047 G 24531 0.0244 PFF1350c acetyl-coenzyme a synthetase 
6 1116171 G 24655 0.0430 PFF1350c acetyl-coenzyme a synthetase 
6 1116315 C 24799 0.0430 PFF1350c acetyl-coenzyme a synthetase 
6 1117520 G 26004 0.0430 PFF1350c acetyl-coenzyme a synthetase 
6 1124426 C 32910 0.0535 PFF1365c HECT-domain (ubiquitin-transferase), putative 
6 1283916 G 13004 0.1978   
7 428373 C 39799 0.1269 PF07_0027 DNA-directed RNA polymerase 2 8.2 kDa polypeptide, putative 
7 449953 C 31672 0.0443   
7 459787 T 21838 0.0276 MAL7P1_27 chloroquine resistance transporter 
7 460216 G 21409 0.0443 MAL7P1_27 chloroquine resistance transporter 
7 461218 T 20407 0.0443 MAL7P1_27 chloroquine resistance transporter 
7 465826 G 39654 0.0953 PF07_0035 cg1 protein 
7 465826 G 16307 0.1580 PF07_0035 cg1 protein 
7 467846 G 41674 0.0130 PF07_0036 Cg6 protein 
7 467846 G 14287 0.0190 PF07_0036 Cg6 protein 
7 475935 T 46758 0.0664 PF07_0037 Cg2 protein 
7 475935 T 26989 0.1009 PF07_0037 Cg2 protein 
7 475948 A 46771 0.0664 PF07_0037 Cg2 protein 
7 475948 A 26976 0.1009 PF07_0037 Cg2 protein 
7 476288 G 47111 0.0591 PF07_0037 Cg2 protein 
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Table S3 (Continued) 
 
7 476305 C 47128 0.0443 PF07_0037 Cg2 protein 
7 476305 C 26619 0.0443 PF07_0037 Cg2 protein 
7 482133 T 10978 0.0133 PF07_0038 Cg7 protein 
7 482133 T 20791 0.0085 PF07_0038 Cg7 protein 
7 485744 G 14589 0.0133 MAL7P1_28 ribonucleases p/mrp protein subunit, putative 
7 485744 G 17180 0.0085 MAL7P1_28 ribonucleases p/mrp protein subunit, putative 
7 488164 A 15424 0.0777 MAL7P1_28 ribonucleases p/mrp protein subunit, putative 
7 488164 A 14760 0.0535 MAL7P1_28 ribonucleases p/mrp protein subunit, putative 
7 490748 C 18008 0.0323 PF07_0040 lysophospholipase-like protein, putative 
7 490748 C 14664 0.0244 PF07_0040 lysophospholipase-like protein, putative 
7 490877 T 18137 0.0323 PF07_0040 lysophospholipase-like protein, putative 
7 490877 T 14535 0.0133 PF07_0040 lysophospholipase-like protein, putative 
7 494285 A 21431 0.0551 MAL7P1_29 hypothetical protein, conserved 
7 505396 G 17088 0.2133 MAL7P1_30 hypothetical protein, conserved 
7 505412 G 17104 0.2133 MAL7P1_30 hypothetical protein, conserved 
7 936167 A 15183 0.0430 MAL7P1_105 hypothetical protein, conserved 
7 940007 G 11940 0.2133 PF07_0085 ferrodoxin reductase-like protein 
7 940111 T 12044 0.2133 PF07_0085 ferrodoxin reductase-like protein 
7 940147 A 12080 0.2133 PF07_0085 ferrodoxin reductase-like protein 
8 336524 T 6205 0.1930 MAL8P1_135 hypothetical membrane protein, conserved 
8 452794 A 778 0.1492 PF08_0105 rifin 
8 862485 A 33846 0.1239 PF08_0054 heat shock 70 kDa protein 
8 866334 C 29997 0.0443 MAL8P1_64 hypothetical protein, conserved 
8 1104023 T 8994 0.0591   
8 1114567 A 8029 0.0873 MAL8P1_23 ubiquitin-protein ligase 1, putative 
8 1117372 G 10834 0.0905 MAL8P1_23 ubiquitin-protein ligase 1, putative 
8 1118090 T 11552 0.0622 MAL8P1_23 ubiquitin-protein ligase 1, putative 
8 1118190 T 11652 0.0091 MAL8P1_23 ubiquitin-protein ligase 1, putative 
9 272201 C 12632 0.1259 PFI0265c RhopH3 
9 282410 G 11553 0.0932 PFI0275w hypothetical protein, conserved 
9 284833 T 12260 0.1492 PFI0280c autophagocytosis associated protein, putative 
9 284842 T 12269 0.1492 PFI0280c autophagocytosis associated protein, putative 
9 284910 G 12337 0.1492 PFI0280c autophagocytosis associated protein, putative 
10 324964 G 45666 0.2335 PF10_0078 histone deacetylase, putative 
12 50106 T 288 0.0873 PFL0030c erythrocyte membrane protein 1 (PfEMP1) 
12 947550 A 63271 0.2335 PFL1130c hypothetical protein, conserved 
12 954384 C 56437 0.2250 PFL1130c hypothetical protein, conserved 
12 990296 T 43303 0.0103 PFL1170w polyadenylate-binding protein, putative 
12 1002740 T 55747 0.0568   
12 1002741 A 55748 0.0568   
14 279667 T 34730 0.0959 PF14_0074 hypothetical protein 
14 960714 G 49486 0.0631 PF14_0228 hypothetical protein 
14 1225984 A 8890 0.0443 PF14_0291 hypothetical protein 
14 1226019 T 8925 0.0443 PF14_0291 hypothetical protein 
14 1226103 C 9009 0.1528 PF14_0291 hypothetical protein 
14 1226130 C 9036 0.0443 PF14_0291 hypothetical protein 
14 1226242 A 9148 0.0314 PF14_0291 hypothetical protein 
14 1226303 T 9209 0.0248 PF14_0291 hypothetical protein 
14 1608531 A 54272 0.2133 PF14_0374 hypothetical protein 
14 2812662 C 35145 0.1722 PF14_0653 hypothetical protein 
14 2812679 T 35128 0.1722 PF14_0653 hypothetical protein 
14 2838163 G 46456 0.2215 PF14_0660 hypothetical protein 
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Table S4.  IC50 drug resistance phenotype data (nM). ND: No data. 
 
 
sample ADQ ARTM ARTN ARTS ATV CQ DHA HFG HFN LUM MFQ PIP QN 
Resistance 
Threshold 20 5 5 10 3 50 2 1.5 5 50 20 30 100 
10_54 16.48 1.551 3.079 2.002 3.335 63.57 0.7305 1.032 1.832 29.22 5.844 30.61 60.14 
36_89 16.63 4.431 4.418 8.947 3.327 79.45 5.916 1.139 1.491 21.22 3.865 30.95 ND 
3D7 6.8168 2.8094 3.6543 8.4817 2.6474 8.8972 2.5971 0.9846 6.6259 86.2639 20.8618 19.0066 24.5422 
51 29.53 3.661 3.688 9.564 4.192 108.2 3.005 ND 2.509 20.59 7.559 41.53 125.9 
608 15.16 3.089 3.07 4.351 6.978 93.25 2.784 1.155 1.198 10.09 5.83 10.47 104.9 
7G8 18.37 1.464 3.1 2.988 4.161 56.18 2.789 0.7968 1.071 31.1 6.053 40.11 38.87 
9_411 ND 1.158 1.66 5.99 ND ND 0.8257 ND 1.525 5.687 0.6979 54.52 ND 
CF04.008_1F ND 3.718 3.035 6.777 0.8209 6.02 2.522 1.094 3.481 36.68 4.939 18.71 82.44 
CF04.009 ND 4.1495 3.771 8.845 ND ND 1.7316 ND 9.792 72.48 10.356 29.865 ND 
D10 15.2461 3.5656 7.2633 8.7383 2.3062 11.6735 4.4617 1.5121 10.5989 92.63 25.4271 38.127 18.1534 
D6 14.92 2.076 3.138 6.612 0.6697 3.611 1.333 0.4141 6.201 29.56 6.216 3.999 4.898 
Dd2 10.0602 3.4412 3.5525 9.2125 1.2793 73.4253 2.3138 0.8717 4.7277 74.7528 14.9576 26.21 78.8966 
FCC2 9.687 3.165 3.202 8.728 1.213 9.47 4.096 1.48 7.74 156.3 35.99 24.36 27.95 
GA3 15.11 3.591 3.203 6.281 2.391 102.1 3.674 1.495 6.49 ND 27.22 43.25 31.96 
GH2 23.3 6.718 5.983 16.78 2.366 98.03 5.694 1.707 16.03 346.7 17.82 48.54 149.1 
HB3 8.703 1.169 3.019 3.117 1.181 9.78 0.9405 1.413 2.764 71.51 11.18 31.22 20.28 
IGHCR14 4.879 0.6559 1.416 1.202 0.4847 4.967 0.382 1.451 1.725 53.57 11.51 9.564 4.99 
Indochina_I 12 20.57 19.6 ND ND 243.1 ND 0.8852 4.00E-04 6.178 3.902 28.99 153 
JST 30.02 2.35 5.658 3.838 2.193 129.1 1.698 1.203 1.296 22.07 6.811 41.34 24.52 
K1 16.07 1.902 3.124 3.176 2.442 86.42 3.509 1.52 1.907 30.84 13.57 35.78 77.81 
M24 7.63 4.6 4.43 5.546 1.524 13.09 2.49 1.158 1.919 59.81 13.48 14.23 55.33 
Malayan_Camp 7.944 2.887 1.811 1.775 1.171 7.279 2.319 1.126 1.283 ND 6.983 31.26 8.196 
Muz51.1 19.64 3.29 3.18 7.449 1.939 60.44 2.271 1.13 1.696 19.5 8.501 28.23 39.73 
PR145 11.11 15.79 13.66 29.7 6.59 51.24 12.02 1.106 16 140.8 53.43 31.58 149.1 
RAJ116 19.23 1.075 1.805 1.367 1.315 68.59 1.035 1.546 0.0049 6.418 4.105 34.31 4.36 
RO33 11.3737 2.6614 6.0825 6.9751 1.8615 11.0702 2.8762 1.6415 3.1416 69.66 8.094 34.0955 13.4901 
Santa_Lucia 20.44 3.629 4.61 8.644 0.3903 11.76 3.567 1.171 0.7153 30.34 5.822 38.02 260.1 
SenP05.02 16.24 5.695 3.178 11.25 2.493 ND 3.518 1.52 0.9853 30.43 6.798 29 ND 
SenP08.04 17.33 4.873 4.15 11.12 1.19 14.85 3.015 0.4386 11.72 62.21 26.03 7.81 44.76 
SenP09.04 4.517 5.332 4.177 15.7 0.7054 8.312 5.092 1.404 9.234 174 25.44 14.78 54.86 
SenP11.02 92.05 12.75 11.15 19.99 1.881 25.83 8.258 0.7377 17.35 88.75 44.76 14.44 94.63 
SenP19.04 7.157 11.66 10.98 24.04 ND 11.4 9.225 1.858 14.71 95.17 50.83 30.21 ND 
SenP26.04 44.23 12.71 3.23 14.82 1.143 40.38 8.889 0.4341 20.6 57.79 84.86 5.288 ND 
SenP27.02 9.269 3.232 3.635 8.222 ND 9.813 2.664 1.258 1.83 31.2 5.972 21.2 ND 
SenP31.01 6.961 1.991 1.999 6.131 0.4997 8.854 2.966 1.214 3.177 78.89 17.03 22.56 ND 
SenP51.02 29.62 5.041 4.748 8.875 0.3225 62.05 3.398 1.627 3.319 48.55 8.601 34.89 50.08 
SenP60.02 15.8 4.084 4.978 9.62 0.9355 99.93 3.854 1.255 1.616 21.99 11.93 21.19 47.78 
SenT15.04 ND 3.595 3.016 6.9315 ND ND 3.3665 ND 5.262 51.32 3.948 49.53 ND 
SenT26.04 16.05 3.149 3.116 4.827 1.19 79.98 2.991 1.43 2.905 30.92 7.877 24.72 121.1 
SenT28.04 11.9 3.744 3.139 7.846 1.1 51.01 2.343 1.461 7.5 62.69 32.64 15.63 139.6 
SenV34.04 21.39 5.1 4.645 6.781 0.5187 ND 3.024 1.627 2.37 30.34 4.018 28.48 ND 
SenV35.04 5.567 3.078 3.68 4.706 0.8165 9.364 5.374 1.359 2.761 45.52 20.6 26.28 ND 
SenV42.05 6.456 1.06 1.565 1.717 0.7363 9.594 1.731 1.016 4.476 13.6 10.04 4.485 ND 
TD203 15.63 8.15 4.736 20.56 8.49 52.86 8.507 1.071 7.938 156.2 30.32 39.2 67.53 
TD257 11.68 11.88 8.532 24.53 2.215 55.41 11.63 1.539 15.96 227.6 50.42 35.53 253.5 
TM327 9.891 6.032 1.7 8.862 1.146 41.12 3.851 2.022 15.49 249.3 41.25 50.89 70.72 
TM90C2A 18.85 16.17 10.31 28.32 3.704 58.94 5.376 1.086 12.51 264.5 28.04 30.04 209.1 
TM91C235 ND 12.43 12.46 17.66 ND ND 7.409 ND 70.65 154.5 57.96 12.69 ND 
V1/S 17.98 1.625 3.459 6.172 4.02 155.5 1.035 1.538 1.739 26.4 12.84 38.58 224.3 
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Table S5. Parasites used in the GWAS indicating their nucleotide and amino acid sequence for 
various positions (indicated by number) in the dhfr, pfcrt, and pfmdr1 gene loci. 
 
 dhfr' pfcrt' pfmdr1'
 Amino&Acid&
Sequence&
Amino&Acid&&
Sequence&
Amino&Acid&
Sequence&
Parasite&
16
!
51
!
59
!
10
8!
16
4!
50
6!
72
!
74
!
75
!
76
!
32
6!
35
6!
37
1!
86
!
18
4!
10
34
!
10
42
!
12
46
!
51# A I C N I Y S M N T N L R N F C D Y 
10_54# A I C N I Y S M N T N L R N F C D Y 
36_89# A I C N I Y S M N T N L R N F C D Y 
3D7# A N C S I Y C M N K N I R N Y S N D 
7G8# A I C N I Y S M N T N L R N F C D Y 
9_411# A I C N I Y S M N T N L R N F C D Y 
A4# A I C T I Y C I E T N I I Y Y S N D 
APO41# A I R N I Y C I E T N I I N F S N D 
CF04.008_12G# A N R N I Y C M N A N I I Y Y S N D 
CF04.008_1F# A I R N I Y C M N A N I R Y Y S N D 
CF04.009# A I R N I Y C M N A N I R N F S N D 
D10# A N C S I Y C M N K N I R N Y S N D 
D6# A N C S I Y C M N K N I R N Y S N D 
Dd2# A I R N I Y C I E T N T I Y Y S N D 
FCC2# A N C N I Y C M N K N I R N Y S N D 
GH2# A I R N I Y C I E T N I I N Y S N D 
HB3# A N C S I Y C M N K N I R N F S D D 
Indochina_I# A I R N I Y C I E T N I I N F C D Y 
JST# A N C N I Y S M N T N L R N Y C D Y 
K1# A N R N I Y C I E T N I I Y Y S N D 
M24# A N C S I Y C M N K N I R N F S N D 
Malayan#Camp# A N C N I Y C M N K N I R N Y S N D 
Muz51.1# A N C S I Y S M N T N L R Y Y S N D 
PR145# A I R N I Y G I E T N I I N F S N D 
PS189# A N C S I Y C M N K N I R N F S N D 
RO33# A N R N I Y C M N K N I R Y F S N D 
Santa#Lucia# A N C S I Y C M N T N I R N F C D D 
SenP05.02# A N C N I Y C I E T N I I Y F S N D 
SenP08.04# A I R N I Y C M N K N I R N F S N D 
SenP09.04# A I R N I Y C M N K N I R N Y S N D 
SenP11.02# A N C S I Y C M N K N I R N F S N D 
SenP19.04# A N R N I Y C M N K N I R N Y S N D 
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Table S5 (Continued) 
 
SenP26.04# A N R N I Y C I E T N I I Y F S N D 
SenP27.02# A I R N I Y C M N K N I R Y F S N D 
SenP31.01# A N C S I Y C M N K N I R N F S N D 
SenP51.02# A I R N I Y C I E T N I I Y F S N D 
SenP60.02# A N C S I Y C M N K N I R N F S N D 
SenT15.04# A I R N I Y C I E T N I I N F S N D 
SenT26.04# A T R N I Y C I E T N I I Y F S N D 
SenT28.04# A  R N I Y C I E T N I I N F S N D 
SenV34.04# A N C S I Y C I E T N I I Y F S N D 
SenV35.04# A N C S I Y C M N K N I R N F S N D 
SenV42.05# A I C N I Y C I E T N I I N Y S N D 
T2_C6# A N R S I Y C M N K N I R N Y S N D 
TD203# A I C N I Y C I E T N I I N F S N D 
TD257# A I C N I Y C I E T N I I N F S N D 
TM327# A I C N I Y C I E T N I I N F S N D 
TM345# A I C N I Y C I E T N I I N F S N D 
TM90C2A# A I C N I Y C I E T N I I N F S N D 
TM90C6A# A I C N I Y C I E T N I I N Y S N D 
TM91C235# A I C N I Y C I E T N I I N F S N D 
V1/S# A I C N I Y C I E T N I I Y Y S N D 
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Table S6. PF10_0355 copy number summary for 38 parasites tested by qPCR using the Delta 
Delta Ct method. Copy number (CN) was compared to the reference locus PF07_0076 and 3D7 
was used as a reference strain. A cut-off of 1.4 was used to define PF10_0355 copy number 
greater than 1; parasites with greater than 1 copy of PF10_0355 are shaded. Parasites are ranked 
by Halofantrine (HFN) IC50: HFN-sensitive parasites are indicated by an S and HFN-resistant 
parasites are indicated by an R. 
Parasite CN HFN 
Indochina_I 0.92 S 
RAJ116 0.92 S 
Santa_Lucia 1.03 S 
SenP05.02 0.98 S 
7G8 0.74 S 
Malayan_Camp 0.94 S 
JST 1.06 S 
36_89 1.07 S 
SenP60.02 1.19 S 
Muz51.1 0.64 S 
IGHCR14 1.63 S 
V1/S 0.89 S 
10_54 0.99 S 
K1 0.87 S 
M24 0.76 S 
SenV34.04 4.92 S 
51 0.77 S 
SenV35.04 0.86 S 
HB3 0.88 S 
RO33 1.26 S 
SenP31.01 0.77 S 
SenP51.02 1.09 S 
CF04.008_1F 0.95 S 
SenV42.05 1.26 S 
Dd2 1.07 S 
SenT15.04 1.71 R 
3D7 1 R 
SenT28.04 0.73 R 
FCC2 0.76 R 
TD203 0.9 R 
D10 1.06 R 
SenP08.04 0.95 R 
TM90C2A 1.43 R 
SenP19.04 1.06 R 
PR145 0.94 R 
GH2 1.71 R 
SenP11.02 7.14 R 
SenP26.04 1.68 R 
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Table S7. Annotation and GeneID Information for identified genes in Figure 1B.  
 
GeneID π  FST Annotation Category Tag 
MAL8P1_23 1.54E-04 0.646 ubiquitin-protein ligase 1, putative enzymes, ACS and 
transporters 
UBQ Ligase 
PF13_0201 6.39E-03 0.216 thrombospondin-related 
anonymous protein, TRAP 
other TRAP 
PFA0650w 4.37E-03 0.323 surface-associated interspersed 
gene pseudogene, (SURFIN) 
pseudogene 
antigens, var, rifin, stevor, 
surfin 
SURFIN 
PF08_0105 6.10E-03 0.204 rifin antigens, var, rifin, stevor, 
surfin 
Rifin 
PFB0960c 4.31E-03 0.036 P. falciparum Maurer’s Cleft 2 
transmembrane domain protein 2.1, 
PfMC-2TM_2.1 
other Mauer’s Cleft 
MAL7P1_27 6.36E-04 0.387 chloroquine resistance transporter enzymes, ACS and 
transporters 
PFCRT 
PF10_0345 6.52E-03 0.240 merozoite surface protein 3 antigens, var, rifin, stevor, 
surfin 
MSP3 
PFI1475w 1.95E-03 0.221 merozoite surface protein 1, 
precursor 
antigens, var, rifin, stevor, 
surfin 
MSP1 
PFB0972w 9.90E-03 0.077 hypothetical protein other * 
PFL0030c 7.95E-03 0.050 erythrocyte membrane protein 1 
(PfEMP1) 
antigens, var, rifin, stevor, 
surfin 
Var2CSA 
PFD0830w 5.96E-04 0.459 bifunctional dihydrofolate 
reductase-thymidylate synthase 
enzymes, ACS and 
transporters 
DHFR 
PF11_0344 6.46E-03 0.074 apical membrane antigen 1, AMA1 antigens, var, rifin, stevor, 
surfin 
AMA1 
PF10_0051 5.32E-03 0.215 ADP/ATP carrier protein, putative enzymes, ACS and 
transporters 
ADP/ATP 
Carrier 
PFB0685c 5.75E-04 0.497 acyl-CoA synthetase, PfACS9 enzymes, ACS and 
transporters 
ACS9 
PFF1350c 2.00E-03 0.584 acetyl-coenzyme a synthetase enzymes, ACS and 
transporters 
ACS 
PFE1250w 1.66E-03 0.602 acyl-CoA synthetase, PfACS10 enzymes, ACS and 
transporters 
ACS10 
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Supplemental Figures 
Figure S1. Principal components analysis of population structure within A) Africa B) the 
Americas, and C) Asia. Plots of the first two principal components using Eigenstrat [16] using 
the Affymetrix array. Each solid circle represents an individual, and the color is assigned 
according to the reported origin. 
 
 
!
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Figure S2: Linkage disequilibrium (LD), measured by r2, for each of the three population 
samples (Senegal, Thailand, Brazil). Plotted are r2 for linked markers (red lines) and for unlinked 
markers (blue lines), as well as the level of background LD expected because of small sample 
size (green lines). 
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Figure S3. Genes were classified by gene ontology (GO) functional categories and stratified by 
level of nucleotide diversity (π) as estimated by Z-scores.  Select categories (highest five and 
lowest five categories along with categories in between that differ by incremental Z-scores) are 
shown.  The majority of genes in GO categories for molecules found at the cell membrane have 
high levels of nucleotide diversity, while most of the genes classified into GO categories for 
conserved molecules lack nucleotide diversity. 
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Figure S4. SNP diversity and divergence by translation consequence. Diversity at assayed SNPs 
(SNP π) and Divergence between different populations as assayed by FST, for different classes of 
SNPs: intergenic (4,263 SNPs), intronic (584 SNPs), synonymous (3,957 SNPs), and 
nonsynonymous (8,778 SNPs). Intronic SNPs have the widest error bars due to their relative 
sparseness on the array. Non-synonymous SNPs are generally among the least diverse and most 
differentiated class of SNPs. 
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Figure S5. Relative extended haplotype homozygosity (REHH) scores. Relative extended 
haplotype homozygosity (REHH) scores prior to any normalization, plotted for each core allele, 
(A) indexed by chromosome and position, and colored by chromosome, and (B) as a function of 
core allele frequency. 
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Figure S6. Long-range haplotype (LRH) analysis yields genome-wide significant candidates for 
recent positive selection. For each core allele, we calculated relative extended haplotype 
homozygosity (REHH), and from the set of all REHH scores we calculated a corresponding 
distribution of Q-values. We plotted -log10(Q-value), for all Q-values <1, for each core allele, 
indexed by chromosome and position, and colored by chromosome. The red dotted line 
corresponds to the typical Q-value significance threshold of 0.05. Gene annotations from 
PlasmoDB.org for some significant scores are labeled. For comparison, the well-known sweeps 
around drug resistance loci pfcrt and dhfr are labeled. This data is also shown in tabular form in 
Table S3. 
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Figure S7. GWAS P-value distributions for Fisher's exact test, permuted Fisher's exact test, and 
Cochran-Mantel-Haenszel (CMH) tests. Quantile-quantile plots (qq-plots) show log P-values for 
every SNP on the y-axis against the null expectation on the x-axis. Fisher's exact test results 
generally show P-value inflation due to confounding effects from population structure for many 
drugs ("Fish"). As such, no results from this test are reported. To account for population 
structure, permutations of the null distribution were performed while preserving phenotypic 
associations to three predefined population clusters ("Fishp"). CMH also performs a stratified 
association test given predefined population clusters ("CMH"). The permuted Fisher's test and 
CMH test results show appropriate correction for population structure, but show no hits at 
genome-wide significance to report. 
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Figure S7 (Contined) 
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Figure S8. GWAS results for the Efficient Mixed-Model Association (EMMA) test. QQ-plots 
show little to no confounding effect from population structure, with the possible exception of 
artesunate (ARTN). The significant ARTN result is not reported in Table 1 or Figure 2 for this 
reason. Manhattan plots depict the genomic location of significant hits, also reported in Table 1 
and Figure 2. 
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Figure S9. GWAS P-value distributions for the Haplotype Likelihood Ratio (HLR) tests for 
association for drug resistance. Population-sensitive permutations of the null model were used to 
calculate P-values from LOD scores. Final distributions of P-values show little to no 
confounding effect from population structure for most tests. Exceptions include the 6-SNP 
artemether (HLR_risk_6_ARTM) test and the 4-SNP amodiaquine (HLR_risk_4_ADQ) test--
these results are not reported in Table 1 or Figure 2. Manhattan plots for other tests that reached 
genome-wide significance are in Figure 2A. 
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Figure S9 (Continued) 
 
  
! 185 
Figure S10. GWAS P-value distributions for Haplotype Likelihood Ratio (HLR) tests for 
association for drug sensitivity. Population-sensitive permutations of the null model were used to 
calculate P-values from LOD scores. Final distributions of P-values show little to no 
confounding effect from population structure. Genome-wide significant hits include piperaquine 
(HLR_protect_4_PIP) on a haplotype that spans PF07_0126, PF07_0127 and MAL7P1_167 and 
amodiaquine (HLR_protect_4_ADQ) on a haplotype in PFL1800w. A chloroquine hit on pfcrt 
just misses genome-wide significance. These results are not reported in Table 1.  
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Figure S10 (Continued) 
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Figure S11. Intensity Z-score for the Affymetrix array across chromosome 5. The results 
illustrate that probes for many of the SNPs assayed within the pfmdr1 (888-988 k) locus exhibit 
notably higher hybridization intensity values in Dd2 relative to the other parasites, with 13 
assays exhibiting average intensities greater than 2 standard deviations higher than observed in 
other strains. This is consistent with the copy number variation reported in the pfmdr1 locus, 
with 3–4 copies present in the Dd2 strain relative to a collection of other strains.  
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Figure S12.  PF10_0355 copy number variation measured by Southern blotting. Select parasite 
isolates were digested with AflIII, EcoRV and XbaI and fragments were detected using probes to 
portions of the PF10_0355 and dhps genes. Primers used for making probes were: dhps F: 5′-
GTG ATT GTG TGG ATC AGA AGA TGA ATA ATC-3′; R: 5′-GGA TTA GGT ATA ACA 
AAA GGA CCA GAG G-3′; PF10_0355 F: 5′-GGG GAA AGC ATA TAA TAA TAC TAT 
AGA TGC-3′; R: 5′-CTT GGA GGA ACA AGA ACC CCC TTA TTA TCA-3′ Radioactivity 
was measured using a phosphorimager plate and quantified using Quantity One software (version 
4.6.5). Halofantrine (HFN) response is listed as sensitive (S) or resistant (R) for each strain. 
 
  
dhps
PF10_0355
V34.04  TM90C6A TM90C2A  TM327    P26.04    P19.04    P11.02   GH2         D10         3D7
PF10_0355 copy number 1.54       2.26      2.43      2.02 1.21      1.18       0.53       2.38 1.06       1.00
HFN response S R         R R         R R R         R R R
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Figure S13. Drug resistance phenotype classification for sweep and GWAS analyses. IC50 data 
were collected for thirteen anti-malarial drugs against all genotyped parasite lines. Quantitative 
IC50s were converted into binary "sensitive" and "resistant" phenotypes at the cutoffs shown (see 
also Table S4). These binary phenotypes were only used for the Haplotype Likelihood Ratio 
(HLR) test. Drug abbreviations: amodiaquine (ADQ), artemether (ARTM), artesunate (ARTN), 
artemisinin (ARTS), atovaquone (ATV), chloroquine (CQ), dihydroartemisinin (DHA), 
halofuginone (HFG), halofantrine (HFN), lumefantrine (LUM), mefloquine (MFQ), piperaquine 
(PIP) and quinine (QN).   
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Supplemental Methods and Figures for Chapter Two: 
Van Tyne et al. (in prep). Modulation of PF10_0355 alters Plasmodium falciparum 
response to antimalarial drugs 
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Supplemental Methods 
PF10_0355 Immunoprecipitation 
 Sorbitol-synchronized schizont-stage Dd2 0355 DR parasitized red blood cells were lysed 
with 0.05% Saponin containing Complete Protease Inhibitor (Roche Applied Sciences, 
Indianapolis, IN) and then washed with 1xPBS to separate parasites from lysed red blood cells. 
Parasites were then lysed with a buffer containing 50mM TrisHCl pH 7.4, 100mM NaCl, 0.5% 
NP40, and Complete Protease Inhibitor (Roche Applied Sciences, Indianapolis, IN). Parasites 
were incubated in lysis buffer on ice and were vortex periodically for 10 minutes, followed by 
filtration through a 0.22µm filter. Anti-HA affinity matrix (clone 3F10; Roche Applied Science, 
Indianapolis, IN) was pre-washed with lysis buffer, and then filtered lysate was added and 
incubated with the affinity matrix for 1 hour at 4 degrees with gentle shaking. Affinity matrix 
was then spun down and supernatant (flow-through or “unbound” protein) was removed. Affinity 
matrix (with bound proteins) was washed 4 times with lysis buffer and was then mixed with 2x 
Laemmli sample loading buffer (Bio-Rad, Hercules, CA) containing beta-mercaptoethanol, 
boiled and analyzed by SDS-PAGE with both Coomassie blue staining (Bio-Rad, Hercules, CA) 
and Silver staining using a SilverQuest kit (Invitrogen, Grand Island, NY). 
Protein Identification 
 Individual protein bands were excised and sent for analysis at the Taplin Mass 
Spectrometry facility at Harvard Medical School. Gel pieces were subjected to a modified in-gel 
trypsin digestion procedure [1]. Gel pieces were then washed and dehydrated with acetonitrile 
for 10 minutes, followed by removal of acetonitrile. Pieces were then completely dried in a 
speed-vac. Rehydration of the gel pieces was with 50 mM ammonium bicarbonate solution 
containing 12.5 ng/µl modified sequencing-grade trypsin (Promega, Madison, WI) at 4ºC. After 
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45 min., the excess trypsin solution was removed and replaced with 50 mM ammonium 
bicarbonate solution to just cover the gel pieces. Samples were then placed in a 37ºC room 
overnight. Peptides were later extracted by removing the ammonium bicarbonate solution, 
followed by one wash with a solution containing 50% acetonitrile and 1% formic acid. The 
extracts were then dried in a speed-vac (~1 hr), and samples were then stored at 4ºC until 
analysis. 
On the day of analysis, the samples were reconstituted in 5-10µl of HPLC solvent A 
(2.5% acetonitrile, 0.1% formic acid). A nano-scale reverse-phase HPLC capillary column was 
created by packing 5µm C18 spherical silica beads into a fused silica capillary (125µm inner 
diameter x ~20cm length) with a flame-drawn tip [2]. After equilibrating the column, each 
sample was loaded via a Famos auto sampler (LC Packings, San Francisco CA) onto the column. 
A gradient was formed and peptides were eluted with increasing concentrations of solvent B 
(97.5% acetonitrile, 0.1% formic acid). As peptides eluted they were subjected to electrospray 
ionization and then entered into an LTQ Velos ion-trap mass spectrometer (ThermoFisher, San 
Jose, CA). Peptides were detected, isolated, and fragmented to produce a tandem mass spectrum 
of specific fragment ions for each peptide. Peptide sequences (and hence protein identity) were 
determined by matching protein databases with the acquired fragmentation pattern by the 
Sequest software program (ThermoFisher, San Jose, CA) [3]. Spectral matches were manually 
examined and multiple identified peptides per protein were required. 
Biacore drug binding 
 Recombinant protein was generated for full-length PF10_0355 and PF10_0348 proteins, 
as well as the DBL domain of PF10_0355. Drug binding analysis was conducted on a Biacore 
3000 using CM5 chips (GE Healthcare, Waukesha, WI). Proteins were immobilized on chips 
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using amine coupling chemistry [4], and drug binding was assessed using a running buffer 
containing 5% DMSO and 0.05% P20 surfactant in 1xPBS. Data were analyzed using 
BIAevaluation software (GE Healthcare, Waukesha, WI), Microsoft Excel (Redmond, WA) and 
GraphPad Prism v5.0d (San Diego, CA). Response units (RU) were solvent corrected and 
normalized to a blank flow-cell that was analyzed in parallel, and Kd values were calculated 
using a non-linear fit model for one-site total binding.  
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Supplemental Figures 
Figure B1. Pull-down of PF10_0355 and identification of interacting partners. A) Western blot 
showing fractions of lysate, flow-through (“Unbound”), wash and protein remaining on anti-HA 
affinity matrix (“Beads”) following pull-down procedure. Anti-HA antibody staining is shown in 
green and anti-LDH antibody staining is shown in red. B) Silver-stained gel of protein remaining 
on anti-HA affinity matrix (“Beads”) following immunoprecipitation. Arrows point to bands that 
were excised and sent for mass spectrometry analysis. Protein bands that were identified by at 
least five different peptide fragments are labeled with their protein matches and likely protein 
domain sizes. 
 
 
 
  
260 
140 
100 
70 
50 
40 
35 
Ly
sa
te
 
U
nb
ou
nd
 
W
as
h 
B
ea
ds
 
α-HA 
(green) 
α-LDH 
(red) 
kDa 
140 
100 
70 
50 
MSP-183kDa 
PF10_0355 
kDa 
SERA 5126kDa 
PF10_0355 
A B 
B
ea
ds
 
!!
197 
Figure B2. Drug binding to recombinant proteins by Biacore. PF10_0348 full length (0348 FL), 
PF10_0355 full length (0355 FL), PF10_0355 DBL domain (0355 DBL) and Carbonic 
Anhydrase proteins were analyzed for their binding to various antimalarials. Binding was 
measured between each protein and A) halofantrine (HFN), B) lumefantrine (LUM), C) 
chloroquine (CQ), and D) artemisinin (ART). Response units (RU) are plotted versus drug 
concentration. Kd values were calculated for binding of HFN and LUM; because CQ and ART 
showed a linear relationship between RU and drug concentration, Kd values were not calculated 
and R-squared values for linear fit are shown instead. 
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APPENDIX C 
 
 
 
Supplemental Figures for Chapter Four: 
Van Tyne et al. (in prep). Monitoring antimalarial drug response in Plasmodium 
falciparum field isolates using an ex vivo DAPI assay 
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Figure C1. Artemisinin IC50s in Senegalese parasites tested with the DAPI ex vivo drug assay in 
2008, 2009 and 2010. Scatter plots show log10-transformed IC50s and horizontal lines indicate 
median IC50 for each year.  Median IC50s were 3.4nM in 2008, 8.6nM in 2009 and 9.5nM in 
2010. 
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Figure C2. Comparison of ex vivo with in vitro IC50s for artemisinin among 24 culture-adapted 
parasites collected in 2009. All parasites were derived from monoclonal infections. Ex vivo IC50s 
were measured using the DAPI ex vivo assay and in vitro IC50s were measured by radiolabeled 
hypoxanthine incorporation. Mean in vitro IC50s are plotted with error bars showing the standard 
error of at least two biological replicates. ρ denotes the Pearson correlation coefficient. 
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